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Drug discovery and development aims to provide therapeutic compounds 
that are safe and effective in improving the quality of life and relieving pain of 
patients. However, the process is usually complex, time consuming and resource 
intensive. Toxicity is one of the primary reasons for the failure of drug candidates 
in later stages of drug development. Moreover, adverse drug reaction (ADR) 
during post-approval stage is among the leading causes of morbidity and mortality. 
Computational methods such as quantitative structure-activity relationship 
(QSAR) methods have been explored as complementary methods for predicting 
and profiling toxicities and have shown promising result for performing these 
tasks. Nevertheless, there are still limitations for current QSAR modeling process 
which affect the quality and prevent the application of QSAR models. These 
include lack of negative data and descriptors, difficulties in determination of 
applicability domain (AD), lack of effective model selection method for ensemble 
modeling, lack of proper model evaluation method and tool for model application. 
This thesis attempts to address these issues with various strategies 
including: using OCC methods to address the lack of negative data issue, adding 
biological information as extra descriptors, developing methods for AD 
determination, model selection and model evaluation, and developing a software 
program to facilitate the application of QSAR models. Some of these strategies 
were applied in real data sets to develop QSAR models to facilitate the detection 
of drug candidates with propensity of toxicity and ADRs. Three types of rare 
and/or serious ADRs including Stevens Johnson’s syndrome/toxic epidermal 
necrolysis (SJS/TEN), Torsade de pointes (TdP) and serious psychiatric ADRs 
were investigated. Another predictive study regarding nephrotoxicity was also 
carried out to explore the possibility of integrating toxicogenomics (TGX) method 
with QSAR method to enhance the model’s prediction ability as well as biological 
understanding. The results showed that the development and application of QSAR 
models could be improved by using the methods discussed in this work. The 
QSAR models for the ADRs are the first to address these endpoints with 
comprehensive and reliable methods and the performances are also encouraging. 
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The integrated model developed using both QSAR and TGX methods for 
nephrotoxicity prediction demonstrated the potential of addition of biological 
information. Lastly, a software program which provides well validated models for 
prediction of ADMET properties was developed to facilitate the application of 
QSAR models. The software possessed many advantages over other similar 
software programs and it is completely free to the public. 
The main purpose of this thesis is to develop and apply computational 
methods and tools for ADR and toxicity prediction. The methods developed in 
this work are potentially useful for development and application of QSAR models 
as well as general predictive models other than pharmaceutical area. The models 
developed for ADRs and toxicity could be applied in drug discovery and clinical 
practice. The independent tool developed by integration of peer reviewed models 
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Chapter 1 Introduction 
Reliable absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
screening filters could eliminate the poor drug candidates so they are important 
for reducing drug attrition rate. Efficient and effective methods for predicting 
ADMET properties, particularly in the early stages, are highly desirable for 
facilitating drug development and safety assessment. Computational methods 
such as QSAR methods are increasingly employed to reduce the time and cost 
needed for evaluating the ADMET properties of drug candidates. The first two 
sections of this chapter give an overview of the application of QSAR methods for 
ADMET prediction. The motivation and significance for this work as well as the 
outline of the structure of this thesis are presented in the remaining three sections. 
1.1. ADMET studies in drug discovery and development 
The purpose of drug discovery and development is to provide therapeutic 
compounds that are safe and efficacious in improving the quality of life and 
reducing pain of patients. It is a multi-step process which starts with the 
identification and validation of the target associated with disease, followed by 
identification and optimization of the lead compounds, and then subsequent 
rounds of preclinical and clinical testing for therapeutic efficacy and safety before 
it becomes approved for general use. Besides advances in knowledge and 
technology in biomedical research area, drug discovery and development is still a 
time consuming and resource intensive process with low rate of novel discovery 
of therapeutic compounds. Recent studies estimated that it takes around 13 years 
from a new drug to be discovered and  finally be available in the market for 
treatment, and the average cost of research and development for each successful 
drug is approximately $1.8 billion [1]. Moreover,  for the drug discovery process, 
among every 5,000 newly identified compounds, approximately five of them 
could pass the preclinical evaluations and enter into clinical testing which 
involves human subjects, and after rounds of clinical trials in patients, on average 
only one of them could finally get approved [2]. To reduce time and cost, it is 
essential to minimize the number of failures in the different stages of drug 
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discovery and development. It is reported that about 40-60% of new chemical 
entities (NCE) failed in the clinical stages because of poor ADMET  properties 
[3]. Therefore, reliable ADMET screening filters which could remove the poor 
candidates are important for reducing the attrition rate. While traditionally 
ADMET tools were usually applied at the end of the drug development pipeline, 
nowadays they are more applied at the early stage by prioritizing the most 
promising compounds to reduce attrition rate and optimize the testing for later 
stages [4]. Hence efficient and effective methods for predicting these ADMET 
properties, particularly in the early design stages, are highly desirable to facilitate 
drug development and safety assessment.  
1.2. QSAR studies for ADR and toxicity prediction 
To deliver promising drug candidates to reach the late stage of drug development 
with a higher chance of success, large numbers of high-throughput screenings for 
ADMET properties have been implemented in recent years and these generated 
large amount of experimental data [5]. The generation of these large and diverse 
datasets has presented opportunities to develop various computational models for 
ADMET properties, using different statistical modeling techniques to find the 
inherent relationship of chemical structures with specific properties and make 
predictions. These models can then be employed to prioritize the compound 
selection for drug discovery and safety assessment [5].  Computational method 
such as QSAR method has been used extensively in ADMET prediction studies [6, 
7]. QSAR relates known physiochemical and biological activities with chemical 
structures of compounds to form models that can predict the activities on new 
compounds. It belongs to the large collection of general structure-property 
correlations (SARs) in medicinal chemistry, which refer to “all statistical 
mathematical methods used to correlate any molecular property (intrinsic, 
chemical or biological) to any other property, using statistical regression or 
pattern recognition techniques” [6].  Compared with in vitro and in vivo testing, 
QSAR methods are extremely appealing because they could deal with large 
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dataset containing either real or hypothetical chemical compounds, and can 
reduce the cost and time of animal testing and clinical trials [8].  
 Among QSAR studies for ADMET prediction, toxicity prediction is 
receiving increasing attention because potential drug candidates often fail due to 
unacceptable level of toxicity in preclinical or clinical studies. It is reported that 
among the attritions in the clinic stage in 2000, around 30% of them were caused 
by toxicity or clinical safety problems associated with the compounds [9]. 
Nowadays, non-clinical and clinical safety still remain as a major issue during the 
clinical phase of drug development as well as the post-approval stage [10]. 
Besides the toxicological effects observed during preclinical studies, the adverse 
drugs reactions (ADR) occur in late-stage clinical trials or post-approval stage can 
impose high risks to patients and cause withdrawals of marketed drugs, thus have 
become a global health concern. According to the definition of World Health 
Organization (WHO), ADRs are “any noxious, unintended, and undesired effect 
of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or 
therapy” [11]. Although rigorous animal testing and human screening are carried 
out in clinical trials , drugs do not always reveal all undesired effects during this 
period so some ADRs might only become apparent when the drug has been 
extensively prescribed and a large population has been exposed to it. It is reported 
that only the some common adverse events (i.e., those with frequency higher than 
1/1000) could be observed and listed in the label at the time of approval so some 
rare ADRs are still observed either in late-stage clinical trials or post approval 
period of the drug [7, 9, 12]. This could be because the toxicological effects of in 
vitro and animal model could not be exactly translated to clinical practice and 
clinical trials are limited with respect to the number and diversity of patients 
exposed, as well as the short duration and controlled nature of the experiment. As 
a result, it is difficult to establish the complete safety profile associated with a 
new drug through animal testing and clinical trials [13]. 
ADRs have been one of the leading causes of morbidity and mortality 
during medical care [14]. It is reported that ADRs contribute for more than 2 
million incidences requiring hospitalizations and more than 100,000 deaths 
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annually in the United States [15]. This ranks them as one of the top six leading 
causes of death and the associated costs for ADRs are estimated as $75 billion 
annually [13]. ADRs have also caused withdrawal of marketed drugs. It is 
reported that during the period of 1990-2006, there are 38 drugs withdrawn from 
various major markets of the world due to various safety issues, including the two 
famous cases of Merck’s rofecoxib and Bayer’s cerivastatin [9, 16]. Hence, to 
prevent potential risks on the patients and save time and expense invested in an 
ultimate failure, determination of the propensity of a drug candidate to cause 
ADRs as early as possible during drug development is of great importance. QSAR 
modeling which has been successfully applied in predicting a wide range of 
toxicological properties is a suitable method [17, 18]. Quantitative Structure-
Toxicity Relationship (QSTR) is the type of QSAR developed for a toxic endpoint. 
The methodology used for QSTR modeling is same as QSAR so in this study the 
general term QSAR is used.  
There are a number of QSAR studies regarding ADRs and toxicities in the 
past few years. Some of the representative studies are summarized in Table 1.1. 
The computational methods and the data sources used for the studies are quite 
different. The performances of most of the models are promising and some of the 
models achieve sensitivity and specificity values higher than 90%. This 
demonstrates the huge potential of the application of the QSAR methods.  Due to 
their high-throughput property and reliable performance, QSAR studies for ADRs 
and toxicity prediction are of keen interest in both industry and academia 
worldwide. They are also being increasingly evaluated and applied by regulatory 
authorities, such as the Critical Path Initiative toolkits by Food and Drug 
Administration (FDA) and ToxCast™ by the Environmental Protection Agency 
(EPA) of United States [19, 20]. For risk assessment of chemicals in commerce in 
the European Union,  the European Chemicals Bureau and the Organisation for 
Economic Cooperation and Development (OECD) are also generating a list of 





Table 1.1 Recent QSAR studies of ADR and Toxicity Prediction 
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Decision tree DrugBank[29] ACC=78.9~90.2% [30] 
 
 In summary, the application of QSAR method for predicting preclinical 
toxicological endpoints and clinical adverse effects has been a favorable method 
to facilitate the development of safe and efficacious medicines. It has been 
demonstrated to be a cheaper and faster alternative method of in vivo and in vitro 
studies and have been gradually accepted by regulatory agencies [31]. 
Nevertheless, the role of all computational methods including QSAR is not to 
eliminate attrition but to shift it earlier in the development process to fail early, 
fail fast and fail cheap [32]. 
1.3. Limitations of current QSAR studies 
A summary of general QSAR workflow is shown in Figure 1.1. It could be 
divided into five steps including data collection, data preprocessing, model 
development, model validation/evaluation and model deployment. Each step 
contains several sub steps. For data preprocessing, it normally involves 
normalization, transformation and feature selection. For model development, 
besides various modeling algorithms, applicability domain (AD) which is 
considered as “the response and chemical structure space in which the model 
makes predictions with a given reliability” [33], need to be determined for QSAR 
models. Moreover, ensemble method is also increasingly used to improve the 
individual model’s performance. Despite the advances in studies of QSAR 
methodologies in the past few years, there are still limitations of current QSAR 
modeling process, especially for classification models. A brief discussion for 
these limitations is as below. More details about these limitations will be 




i. Lack of negative data 
Most of QSAR models are developed using machine learning algorithms whose 
performance is highly dependent on the information contained in the data. For 
some QSAR studies such as modeling of mutagenicity, the determination of 
mutagens and nonmutagens of the training data is relatively straightforward and 
binary classification method could be applied directly for prediction purpose [34]. 
For some other QSAR studies such as ligand-based virtual screening studies, lack 
of negative data has become a common problem [35]. Moreover, for QSAR 
studies regarding ADR prediction, it is easy to determine that a compound causes 
a specific ADR from experiment or clinical case report, but difficult to confirm 
that a compound definitely does not cause the specific ADR, since some ADRs 
Figure 1.1 General QSAR workflow, limitations and proposed methods. 
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may take a long time to occur or they occurred but have not been reported yet. 
This is especially true in the modeling of QSAR for ADRs with complex 
mechanisms. For these cases, only the positive data (compounds which cause the 
ADR) are available and the negative data (compounds which do not cause the 
given ADR) are either hard to obtain or not available at all.  
ii. Limitation of molecular descriptors 
Although molecular descriptors of chemical compounds have demonstrated to be 
successful in QSAR studies, it is found that the information of molecular 
descriptors calculated based on chemical structures and experiment measurements 
could not fully capture the real relationship of the compounds with the target 
endpoints, especially for those with complex mechanisms. This could be because 
that the structure activity relationship for these endpoints is less straightforward 
since multiple mechanisms of action are involved [36]. 
iii. Lack of applicability domain 
Many QSAR prediction models are developed every year but not all of them are 
suitable to perform predictions on new compounds. One reason is that some of the 
models do not always fully conform to the validation principles for QSAR models 
laid out by the OECD. They are “1. a defined endpoint; 2. an unambiguous 
algorithm; 3. a defined domain of applicability; 4. appropriate measures of 
goodness-of-fit, robustness and predictivity; 5. a mechanistic interpretation, if 
possible” [37]. One of the non-conformity is the lack of determination of AD. 
Without defining AD for a QSAR model, the model theoretically could make 
prediction on any compounds which will lead to unjustified extrapolation and thus 
inaccurate prediction [38]. Therefore, lack of proper AD is a critical problem for 
QSAR model development.  
iv. Difficulty of  model selection for ensemble modeling 
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Ensemble modeling is a technique used in modeling studies to improve the 
performances of individual models (classifiers) by combining multiple models 
together [39]. Ensemble methods have been popular in QSAR studies recently and 
many studies have demonstrated that ensemble models could achieve better 
performance than a single model [40-42]. However, when a large set of models 
were produced, how to effectively select an optimal or good set of models has 
become a problem [43].  
v. Limitation of current model evaluation method 
Model evaluation is an important process in QSAR modeling workflow, as well 
as the general predictive modeling process. It is used to help ranking different 
models according to their performance. The rankings are then used during feature 
selection and modeling parameter optimization to select the optimum features and 
modeling parameters. Current evaluation methods do not consider the 
representativity of the dataset and thus have limited generalizability (i.e. poor 
prediction of data that is not used during the training process). It is commonly 
expected that a model will have relatively good performance for compounds that 
are similar to those used in the modeling process and have poorer performance for 
compounds that are dissimilar. However, the current evaluation methods only 
give a single prediction performance for all types of compounds and thus do not 
adequately show the difference in prediction performance for different types of 
compounds.  
vi. Difficulty of QSAR model application 
Generally, the purpose of developing QSAR models is to utilize them for 
prediction on new compounds, so the application of QSAR models is an 
important concern for modelers. However, for most QSAR models, after 
publication, very few of them could actually be reused due to lack of development 
of user-friendly tools. After putting substantial efforts in data collection, model 
development and preparation for publication, it is difficult to apply these models 
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in practical problems to benefit larger population [44]. Therefore, there is a need 
to develop a tool which provides well validated models with good quality and 
ease of use. 
1.4. Objectives and significance 
The ultimate objective of this thesis is to improve the development and 
application of QSAR models by creating or improving methods and tools for 
QSAR model development, evaluation and application. In this work, six strategies 
to address the current limitations in QSAR will be used to achieve this objective.  
The first strategy is to apply newer machine learning methods, such as one-class 
classification methods including one-class support vector machine (SVM) for the 
development of QSTR models. The application of these methods is to address the 
issue of lack of negative data. These methods have shown promising results in 
other area such as disease diagnosis [45], document classification [46] and 
network intrusion detection [47]. It is of interest to apply these newer methods in 
QSAR studies.  
 The second strategy is to construct QSAR models using both QSAR and 
toxicogenomics methods to improve the QSAR model’s prediction performance. 
Besides the molecular descriptors derived from the structures of the compounds, 
other toxicity related information, such as the toxicogenomics data collected on 
chemical compounds, could provide another source of molecular information. 
Therefore, the addition of biological information could address the second issue 
of lack of descriptors and is useful for predictive toxicity studies. 
The third strategy is to develop a method to determine the AD of the 
QSAR models to improve the reliability and generalizability of the models. AD 
has been regarded as an important requirement in OECD guidelines for QSAR 
model validation so a reliable and efficient method to determine AD is important. 
The method developed in this work could define a proper AD for classification 
models to address the third issue.  
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The fourth strategy is to employ model selection methods for ensemble 
modeling to combine different QSAR models. There are many QSAR models for 
a single ADR or toxicity that are developed using different sets of descriptors and 
modeling algorithms, and it has been demonstrated by several studies that the 
ensemble model could improve the overall prediction accuracies for the respective 
property. The two model selection methods introduced in this work provide 
options for more effective ensemble modeling. 
The fifth strategy is to develop a novel method to improve the evaluation 
of the QSAR models. Unlike conventional evaluation methods, the proposed 
method takes the representativity of the data into consideration to provide a 
performance profile of the testing set instead of a single value, so the performance 
of the model could be more comprehensive and reliable.  
The last strategy is to develop a software program for ADMET prediction. 
This is to address the last issue, i.e., to facilitate the application of these QSAR 
models. A software program which provides well-validated QSAR models to 
cover a broad spectrum of endpoints and is easy to use for both professionals and 
non-specialists will be developed in this study.  
In summary, this thesis endeavors to develop and improve various 
methods in the QSAR workflow to improve the prediction ability, reliability and 
application of QSAR models. The methods proposed in the studies provide 
alternative solutions or inspiring ideas for fellow predictive modelers, not only in 
the pharmaceutical industry but also the general data mining field. The QSAR 
models developed for ADRs and toxicities are useful in both drug discovery and 
clinical practice. The independent tool developed by integration of peer reviewed 
models provides an option for users to obtain reliable ADMET property 
prediction. 
1.5. Thesis structure 
The whole thesis is divided into five parts with ten chapters.  
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 Part I is the introduction and over of the materials and methodology of 
the study which consists of two chapters. Chapter 1 introduces the rationale, 
objectives and significance of this thesis. Chapter 2 gives an overview of the 
datasets and methodologies used in this study. The general workflow of 
developing a QSAR model, including data preprocessing, molecular descriptor 
calculation, model development using different machine learning algorithms, AD 
determination, ensemble modeling, followed by model validation and 
performance measures for model characterization. Different methods and tools are 
introduced sequentially according to the different stages of the workflow. 
Additional features of the methods will be explained in details in the respective 
application in following chapters. 
 Part II is dedicated to the development and application of different 
methods to improve QSAR model’s quality. According to the order of the general 
QSAR working flow, five main methods were presented including the one-class 
classification method in Chapter 3, the combinatorial study of prediction of 
nephrotoxicity using QSAR and toxicogenomics approaches in Chapter 4, AD 
determination method in Chapter 5, model selection method for ensemble 
modeling in  Chapter 6 and model evaluation method in Chapter 7. Comparison 
of the methods with existing methods will also be discussed if necessary. 
Part III presents the four models developed using the methods from Part 
II and discussed the important information related to the final models developed 
from the entire dataset in details. Part III consists of one long chapter-Chapter 8. 
It presents important information for all models developed in this study since the 
general workflows for the model development of them are similar.  
Part IV describes the tool developed for QSAR model application. The 
only chapter in this part, Chapter 9, presents a software program to facilitate the 
application of QSAR models. This chapter describes the availability of the 
respective ADR and toxicity models for public use. The development procedure 
of the software is presented and comparison with other similar software is 
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established. A simple experiment of the computation time for prediction is 
presented as well.  
The last part, Part V consists of a short Chapter 10 which summarizes 
the major findings and contributions of this work. Limitations of the present work 




























Chapter 2 Materials and methods for model development 
This chapter focuses on the three main components of QSAR: the ADMET data, 
structural and physiochemical descriptions of compounds and the statistical 
learning methods to correlate the first two components. Firstly the datasets used 
in this work for QSAR model development are introduced.  Then the general 
methods used in this work for developing QSAR or general predictive models are 
described. The organization of the sections follows the common workflow of 
QSAR, including data collection and processing, descriptor calculation and 
selection, model development and validation. Software programs used for QSAR 
model development were also mentioned. 
2.1. Endpoints and datasets 
Although some organ specific toxicities such as drug induced 
hepatotoxicity and cardiotoxicity have been studied frequently using QSAR 
methods recently, attention has not been sufficiently paid for rare and/or serious 
ADRs while some of them are highly attributed by drugs and could be life-
threatening. Hence three types of rare and/or ADRs were investigated in this 
study including Stevens Johnson’s syndrome/toxic epidermal necrolysis 
(SJS/TEN), Torsade de pointes (TdP), serious psychiatric ADRs. SJS/TEN and 
TdP are selected instead of other  rare and serious ADRs because they are typical 
examples of designated medical event, which is a rare and serious ADR with a 
significant proportion of the occurrences caused by drugs [48, 49]. Moreover, 
they are often caused by drugs used to treat common diseases such as antibiotics, 
antimalarial and anticonvulsants, yet attention has not been sufficiently paid to 
these ADRs so far [50]. TdP has been studied by some researchers but the 
development procedures do not fully comply with the recent OECD guidelines 
and our study will address the limitations of existing models. The SJS/TEN study 
is the first QSAR study for the rare and serious ADR hence it is of great 
significance for the prediction of SJS/TEN causing potential of drugs.  Serious 
psychiatric ADRs are rarely studied by computational scientists probably due to 
the difficulties in evaluation and classification of the psychiatric ADRs and the 
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collection of the related data. However, a rapid and reliable alert of potential 
serious psychiatric ADRs will have great potential in clinical practice and 
regulatory work. In addition to these ADRs, a predictive study of nephrotoxicity 
was also carried out to explore the combinatorial study of predictive modeling 
using both QSAR and toxicogenomics (TGX) methods. This endpoint was 
selected because it has not been explored using integrative QSAR and TGX 
method yet. The data collection processes for three types of ADRs are similar 
while slight differences also exist such as different data sources for different 
ADRs and different classification criteria for the negative data which were 
adjusted based on the characteristics of given endpoints. Thus, the details of the 
data collection process were collectively presented in following sections. The data 
for nephrotoxicity study was collected from literature and public databases. 
QSAR models were developed for all of the endpoints and toxicity. Additional 
TGX models and integrative QSAR&TGX models were developed for 
nephrotoxicity. The data preparation process for nephrotoxicity study was 
described in details in Chapter 4. 
2.1.1. SJS/TEN 
2.1.1.1. Introduction 
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe 
cutaneous adverse reactions characterized by extensive detachment of epidermis 
and erosions of mucous membranes [51]. Although they are distinguished by the 
percentage of affected body surface area, more and more studies showed that they 
are the same disease with common causes and mechanisms, so they are mentioned 
together as a collective term SJS/TEN in this study [52]. SJS/TEN has a great 
impact on public health because of significant mobility and mortality associated 
with it [53, 54]. Although the etiological factors of SJS/TEN are diverse, 
including infections and genetic factors, the major cause is still medications [55].  
A difficulty with the determination of the causality of rare and severe 
ADRs is that they are seldom detected during clinical trials due to the rarity of 
such events and the small number of patients enrolled in such trials. Hence, these 
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ADRs are usually identified only through post-marketing surveillance (e.g. case 
report literature) [56, 57]. This is not ideal as a large number of patients may be 
exposed to a potentially harmful drug and a lot of time and money had already 
been invested on the drug. This prompts the investigation of methods which can 
determine the propensity of a drug candidate to cause such ADRs as early as 
possible during drug development. QSAR method which has been applied to 
predict a wide range of chemical and biological properties is a suitable method 
[17, 18]. 
2.1.1.2. Data preparation 
A total of 1127 marketed drugs listed in the FDA Orange Book were screened for 
their potential in causing SJS/TEN using online database Micromedex Healthcare 
Series [58]. Drugs with clinical studies and/or case reports of causing SJS/TEN 
were identified as ST
+
. It is difficult to reliably identify drugs that do not cause 
SJS/TEN (ST
-
). Thus only ST
+
 drugs will be used to develop the prediction 
models to prevent misclassification of drugs from affecting model quality. 
However, it is still essential to identify tentative ST
-
 drugs so that the performance 
of the prediction models could be measured. Hence, drugs which had no clinical 
studies and case reports of SJS/TEN or similar symptom erythema multiforme 
(EM), and had been used by a large number of patients were tentatively identified 
as ST
-
. Determination of whether the drugs had been used by a large number of 
patients was performed by checking the drug indications (the drugs should be 
used to treat common diseases such as flu, diabetes, hypertension, bacterial 
infection etc.) and the time in market (at least 30 years). The chemical structures 
of these drugs were obtained from drug databases such as PubChem and verified 
with the standard drug structures provided by the WHO International Non-
proprietary Names drug list to ensure the structures were correct [59, 60].  
2.1.2. TdP 
2.1.2.1. Introduction 
Torsade de pointes (TdP) is an atypical rapid form of polymorphic ventricular 
tachycardia characterized by a gradual change in the amplitude and twisting of the 
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QRS complexes around the isoelectric line [61]. TdP is potentially fatal due to the 
propensity for it to degenerate into ventricular fibrillation [62]. Although the exact 
incidence is not known, the awareness of drug-induced TdP in last few years has 
resulted increased number of spontaneous reports [63]. Some structurally 
unrelated drugs have been withdrawn from the market because of their TdP-
causing potential such as terfenadine, astemizole, grepafloxicin and cisapride [64]. 
Therefore, to minimize the risk of patients exposed to a harmful drug and the time 
and money spent on the development of such drugs, a fast and accurate 
assessment of the risk of a drug during preclinical studies to cause TdP is 
necessary. However, it is rather difficult to screen for drug-induced TdP during 
clinical trial due to its rarity [64]. Some biomarkers which are more easily 
observed have been associated with TdP risk [65]. Although the detailed 
mechanisms of drug-induced TdP are not completely known yet, most drugs that 
cause TdP prolong the QT interval on electrocardiogram, which is the time 
between the start of ventricular depolarization and the end of ventricular 
repolarization. This prolongation is believed to be caused by blocking cardiac 
potassium ion channels, specifically the rapid human Ether-à-go-go-Related Gene 
(hERG) K
+
 channel [66]. Therefore, the level of inhibition of the hERG K
+
 
channel and the symptom of QT prolongation were commonly used during drug 
development and by clinicians as surrogate markers to predict the risk of drug-
induced TdP [67, 68]. However, sufficient evidence has been provided that there 
is no clear and linear incremental relationship between hERG K
+
 channel 
inhibition or QT prolongation and the risk of TdP [69]. For example, 
procainamide and disopyramide cause TdP but are not potent inhibitors of the 
hERG K
+
 channel, whereas verapamil and ziprasidone causes QT prolongation 
but not necessarily TdP [70, 71]. It was proposed that these discrepancies could 
be due to the blocking of multiple ion channels so a simple correlation with single 
channel might not provide a good prediction [65]. Thus, it is necessary to develop 
a specific method capable of predicting the TdP-causing potentials of drugs 
without complete knowledge of the mechanisms.  
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2.1.2.2. Data preparation 
 The data collection and curation process is similar to SJS/TEN study. A 
total of 1127 marketed drugs listed in the FDA Orange Book were screened for 
their TdP-causing potential using the drug information resource Micromedex 
Healthcare Series and the specific QT drug database ArizonaCERT [25, 26, 72]. 
Drugs with clinical studies and/or case reports of causing TdP were identified as 
TdP
+
. Similar as the criteria used for classifying ST
-
 drugs, drugs which had no 
clinical studies and case reports of TdP or similar symptom (QT prolongation, 
ventricular tachycardia or ventricular fibrillation etc.) and had been used by a 
large number of patients were tentatively identified as TdP
-
.   
2.1.3. Serious psychiatric ADRs 
2.1.3.1. Introduction 
Psychiatric ADR is reported as the second most common ADR type 
following gastrointestinal tract ADR in a general practitioners survey in Italy [73] 
and is the third most common ADR type in New Zealand [74]. Psychiatric ADRs 
include depression, hallucination, psychosis, delirium, suicidal thoughts etc. They 
may be induced by drugs used to treat neurological and mental disorders as well 
as by drugs prescribed for the treatment of diseases affecting other organ-systems 
[75], such as antibiotics [76], anti-inflammatory drugs [74], antiobesity drugs [77] 
and antiviral drugs [78]. Serious psychiatric ADRs can be life-threatening and 
have caused withdrawal of drugs, such as triazolam [79] and rimonabant [80], 
from the market in some countries. In March 2007, the Japanese government 
restricted the use of anti-influenza drug oseltamivir in patients aged 10-19 years 
due to serious psychiatric ADRs [81]. Conventionally, the potential of drugs to 
cause serious psychiatric ADRs were determined from clinical trials which are 
costly and time consuming. This study aims to determine the prevalence of 
serious psychiatric ADRs amongst marketed drugs, and to develop a QSAR 
model to predict the potential of a drug to cause serious psychiatric ADRs.   
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2.1.3.2. Data preparation 
Similar as SJS/TEN and TdP studies, a total of 1127 marketed drugs were 
screened for their potential to cause serious psychiatric ADRs. Serious psychiatric 
ADRs were defined as those critical terms that are listed in WHO adverse reaction 
terminology (WHO-ART) for psychiatric disorders (code 0500 for the system-
organ class). A requirement for computational modeling is that there should have 
sufficient number of drugs causing a particular serious psychiatric ADR. 
Otherwise, it will be difficult for the computational model to identify those 
aspects of a drug’s structure that may predispose it to cause a particular serious 
psychiatric ADR. Hence, in this study, each serious psychiatric ADR was required 
to have a minimum of 50 drugs that are known to cause it before it was included 
into the model. In the end, seven serious psychiatric ADRs were considered 
including depression, hallucination, psychosis, aggressive reaction, suicide 
attempt, delirium and manic reaction. The drugs that were associated with these 
ADRs were classified as PADR+. 
Similar as SJS/TEN and TdP study, to reduce the possibility of identifying 
a wrong drug with no serious psychiatric ADRs (PADR-), drugs which had no 
case reports of any psychiatric ADRs and had been used by a large number of 
patients were tentatively identified as PADR-. 
2.2. QSAR process 
2.2.1. Introduction 
QSAR is the process of applying mathematical and statistical methods to establish 
and explore the relationship (QSAR models) between chemical structures and 
biological activities of a group of compounds. It provides an efficient and 
effective solution for the prediction of biological activities of compounds based 
on their chemical structures. Formally, a QSAR model can be expressed in a 
generic format as below: 




Where X1, X2,…,Xn are molecular descriptors of compounds, Yi are the 
targeted physiochemical or biological properties and f is the established 
mathematical function between the two. The relationship between values of 
descriptors X and target properties Y can be constructed using simple linear 
method such as multiple linear regression (MLR) method. However, the 
relationship between chemical structure and biological activity is often complex 
and nonlinear, so nonlinear machine learning methods such as k-nearest neighbor 
(KNN), support vector machines (SVM) and artificial neural networks (ANN) are 
usually used to establish the relationship (QSAR models). Taking KNN method as 
an example, the descriptor values are used to characterize the similarities between 
compounds, which are then used to compute the chemical properties of interest 
without linear assumption of the data. The underlying foundation of all QSAR 
studies is from medicinal chemistry which is that structurally similar compounds 
are supposed to have similar biological activities [82]. Therefore the main purpose 
of QSAR modeling is to establish a relationship between descriptor values and the 
biological activity of interest and use this relationship to predict the biological 
activity of unseen compounds without the carrying out the actual experiments. 
2.2.2. Data curation  
Similar to other statistical learning process, the quality of QSAR model is highly 
dependent on the quality of the data which is used to derive the model so data 
curation is critically important for QSAR modeling [83]. Since the molecular 
descriptors were calculated from the chemical structures of the compounds, 
incorrect compound structures will affect the model’s performance and cause 
wrong predictions in the end. It was reported that the error rates in some large 
chemical databases could be up to 3.4% [83] and around 10% of the compounds 
for some public datasets should either be removed or examined carefully before 
usage [84]. The chemical structures of all the compounds used in this study were 
downloaded from PubChem [85] and the data curation steps carried out in this 
study are presented as below. 
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1. Remove compounds which contain inorganic atoms as an essential part of the 
drug (e.g. cisplatin) or are macromolecules such as peptides and 
polysaccharides, as most molecular descriptor calculation programs are unable 
to handle them. This step was carried out by running script programs to 
identify the compounds with inorganic atoms. 
 
2. Standardize the structures of compounds by removing salt, adding hydrogen 
atoms and normalizing the nitro groups in the compound structures. Without 
normalization, different types of nitro group representation will cause 
different descriptor values to be calculated. Several software programs are 
available for this step and some of them are free (or free to academic) such as 
OpenBabel [86] and PaDEL-Descriptor [87] etc. Different versions of 
PaDEL-Descriptor were used throughout the study. 
 
3. Remove duplicates. Duplicates will cause bias for the modeling process 
especially when the same compound is included in different classes. In this 
study the duplicates were identified as the compounds with exactly the same 
set of descriptor values and then removed.  
 
4. Besides the above steps, manual inspection is always carried out during the 
processes to check for any problems. 
 For all ADRs, the drugs collected were curated using above procedures. In 
the end, 255 ST
+
 drugs and 239 ST
-
 drugs, 103 TdP
+
 drugs and 157 TdP
-
 drugs 





respectively. All the information of the datasets 
could be found in the supporting information of the publications [88, 89] or from 
the PaDEL-DDPredictor website [90]. 
2.2.3. Molecular descriptors 
Molecular descriptors are numerical values obtained by well specified 
mathematical algorithms that characterize the structural and physicochemical 
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properties of a compound [91]. They are formally defined as “the final result of a 
logical and mathematical procedures which can transform chemical information 
encoded within symbolic representation of molecules into useful number or the 
result of some standardized experiment” [92]. There are various types of 
molecular descriptors available and they are essential for the measurement of 
molecular diversity [93]. Molecular descriptors are useful for QSAR and QSTR 
studies to look for the inherent relationships,  as well as other studies such as 
structure similarity analysis and substructures searching [92, 94].  
According to the description in the Handbook of Molecular Descriptors 
[92], molecular descriptors can be grouped into three broad categories according 
to the dimension of the molecules that the molecular descriptors are calculated. 
They are 1D (one dimensional), 2D (two dimensional) and 3D (three dimensional) 
molecular descriptors. 1D molecular descriptors consist of counts of different 
molecular groups, physicochemical properties of compounds etc. 2D molecular 
descriptors consist of information such as connectivity indices and counts of paths 
derived from the molecular graphs. 3D molecular descriptors were calculated 
based on geometric shape and functionality of molecules [95].  
 There are many software programs available for molecular descriptor 
calculation such as Dragon [96] and MODEL [97]. All the molecular descriptors 
for this study were calculated using our in house software PaDEL-Descriptor 
since it is free, fast and easy to use [87]. Since the studies were carried out at 
different time period, different versions of PaDEL-Descriptor were used with 
different number of descriptors. For SJS/TEN study, PaDEL-Descriptor version 
2.7 was used to calculate the molecular descriptors and fingerprints in this study. 
A total of 672 1D&2D molecular descriptors were calculated. For TdP study, 
PaDEL-Descriptor 2.11 was used and 722 1D&2D descriptors were calculated. 
For study of serious psychiatric ADRs, PaDEL-Descriptor 2.14 was used and 722 
1D&2D descriptors were calculated The current version PaDEL-Descriptor 2.18 
could calculate 905 descriptors (770 1D, 2D descriptors and 135 3D descriptors) 
and 10 types of fingerprints. The descriptors and fingerprints are calculated using 
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The Chemistry Development Kit with some additional descriptors and 
fingerprints. The detailed list of molecular descriptors is available in the PaDEL-
Descriptor website (http://padel.nus.edu.sg/software/padeldescriptor/). 
2.2.4. Data preprocessing 
Since most QSAR models are built using machine learning algorithms, whose 
performance are highly dependent on the input data, the quality and representation 
of the samples of the data is critically important [98]. The data preprocessing step 
is to remove the irrelevant and redundant features or noisy and unreliable samples 
in the data to facilitate the statistical learning or pattern recognition process in 
QSAR model development. The two basic and important data preprocessing 
methods, scaling and feature selection, were used in this study.  
2.2.4.1. Scaling 
Molecular descriptors are normally scaled before they can be employed for 
machine learning studies to ensure that each descriptor has an unbiased 
contribution in building the models. There are several scaling methods available 
such as auto-scaling, range scaling etc. In this study, range scaling is used to scale 
the molecular descriptor data with a minimum and maximum value of 0 and 1 
respectively. Range scaling (normalization) is carried out by dividing the 
difference between the descriptor value and the minimum value of that descriptor 
with the range of that descriptor. For some descriptors there might be a huge 
difference between the minimum and maximum values, e.g. 0.01 and 100. 
Normalization could scale down the descriptor value magnitudes to appropriate 
low values. This is important for many machine learning algorithms such as SVM 
and KNN algorithms [98].  
2.2.4.2. Feature selection 
In QSAR studies, the features are the molecular descriptors. Generally 
feature selection works by removing irrelevant or redundant features, so as to 
reduce the dimension of the data, improve computation speed, performance and 
interpretability of computational models. The main purpose for feature selection 
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method is to select a small set of features in order to reduce the time and memory 
cost of the modeling process, as well as to achieve an acceptably good model 
performance. Many different feature selection algorithms have been developed to 
select an optimal subset of features from a large set of available features [99]. 
Depending on whether the feature selection methods require the use of the 
modeling algorithm to evaluate the selected subset of features, they could be 
grouped into two broad categories: filter and wrapper methods [100].  
The filter method is independent of the modeling algorithm and is 
frequently used to remove redundant features or features with low information 
content, e.g., feature columns with constant values. For wrapper method, the 
modeling algorithm was used with the evaluation function for the feature 
selection process [98]. This can be achieved through exploration of the different 
combinations of descriptors and the corresponding evaluation performance of the 
model. Heuristic exploration methods include forward selection and backward 
elimination, as well as genetic algorithm and simulated annealing. In forward 
selection, one descriptor is added iteratively at each round of evaluation until a 
certain stopping criterion has been achieved. In contrast, backward elimination 
operates by removing descriptors one by one. The difference is that, because 
backward elimination initiates with the full set of descriptors, it usually takes a 
longer computation time and is more likely to deliver a bigger set of selected 
descriptors.  
Both filter and wrapper methods were employed in this work including 
removing descriptor columns with constant values and forward selection in the 
modeling process.  
2.2.5. Model development 
In this study, all computational models were developed using RapidMiner [101], 
an open-source software with a large collection of computational methods for data 
analysis and model development. Since only classification models were 
developed in this study, we focus on machine learning algorithms for 
classification problems. Machine learning methods apply mathematical and 
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statistical algorithms to develop models to find inherent relationships or patterns 
from training data and then make prediction on independent test data. Depending 
on the desired outcome of the algorithm, most machine learning methods could be 
divided into two broad categories: supervised and unsupervised learning. 
Supervised machine learning generally requires labeled training data to produce 
an inferred function that relates inputs to desired outputs. Common supervised 
machine learning algorithms includes naïve Bayes, support vector machine, 
artificial neural network etc. Unsupervised machine learning does not require 
labeled data and it works by finding the inherent pattern of data. Examples of 
unsupervised machine learning algorithms include clustering, self-organizing map 
etc. Only supervised methods were employed in this study for model development 
since all the data are labeled already. The binary classification algorithms 
involved in this study were described in details as below. 
2.2.5.1. Support vector machine 
SVM is defined as “a supervised learning method used for classification and 
regression tasks based on the structural risk minimization principle of statistical 
learning theory” [102]. For binary classification cases of linearly separable data, 
SVM generates a hyperplane to separate positive and negative classes of 
compounds with a maximum margin. Suppose a compound is represented by a 
vector xi composed of its molecular descriptors. The hyperplane is optimized by 
finding a normal vector w and a parameter b that minimizes ||w||
2
 (i.e. maximizing 
the margin 
 
     
) with some linear constraints. For classification of nonlinearly 
separable data, which is common for some QSAR studies that classify compounds 
with diverse structures, SVM uses kernel transformations to project the input 
vectors into a higher dimensional space where the compounds could be linearly 
separated.  
SVM is reported to have lower risk of over-fitting and less affected by 
sample redundancy [103], so it has been applied in various machine learning 
studies. SVM is of particular interest for QSAR studies because it classifies 
compounds based on the separation of positive and negative compounds in a 
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hyperspace represented by their physicochemical profiles instead of structural 
similarity to positive compounds [104]. Moreover, it has the advantage for 
classification of compounds with limited information on the mechanism or 
specific relationship between the molecular structures and activities [35, 105]. 
SVM shows consistently outstanding classification ability in toxicity and ADR 
prediction, such as TDP causing potential [17], hepatotoxicity [40] and many 
other toxicological endpoints for compounds with diverse structures.  
2.2.5.2. K-nearest neighbor  
K-nearest neighbor (KNN) is amongst the most fundamental and simple 
classification method [106]. KNN works by measuring the distance (Euclidean 
distance, Manhattan distance etc) between a given sample and each sample in the 
training set. The class of the unseen sample will be determined by the majority of 
the class of the k training samples nearest to the given sample. It is important to 
optimize the number k during model development and an odd number k (k = 1, 3, 
5, 7, etc) is usually chosen to prevent ambiguity in the prediction. KNN has been 
applied in various QSAR studies [107, 108]. In this work, KNN was used in the 
experiment for model evaluation method in Chapter 7 to obtain diverse types of 
classification models. 
2.2.5.3. Artificial neural network 
Artificial neural network (ANN) is a supervised machine learning method 
inspired by biological neural networks. ANN works by training a hidden-layer 
containing network and using the interconnected structure to establish the 
complex relationship between inputs and outputs. A common ANN consists of 
three layers as illustrated in Figure 2.1, in which the circular unit represents an 
artificial neuron and the arrow represents a connection between the neurons. The 
“input” layer is connected to “hidden” layer, which is then connected to “output” 
layer. Because of its strong ability to learn relationship from complex or noisy 
data, ANN is usually used for modeling complex relationships or exploring 
patterns in data that could not be accomplished by other computational algorithms. 
ANN has been applied in many QSAR studies [109, 110]. In this work, ANN was 
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used in the experiment for model evaluation method in Chapter 7 to obtain 
diverse types of classification models. The ANN method in RapidMiner builds a 
model using a feed-forward neural network with backpropagation learning.  
 
Figure 2.1 An example of a simple feed forward network. 
2.2.5.4. Naïve Bayes 
Naïve Bayes (NB) is a type of supervised learning algorithms derived from the 
well-known Bayes’ theorem with the assumption that the features (i.e., molecular 
descriptors in QSAR) are independent with one another. In the training stage, NB 
classifiers build a simple probabilistic model between the molecular descriptors 
and the class label, after which the most likely class of an unknown compound 
could be inferred using Bayes’ theorem. Despite the fact that NB method is based 
on over-simplified conditional independence assumptions, NB classifiers 
outperform more sophisticated classification algorithms in many studies [111]. 
Besides, since the model parameters of NB classifiers could be estimated from a 
small set of data and the independence assumption alleviates the problem of high 
dimensionality, NB classifiers are simpler and faster than many other machine 
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learning methods.  In this work, NB was used in the experiment for the AD 
method in Chapter 5 for its simplicity and efficiency. 
2.2.5.5. Random forest 
Random forest (RF) is an ensemble learning method for classification and 
regression that works by building a number of decision trees on various subsets of 
samples of the dataset [112]. For classification problems, the final output class is 
determined by majority voting of the outputs from individual trees which is to 
reduce over-fitting and improve the prediction performance. RF could be applied 
on dataset with large number of samples and features and it is less affected by the 
noise of data [112]. RF has been applied in many QSAR studies and was 
recommended for QSAR modeling because of its relatively high prediction 
performance and other advantageous properties [113, 114]. In this work, RF was 
used the experiment for the AD method in Chapter 5 for its robust prediction 
performance and efficiency. 
2.2.6. Model validation/evaluation 
The ultimate purpose for developing a QSAR model is that it could be applied on 
unseen compounds to predict the targeted properties. It is therefore important that 
QSAR models are rigorously validated for the accuracy and reliability of its 
prediction. This is usually achieved by using either internal validation (e.g. cross 
validation) or external validation (use of an external dataset). Although external 
validation is preferred since it could capture the real performance of the model on 
unseen data, it is not always possible because of the small size of the dataset [115], 
which is common for a lot of QSAR studies. Hence internal validation such as 
cross validation plays an important role in QSAR studies. 
2.2.6.1. Validation set and cross validation 
During the model development process, the model need to be evaluated on an 
testing set to facilitate the tuning of the parameters of the algorithms used for 
modeling or selection of models. Therefore, the data used for modeling need be 
further split into another training set and testing set (internal validation). To make 
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use of all data and avoid bias of single round of testing, many internal validation 
methods were developed such as random split validation, cross-validation and 
bootstrapping etc. Cross validation is a statistical method used to evaluate and 
compare models’ performance and it was used throughout this study. For 5-fold 
cross validation, the training set is divided into five subsets with approximately 
equal size. A model will then be trained with four subsets of data, after which the 
performance of the model is tested with the 5th subset. This process repeats five 
times so five models are developed and every subset is used as the testing set once. 
The average of the performance of the five models is the performance of the 
model for the 5-fold cross validation. This result could be used to tune the 
parameters to optimize the preprocessing or modeling algorithms or to compare 
models’ performance. 
The optimal model parameters obtained from internal validation can then 
be used to build a final model using the entire data set. A model usually will 
perform well on the dataset used to train it since it will remember the relationship 
of the features and labels and this may cause over-fitting. Hence, to test the 
model’s real performance, an external set which has not been used in the training 
process is needed. This dataset, which could be a new dataset or a subset of data 
held out before model development, is called validation set (external validation).  
The prediction performance on this set further indicates the real performance of 
the model. However, the external validation result is expected to be different from 
the cross validation result. Studies have shown that the cross validation result may 
not correlate well the external validation result [116]. The external validation 
result may not be as good as that for cross validation [35]. Nevertheless, for a 
good model with low risk of over-fitting and good generalization power, the 
external validation result should not deviate too much from the cross validation 
result. 
2.2.6.2. External cross validation 
In QSAR studies, usually an independent validation set is used to evaluate the 
performance of the model. However, in this study, to fully utilize the available 
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data, the entire dataset was used to develop the model. Thus, in order to more 
rigorously validate the final model, the external cross validation approach 
proposed by a group of QSAR experts was used [117]. This validation approach 
involves repeating the whole model development process stated above n times 
using different and complementary pairs of training and validation sets. Suppose n 
is set as 5. Firstly, the whole dataset was randomly divided into five subsets of 
approximately equal size. Then, one subset was selected as the validation set and 
the remaining four sets as training set. For example, in run 1, subset 1 was taken 
as validation set while the remaining four subsets are taken as the training set. The 
training set was subsequently used to develop models using exactly the same 
approach used to develop the model using entire dataset. The validation set, which 
was not used in the model development process, was used to estimate the 
prediction ability of the best model. This process was repeated for five times until 
all subsets had been used as validation sets and five sets of model performances 
were obtained. Finally, the average of the five set of model performances was 
used to estimate the performance of the final model.  
2.2.7. Applicability domain 
Ideally, QSAR models should only be used to make predictions within its AD, 
which could be regarded as a defined boundary for the model. The prediction 
abilities for compounds that are within the boundary (within AD) are estimated by 
the training set, cross-validation and validation set. The prediction abilities for 
compounds that are outside the boundary (outside AD) are the same as that of a 
random model.  
Currently, there are no optimal methods to determine the AD for a model. 
For qualitative method, usually a common threshold is used to define the AD for 
the model. For quantitative methods, there are range method, distance-based 
method, Hotelling T
2
, leverage, geometric method and probability density 
distribution method [118]. All these methods define the AD based on the training 
set and are independent of the modeling methods. An AD method was developed 
in this study and will be introduced in details in Chapter 5. 
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2.2.8. Ensemble modeling 
Usually, after model development, the best performing model on the training data 
was selected for making prediction in the future. However, it has been suggested 
that individual models may overemphasize, underestimate or even ignore some 
features [119]. An ensemble model combined by multiple models may reduce the 
risk of using an inappropriate model and hence provide more reliable predictions 
[42, 120-124]. Ensemble method or consensus modeling is a technique introduced 
to modeling studies to improve the performances of individual (constituent) 
models (sometimes referred as base models or classifiers) [39]. The multiple 
models could be generated by sampling different training sets using methods like 
bagging and boosting, or from the same training set but with different subset of 
features, or from the same training set and same feature groups but using different 
modeling algorithms.  
Intuitively, ensemble model is supposed to work better than individual 
models since it has been a protective mechanism in human decision-making to 
combine diverse and independent opinions (e.g. stock portfolio) [125]. 
Theoretically, it was discussed that ensemble model may outperform single 
models for three reasons: statistical, computational and representational reason 
[126].  For statistical reason, the training dataset might be too small compared to 
the size of the information space required for the problem, hence combination of 
the base models by aggregating their results could reduce the risk of selecting a 
wrong model [126]. For computational reason, the statistical learning algorithm 
might stuck in local optima so base models could not produce the best solution of 
the problem. It is especially common for algorithms such as ANN and decision 
tree where it is computationally infeasible to obtain the best model. Hence an 
ensemble model constructed by combing models from different starting points 
might have a closer approximation of the true relationship than base models [126]. 
For representational problem, when the true relationship cannot be captured by 
any of the base model, ensemble model is likely to increase the representation 
space by taking aggregated results from individual model’s space [126]. 
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Due to above reasons, ensemble methods have been regarded as a 
powerful tool for improving the robustness as well as the accuracy of machine 
learning problems. In the past several years, ensemble method have applied and 
demonstrated its advantage in considerable number of studies in various areas, 
including recommendation systems, anomaly detection, text mining and web 
applications [125]. For a number of QSAR studies, ensemble model has been 
demonstrated to outperform the best performing model as well [40, 122-124, 127]. 
In this study, two model selection methods were introduced to develop ensemble 
models and will be introduced in details in Chapter 6. 
2.2.9. Performance evaluation 
The following statistics are usually calculated to determine the predictive 
capability of a QSTR model: sensitivity (SE), specificity (SP), accuracy (ACC), 
Area under curve (AUC) values and Matthew's correlation coefficient (MCC). 
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TP is the number of true positives and FN is the number of false negatives. 
Similarly, TN is the number of true negatives and FP is the number of false 
positives. Sensitivity and specificity are the classification accuracies of a model 
for the positive and negative data classes respectively. Overall accuracy (ACC) is 
the classification accuracy of the model for the entire data. The limitation of the 
overall accuracy is that for imbalanced data, the overall accuracy might be high 
even if either sensitivity or specificity is low. Hence sometimes AUC and MCC 
are preferred as a single value to evaluate the model’s performance. AUC value is 
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a single scalar value representing the classifier’s performance instead of two-
dimensional ROC curve [128]. The AUC value is equivalent to the probability 
that the classifier will rank a randomly chosen positive instance higher than a 
randomly chosen negative instance. Thus a good classifier usually has AUC value 
larger than 0.5.  MCC value is from −1 to 1, with C = 1 indicates the best possible 
prediction in that every sample was correctly predicted and C = -1 where every 





























Chapter 3 One-Class Classification 
This chapter is to address the first issue of the QSAR workflow in Chapter 1: lack 
of negative data, by introducing and applying one-class classification (OCC) 
methods. Three OCC methods were introduced including one-class SVM, one-
class local outlier factor (LOF) and one-class probability density (PD). SVM, 
LOF and PD methods have been used intensively in machine learning studies for 
various purposes whereas this is the first time that they were used to build one 
class QSAR models. Three QSAR studies using OCC methods to develop models 
to predict the potential of drug candidates to cause SJS/TEN, TdP and serous 
psychiatric ADRs were investigated to demonstrate the potential of OCC methods. 
3.1. Introduction 
Binary and multiple classifications have been popular methods in predictive 
modeling to build classification models for categorical endpoints. For most of the 
classification tasks such as recognition of digits, prediction of consumers’ 
behavior or classification of inhibitors and non-inhibitors in QSAR study, data 
with well-defined classes are usually available to train the model. However, 
sometimes only one class of the data is readily available and other classes are 
difficult, expensive or even impossible to characterize or obtain. For example in 
clinical area, suppose patients with healthy kidneys are regarded as positive 
samples. Then positive samples are easy to identify (e.g., patients with no kidney 
disease) whereas the negative samples are expensive, time-consuming and might 
pose risks to the health of patients as most of such tests are invasive [129]. 
Another case is the examination of mammograms in radiology, most of the 
mammograms are normal and only 0.58% of the cases are cancerous [130]. 
Normal mammograms share similar pattern while abnormal ones usually have 
random patterns so they are more difficult to characterize than normal ones. In 
QSAR related research area such as ligand-based virtual screening studies, lack of 
negative data has also become a common problem  [35]. The reason might be that 
inactive compounds should be collected in the same conditions as for the active 
ones, but usually information on inactive compounds is not available or is too 
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limited compared with the active class [131]. Although some novel methods have 
been proposed to create putative negative data using different rules, there are still 
limitations since the putative negative samples may be real positive [131]. 
Similarly, in classification studies for drugs with potential for causing certain 
ADRs, positive drugs that cause the ADR could be identified from the case report 
or literature while drugs with no potential of causing the ADR is hard to confirm, 
since some ADRs may take a long time to occur or they have not been reported 
yet. As a result, limited availability or clarity of the negative data becomes a 
problem in classification studies. For such cases, application of standard binary is 
inappropriate when the negative data is not rigorously defined.  
 To address this issue, one-class classification (OCC) method which could 
train a classifier to distinguish one class from the other classes given only one 
class of data could be used. Compared with binary classification methods, OCC 
methods could reduce the computation time and memory space, because only 
positive data are used to train the model [132]. OCC methods could also produce 
comparable or better results than binary classification methods for the same 
problem [133, 134]. OCC methods have been applied in various studies such as 
document classification [46] and network intrusion detection [47] with different 
purposes including outlier analysis and anomaly detection. Nevertheless it has not 
been explored much in QSAR studies yet, especially for the prediction of ADRs 
and toxicity assessment. In one recent study, OCC method was used to create a 
virtual screening system based on auto-encoder neural networks and was 
suggested as a powerful post-processing technique of ligand based virtual 
screening [131]. In our study, the OCC method was applied to develop QSAR 
models to distinguish the positive data with the “negative” data. The general 
principle is, given a set of data to train a model, OCC algorithms will determine 
whether the new sample is in the same class as the training data (positive class) or 
not (negative class). To obtain a diverse set of prediction models, three OCC 
algorithms, one-class support vector machine (OCSVM), one-class local outlier 
factor (OCLOF) and one-class probability density (OCPD) algorithms were 
applied in this work. 
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3.2. Materials and methods 
3.2.1. OCC methods 
3.2.1.1. One-Class Support Vector Machine 
As introduced in Chapter 2, conventional two-class SVM or binary SVM 
methods have been applied intensively in QSAR studies [17, 135, 136]. OCSVM 
is an extension of the original two-class SVM learning algorithm and was first 
proposed by Schölkopf et al  [137]. OCSVM method is able to train the classifier 
based on the information of only one class of data so it is quite suitable for 
classification problems with only one well-defined class. OCSVM was originally 
applied for outlier detection by finding data that are different from most of the 
data in a given dataset [129].  To separate the outliers from the remaining data 
points, the data was mapped into a high dimension feature space, then a 
hyperplane is iteratively found that best separates the data points from the origin 
with maximum margin [138]. The principle is the same for classification 
problems with the training data as the “normal samples”. The basic principle of 
OCSVM is illustrated in Figure 3.1. The circle labeled with ‘+’ and ‘-’ indicate 
positive and negative data respectively. The origin is regarded as belong to 




Figure 3.1 Graphical illustration of one-class SVM 
Briefly for the training stage, OCSVM model was developed by finding the 
optimal margin support or the ‘boundary’ that incorporate most of the training 
data based on the positive data only [139]. Then for the prediction stage, if the 
sample in the testing set fell within the boundary then it was classified as positive 
class, otherwise it is classified as negative class. As in the case for binary SVM, 
for non-linear cases the kernel function was applied to transform the data to a 
higher dimensional space, allowing more complicated cases to be handled by 
OCSVM [132]. OCSVM has been widely used in various real world applications, 
such as the aforementioned mammogram detection, protein fold recognition, 
diagnosis of attention-deficit hyperactivity disorder (ADHD) [45], faulty 
detection and text categorization [140] etc. There are different versions of 
OCSVM implementations and the OCSVM function in LibSVM was used in this 
study [141].  The most popular kernel function radial basis function (RBF) and 
default parameters were applied for computation efficiency. 
3.2.1.2. One-Class Local Outlier Factor  
Local outlier factor (LOF) is an outlier detection algorithm proposed by Breunig 
et al [142]. The key idea of LOF is to compare the local density of a sample's 
































reachability density. Based on the average ratio of the local reachability density of 
a sample and its k-nearest neighbours (e.g. the samples in its k-distance 
neighbourhood), the LOF value is then computed as the indicator of the degree of 
the object being outliers. The samples with a LOF value beyond a certain 
threshold are considered as outliers.  A simple illustration of the basic idea of 
LOF is shown in Figure 3.2. For better visualization, object p and its three nearest 
neighbours are marked in black and the remaining objects are marked in grey. The 
object p has a much lower density than its neighbours because it lies some 
distance away from a cluster of objects C. The number of neighbours k was set as 
3 for ease of understanding.  
 
Figure 3.2 Graphic illustration of basic idea of LOF. 
 A brief description of the workflow LOF algorithm is presented as below. 
A more detailed version could be referred to the original paper [142].  Basically 
there are four steps: 
i. For each sample p, the k-distance distk (p) and k-distance neighborhood 









nearest neighbor. Nk(p) is the set of k nearest neighbors of p, which could 
be bigger than k since multiple objects may have identical distance to p.  
Nk(p) = {q| q in C, dist(p, q) ≤ distk(p)} ( 3.1) 
ii. Then the reachability distance of p from q could be defined as: 
reachdistk (p,q)=max{distk(p), dist(p,q)}  ( 3.2) 
where dist(p,q) is real distance from p to q. 
iii. The local reachability density of p is defined as:  
    ( )= 
   ( ) 
∑           (   )    ( )
 ( 3.3) 
which is the inverse of the average reachability distance of the object p 
from its neighbors. 
iv. The local reachability density of p is then compared with those of the k 
nearest neighbors using 
LOFk(p) = 
∑
    ( )
    ( )
    ( ) 
   ( ) 
  ( 3.4) 
 
which is the average local reachability density of the k nearest neighbors 
divided by the local reachability density of sample p. The lower the local 
reachability density of p, and the higher the local reachability density of the k 
nearest neighbors of p, the higher LOF is. A LOF value of 1 indicates that the 
object is comparable to its neighbors and thus not an outlier. A value less than 1 
indicates a higher density so the object is normal whereas LOF value significantly 
larger than 1 indicates the object is likely to be an outlier. 
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LOF algorithm or its modified version has been used as a common tool in 
outlier detection and fault detection studies [143]. Moreover, it has been 
demonstrated by established comparison studies that it could outperform other 
similar outlier detection algorithms such as distance based outlier detection 
method and unsupervised SVM algorithm in network intrusion detection study 
[144]. However, it has not been explored much as a classification method for 
prediction of unseen data. In this study, it was used to classify the normal class 
(positive data) from outliers (negative data).  During the application, only the 
positive class was used to compute the LOF and the samples with a LOF value 
larger than a certain threshold are considered as outlier (negative data). 
3.2.1.3. One-Class Probability Density 
Probability density (PD) estimation is a statistical technique used to construct an 
estimation of the distribution of the underlying population based on available data. 
Similar as LOF method, PD method is commonly used for outlier detection based 
on the density distributions of the data [145]. Recently, PD method has been 
increasingly explored to solve machine learning problems [146]. The PD based 
approaches are of particular interest for their low time complexity of either  O(n) 
or O(nlogn) (n is the sample size) when constructing an estimator [147]. When 
PD was used for classification purposes, the class of the testing sample is usually 
based on estimating the density for each of the classes. A recent study which 
compared PD method with SVM has shown that PD based classifier was capable 
of delivering the same level of prediction accuracy in addition to several 
distinctive advantages [148]. PD based binary classification method  has been 
applied in prediction of biological activities of compounds recently [149]. It is 
suggested that it can deal with both noisy data and sparse data and it is possible to 
apply the method to datasets with large number of compounds. Therefore, PD 
based methods could be favorable choice for applications that involve large and 
complex datasets or databases [147]. 
 In our study, PD method was used for OCC. The OCPD method 
developed the classification model by calculating the density value for each 
42 
 
sample which correlates with the probability that the sample belongs to the dataset. 
The lower the probability is, the more likely that the sample is an outlier 
(negative).  Only the positive class was used to generate the density distribution. 
A proportion or threshold value was set and the samples beyond the proportion or 
the threshold value were considered as outliers.   
3.2.2. Application of OCC methods in real studies 
3.2.2.1. General modeling workflow 
All models were developed and optimized using the open source software, 
RapidMiner [150]. The general workflow of model development and validation 
process is shown in Figure 3.3. The “model development using entire dataset” 
process produced the final model and the “external 5-fold cross validation (CV)” 
process estimated the performance of the model. Despite the difference of the 
datasets used to train the model, the same model development procedure was used 
in both processes. The process in the dash line rounded rectangle shows the 
detailed steps for model development, which is the same for both final model 
development using entire dataset and external 5-fold CV process. In this chapter, 
only the model development process in the dash line rounded rectangle was 
covered. The remaining part including the AD determination and ensemble model 










Figure 3.3 General workflow of model development and validation. 
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3.2.2.2. Model development 
To generate diversity among the base models, different descriptor subsets and 
different modelling methods were used. The different descriptor subsets were 
obtained using a modified forward selection process. The modification involved 
an initial random selection of a descriptor pool from the entire descriptor set. A 
predictive subset of descriptors was then selected from this descriptor pool using 
the forward selection method. During the forward selection process, models were 
developed using different algorithms and evaluated by calculating their MCC 
value using a 5-fold internal CV process in order to identify relevant descriptors. 
The modified forward selection process was repeated 100 times to produce 100 
models with different descriptor subsets for each modelling method. These 
models are regarded as base models. The three OCC methods, OCSVM, OCLOF 
and OCPD were employed to develop base models. The AD of each base model 
was defined using the double thresholds method described in Chapter 5. To 
characterize the models, several statistical measures were used to evaluate 
prediction performance of the models including accuracy, sensitivity, specificity, 
AUC and MCC values.  
 After model development, to prepare a candidate model pool for ensemble 
model development, the based models were screened using two criteria to remove 
the weak models. These include cut-off values for sensitivity and specificity for 
both training performance and internal CV result to remove base models with 
poor performance and cut-off value for the difference between MCC values of 
training performance and internal CV result to reduce the chance of base models 
to be over fitted. After that, the best performing model with the highest MCC 
value for internal CV performance was selected as the best base model (BM). 
Then a subset of the remaining models was selected using certain model selection 
algorithms to obtain the best ensemble model (EM). Although the EMs were the 
final models to be delivered at the end of all studies, the performances of the BMs 
directly reflected the classification ability of OCC methods. Therefore, this 
chapter will only focus on the best performing BMs in the model pool to 
investigate the prediction ability of OCC methods. The detailed model screening 
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criteria, ensemble model development process and the final performances of the 
best EMs will be covered in Chapter 6.  
3.2.2.3. Model validation 
The rigorous external 5-fold CV process introduced in Chapter 2 was used to 
evaluate the final ensemble model EMall. In the first step, EMall was developed 
according to the base and ensemble model development process aforementioned 
using entire dataset. Then an external 5-fold CV was carried out on the same 
dataset, resulted in five pairs of training sets (Trainn, n=1, …, 5) and validation 
sets (Validationn, n=1,…,5). For each CV run, an ensemble model (EMn, n=1,…,5) 
was developed for each training set using the same model development process as 
EMall and then validated by the corresponding validation set. The performance of 
EMall was then estimated using the external 5-fold CV result which is the average 
of the five set of performances (Performancen, n=1, …, 5) of five ensemble models 
from the five CV runs. In addition, if there are independent external dataset 
available, the final model EMall was further evaluated using the external 
validation set. It is important to note that the external 5-fold CV was used solely 
to measure the performance of the final ensemble model and was not used for 
descriptor selection or model selection. A separate internal 5-fold CV was used 
for those purposes.  
 The validation process for the best BMs was the same as EMs, except that 
for each run of the external 5-fold CV, the best BM was selected instead of the 
best EM. Therefore, there were five BMs and five sets of performance results for 
each study. 
3.3. Results  
3.3.1. SJS/TEN study 
During the rigorous validation process, the number of base models selected as 
qualified candidate models is from 16 to 64 for the five runs after applying two 
preprocessing criteria. The detailed performances on the training and validation 
set of the best BMs from the five runs are shown in Table 3.1. 
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Table 3.1 Performances of best base models from external 5-fold cross validation 
for SJS/TEN study. 





  71.1 75.5 66.5 0.422 0.708 
BM
2
  69.8 74.0 65.3 0.395 0.711 
BM
3
  68.3 56.1 81.5 0.387 0.7 
BM
4
  69.3 81.9 55.8 0.391 0.741 
BM
5
  66.9 71.4 62.1 0.337 0.708 





  53.5 51 56.3 0.072 0.555 
BM
2
  67.8 68.6 66.7 0.353 0.668 
BM
3
  61.9 46.0 78.7 0.261 0.648 
BM
4
  55.6 62.8 48.0 0.108 0.556 
BM
5
  59.2 70.6 46.8 0.179 0.594 
Average 59.6±5.6  59.8±10.9  59.3±13.5 0.195±0.114 0.604±0.052 
 
*
 The best base models are noted as BMn. n is the index of CV runs. 
3.3.2. TdP study 
The model development process was the same as the workflow presented in 
Figure 3.3. The validation method was also similar except that there was no 
external validation set available for this study. 
 During the rigorous validation process, the number of base models 
selected as qualified candidate models is from 38 to 76 for the five runs after 
applying the two preprocessing criteria. The MCC threshold is the same as 
SJS/TEN study while the criteria for sensitivity and specificity are sensitivity ≥ 
0.7 and specificity ≥ 0.7.  For sensitivity and specificity values, lower cut-off 
values such as 0.5, 0.6 were also tried but the performances of the ensemble 
models were poorer, probably due to the inclusion of low quality base models in 
the ensemble. Higher cut-off values will result in less candidate models so were 
not considered. For MCC value, 0.1 was used instead of 0.05 or 0.2 so as to 
achieve a balance between the number and quality of suitable candidate models. 
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The detailed performances on the training and validation set of the best base 
models from the five runs are shown in Table 3.2.  
Table 3.2 Performances of best base models from external 5-fold cross validation 
for TdP study. 
  Model  ACC(%) SE(%) SP(%) MCC AUC 
Training 
Performance 
BM1  85.4  88.0  83.6  0.706  0.899  
BM2  88.3  88.0  88.5  0.760  0.894  
BM3  74.9  39.5  97.6  0.483  0.801  
BM4  88.0  86.6  88.8  0.749  0.924  
BM5  89.4  82.9  93.7  0.777  0.924  
Average 85.2±5.9 77±21.1 90.4±5.4 0.695±0.121 0.888±0.051 
Validation 
Performance 
BM1  84.3  79.0  87.5  0.664  0.837  
BM2  78.0  60.0  90.0  0.535  0.697  
BM3  71.2  28.6  100.0  0.439  0.767  
BM4  72.0  70.0  73.3  0.428  0.771  
BM5  78.4  65.0  87.1  0.540  0.846  
Average 76.8±5.4 60.5±19.2 87.6±9.5 0.521±0.095 0.784±0.061 
3.3.3.  Serious psychiatric ADR study 
All models were developed and validated using RapidMiner 5.2 [150]. 
The model development process was the same as the workflow presented in 
Figure 3.3 for SJS/TEN study. For model validation process, besides the rigorous 
external 5-fold cross-validation, the final ensemble model was also validated 
prospectively. This is done by developing the final ensemble model using a 
dataset consisting of drugs that were marketed before 1999. Drugs that were 
marketed after 1999 and which causes serious psychiatric ADRs were then used 
as a prospective validation set to test the final ensemble model’s ability to predict 
“future” drugs.  
 After the rigorous validation process, the same criteria for sensitivity and 
specificity values in SJS/TEN study with sensitivity ≥ 0.5 and specificity ≥ 0.5 
was used to remove models with weak performance. The criterion for MCC 
difference was not applied in this study to retain enough models for ensemble 
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process. The number of base models selected as qualified candidate models is 
from 8 to 38 for the five runs after applying the screening criteria. The detailed 
performances on the training and validation set of the best base models from the 
five runs are shown in Table 3.3.  
Table 3.3 Performances of best base models from external 5-fold cross validation 
of the serious psychiatric ADR study.  
3.4. Discussion 
3.4.1. OCC methods 
OCC methods were used in this study instead of binary classification 
methods because it is difficult to confirm that a drug does not cause the given 
ADRs. Although strict selection criteria that the drug should have been applied on 
a large number of people (surrogated by requiring no case report of respective 
ADRs for drugs with long market period and indicated for common diseases) 
were used to identify negative drugs, these could not be considered as 
confirmatory. This is because a drug with no known case report of causing the 
ADR does not mean that it definitely has no potential of causing the ADR. It is 
possible that some drugs which are currently identified to be negative class could 
actually have the potential to cause the ADR since some rare ADRs such as 
SJS/TEN and TdP occur relatively rarely and such cases may not be reported or 
occurred yet. There have been instances of drugs which were only detected to 
cause TdP after they had been in the market for some time [151]. Therefore, in 
  Training set performance Validation set performance 
Model ACC(%) SE(%) SP(%) ACC(%) SE(%) SP(%) 
BM1 68.8 66.7 71.4 42.9 33.3 50.0 
BM2 78.4 73.7 83.3 37.5 40.0 33.3 
BM3 80 78.9 81.3 40.0 100.0 0.0 
BM4 100 100 100 44.4 16.7 100.0 
BM5 81.6 88.5 66.7 56.3 54.5 60.0 
Average 81.7±11.4 81.6±13 80.5±12.9 44.2±7.2 48.9±31.6 48.7±36.6 
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order to prevent such errors from affecting the quality of the QSAR models, only 
the positive drugs were used to train the models. If the two classes could be 
clearly defined for the data, binary classification method is a good choice. When 
only one class of the data could be confirmed, OCC methods are more reliable 
since no additional potentially wrong negative data is included. Therefore, one-
class models were more practical for clinical and regulatory purposes which 
reliability is a critical factor. Although there could be potential errors in the 
negative dataset, it is necessary to use it to evaluate the model’s performance. 
Otherwise, a useless model which predicts every drug as positive class will have 
100% accuracy.  
3.4.2. Performances of OCC models 
To the best of our knowledge, currently there are no available QSAR 
models for predicting the SJS/TEN-causing potential of drugs. Hence it is not 
possible to compare the performance of the model developed in this study with a 
similar study. Nonetheless, a tentative comparison could be made with QSAR 
models developed for other toxicological properties such as genotoxicity and 
hepatotoxicity [40, 121]. As shown in Table 3.1, the average accuracy values are 
approximately 69.1% and 59.6% on training and validation set respectively. 
Although they were lower than models for these well studied properties, the 
model could still be considered as useful since SJS/TEN is a very complex 
disease with multiple mechanisms affecting its occurrence.  
For TdP study, the result in Table 3.2 shows that the average sensitivity 
and specificity values for training and validation set are 77%, 60.5% and 90.4%, 
87.6% respectively. Compared with two similar studies of TdP using binary 
classification method which have sensitivity value 97.4% and 97%, specificity 
value 84.6% and 90% on validation set respectively [17, 27], the performances of 
the OCC models are relatively lower.  
For serious psychiatric ADR study, the result in Table 3.3 shows that 
there is big variance of the models’ performances across five runs on training and 
validation set for the five CV runs. Moreover, the accuracy values on validation 
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set are even lower than 50% which means the models have poor performances on 
unseen data. The large discrepancy of the performances on training and validation 
set could be because that the criterion for MCC value was not applied before 
ensemble modeling. However, less stringent filtering criteria of performances of 
the models were used for this study compared with SJS/TEN and TdP study was 
to achieve a balance between the number and quality of the models. The lower 
performances of the models could be because that multiple endpoints are covered 
for serious psychiatric ADRs, which makes the relationship of the chemical 
structures and the endpoints more complex to capture by the models.  
Based on above observations, the models developed from OCC methods 
show weaker performance than other toxicity studies using QSAR methods. 
However, the results are still promising. Firstly, the ADRs we investigated are 
either rare or complex ones so the mechanism is not as straightforward as the 
other toxicity studies. Moreover, OCC method was used in this study whereas 
binary classification methods were usually used for previous predictive toxicity 
studies. Studies have shown that OCC could have poorer prediction performance 
compared to binary classification when the two classes are properly defined [152, 
153]. This could be because less information is available to the OCC for model 
development. Considering that relatively less information was available (only 
positive drugs) to develop the model, our result is still encouraging. In addition, 
for the three studies, the performances for TdP models are higher than those for 
SJS/TEN and psychiatric ADRs.  It could be because the mechanism for TdP is 
not as complex as SJS/TEN and psychiatric ADRs. Therefore, the performances 
of the models were highly dependent on the quality of the training data, the 
learning ability of the modelling algorithm and the inherent aetiology of the 
disease. None of them could be improved with trivial effort.  As the pioneering 
studies of using OCC methods in QSAR model development, our study not only 
provides QSAR models for prediction of the potential of drugs to cause the three 
types of ADRs, but also offers a possible solution that can be used for other 
QSAR studies while negative information is not readily available. 
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Nevertheless, despite the promising results, the variance of the sensitivity 
values across five runs of the cross validation for all three studies are quite high, 
i.e., with most standard deviation values for average sensitivity and specificity 
higher than 10%. This result suggests that the performances of the best base 
models for different runs are not stable. This could be due to the different 
characteristics of the best performing models since they were developed using 
different algorithms with different training sets. To address this problem, 
ensemble method will be used to combine the individual models’ strength to 
improve the final model’s performance. The details of the ensemble model 
development process will be described in Chapter 6.  
In summary, for binary classification problem, when the two classes are 
clearly defined and data for each class is readily available, binary classification 
method is recommended since it could fully utilize the information. Otherwise, if 
the data of one class is not available or difficult to obtain, application of OCC 
methods could be a good solution to provide reliable results. All three OCC 
algorithms used in this study have been proved theoretically or empirically in 
several previous studies and have been applied in many real world applications. 
The present work is nevertheless a first step towards the application of these OCC 
methods together in QSAR studies.  
3.5. Conclusion 
In this chapter, OCC methods were introduced and three OCC algorithms 
were applied in three QSAR studies for ADR prediction. The results suggest that 
OCC methods are useful in QSAR studies to distinguish outliers (negative class) 
from the training data (positive class). Currently there are limited algorithms 
available for OCC classification, which restricts the improvement of OCC models’ 
performance and application of OCC models. With more OCC methods 
developed in the future, OCC models will provide more solutions for QSAR 
studies. A possible future direction could be application of OCC methods to larger 




Chapter 4 Addition of biological information 
This chapter is to address the second issue of the QSAR workflow presented in 
Chapter 1, the lack of descriptors. Besides the chemical descriptors (molecular 
descriptors) used conventional QSAR method, biological information (gene 
expression data) was used to develop an integrative predictive model.  68 
compounds were analyzed to explore the relationship of their chemical structures 
and gene expression changes associated with renal tubular toxicity. Predictive 
models were developed including QSAR model based on chemical descriptors, 
TGX model based on genomic data, and hybrid model based on combination of 
them using SVM and NB methods. Four types of ensemble models were then 
developed using the QSAR models, TGX models, hybrid models and the 
combination of both QSAR and TGX models and their performances were 
compared. The results showed that ensemble models with both chemical and 
biological information offered higher performances than ensemble model based 
on any of them. Therefore, the addition of biological information can improve the 
performance of QSAR models.   
4.1. Introduction 
Multiple organ and system toxicities, including hepatotoxicity, cardiotoxicity, 
immunotoxicity and nephrotoxicity, are the leading cause of attrition during 
preclinical and clinical stages of drug development. Based on the principle of “fail 
earlier and fail cheap”, identification of the most promising compounds with 
better safety profile in the early stage of the drug development is very important. 
Therefore the determination of candidate compounds’ potential to cause such 
organ injuries at the early stage of drug development is important for reducing the 
attrition rate of drug candidates and finally the investment of time and money 
during drug development.  
 Nephrotoxicity is defined as “a renal disease or dysfunction, is often 
caused by drugs, chemicals, industrial or environmental toxic agents” [154]. The 
human kidneys are highly vascularized and primarily involved in the metabolism 
and elimination of drugs or drug metabolites, while these substances may reach 
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high concentrations and become toxic for the kidney [154, 155]. Therefore, 
kidneys are particularly vulnerable to the toxicities of these substances. 
Nephrotoxicity has been an important concern for drug development and/or in 
clinical care due to the damage of kidney. Many drugs can cause renal 
dysfunction through various mechanisms, which can cause significant morbidity 
[156].  It has been reported that drug-induced nephrotoxicity has been estimated 
to contribute to 19% to 25% of the cases of kidney failures in patients [157, 158]. 
The tubular cells of the kidney are one of the most sensitive components of the 
kidney so they are more likely to get damaged. Drug-induced tubular injury has 
been well documented and extensively studied recently [159].  
 Currently, the evaluation of toxicity of drug candidates is mainly achieved 
by sophisticated histopathological or clinical pathological techniques [160]. The 
standard approach for toxicity investigation of drug candidates recommended by 
major regulatory authorities such as FDA is still histopathological observation on 
an animal system [161]. In the kidney, the area and intensity of renal insult can be 
directly observed and characterized. However, to obtain detailed information, a 
large number of animals for histopathological observation at different time points 
are required [162]. This would cause increase of cost, time and animal usage of 
the drug development process so it is not practical to use these methods for 
screening and evaluation of nephrotoxicity of compounds especially for large 
scale studies. In addition, although these standard techniques have been successful 
in many toxicity studies, they may not be able to detect prodromal and early 
stages of toxicity [160]. Therefore, alternative or complementary methods which 
are more sensitive and efficient are desirable. Current computational methods 
based on chemical or biological information such as QSAR and TGX have been 
applied intensively to predictive toxicity studies and demonstrated good 
performance for several major organ toxicities such as hepatotoxicity, 
cardiotoxicity and nephrotoxicity etc [17, 40, 163]. The QSAR models have been 
well reviewed in many publications so here only the models based on biological 
information were summarized in Table 4.1. 
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Table 4.1 Some predictive studies of toxicities based on biological information. 
 
4.1.1. QSAR modeling 
As introduced in Chapter 2, QSAR models are predictive models that 
correlate the biological activities of chemical compounds with descriptors 
representative of the structure and properties of the compounds. The underlying 
principle of QSAR is that compounds with similar structures will have similar 
biological activities [172]. QSAR has been applied in many areas such as drug 
discovery, toxicity prediction, risk assessment and regulatory decisions [122]. 
QSAR models have demonstrated good prediction ability especially for specific 
end points such as solubility or binding affinity to a certain target [122]. However, 
for complex end points such as hepatotoxicity and nephrotoxicity, the 
performances of QSAR models are not that satisfactory, which could be because 
Endpoints 
Dataset  









Renal tubular toxicity 41 SE=93%, SP=90% [165] 
Nongenotoxic 
hepatocarcinogenicity 
62 ACC=77~82% [166] 
Hepatotoxicity 
mechanisms 
150 ACC=95% [167] 
Carcinogenicity 152 63~69%, 55~64% [168] 
Renal tubular toxicity 10  SE=88%, SP=91% [160] 
Nongenotoxic 
carcinogenicity 
52 ACC=84% [169] 
Renal tubular toxicity 85 ACC=76% [170] 
Nephrotoxicity 6 SE=82%, SP=100% [171] 
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the structure activity relationship for these endpoints is less straightforward since 
multiple mechanisms of action are involved [36]. 
4.1.2. Toxicogenomics   
Toxicogenomics (TGX) is the method to “combine transcript, protein and 
metabolite profiling with conventional toxicology to investigate the interaction 
between genes and environmental stress in disease causation” [173]. Different 
from QSAR, the fundamental principle of TGX is that “compounds with similar 
mechanisms of toxicity and efficacy will have similar gene expression profiles” 
[174]. One of main purposes of TGX study is to identify a set of important genes 
or RNAs as biomarkers based on the gene expression profile for a group of 
compounds and then apply these biomarkers on new compounds to predict 
corresponding mechanisms or toxicities [174]. It is found that genomic data can 
be more sensitive and objective than traditional methods for the early prediction 
of drug induced toxicity [170]. Moreover, gene expression changes associated 
toxicity may also assist our understanding of the mechanisms of drug action and 
their toxicities [160]. Lastly, TGX method based on gene expression profiling is 
faster, cheaper and with less usage of animals when it was used for toxicity 
detection [175]. Hence, along with the development of large scale gene 
expression profiling technologies, TGX method could be used as a 
complementary or possibly alternative approach to identify potential safety 
liabilities and to understand the mechanism of toxicity of drug candidate [156, 
176].  
TGX methods have been applied in several studies for preclinical 
diagnosis and prediction of renal tubular toxicity of compounds based on gene 
expression profile. Fielden and colleagues generated and assessed a set of 
genomic biomarkers for prediction of future onset of renal tubular toxicity before 
observations of the pathology signs and achieved a prediction accuracy of 76% 
[170]. Moreover, in a similar study using the expression profiling endpoints of ten 
nephrotoxic compounds together with histopathological analysis techniques, the  
SE and SP are 88% and 91% respectively on an external testing set [160].  In a 
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recent predictive study of renal tubular toxicity, the model achieved SE of 93% 
and SP of 90% when it was evaluated using 5-fold cross validation [165]. Besides, 
the author also demonstrated that the prediction performance of the model was 
significantly better than that developed by using either genomic biomarkers or 
histopathology approach [165]. On top of these promising results in research, 
information obtained from TGX studies is increasingly becoming accepted as part 
of submissions by various regulatory agencies [177]. Therefore, TGX method 
based on gene expression profiling is potentially useful for prediction the drug 
induced renal toxicity.  
4.1.3. Integrative study using both QSAR and TGX methods 
 Although QSAR methods have been used in toxicity prediction for a long 
time and TGX modeling methods is playing a more important role in toxicity 
assessment, most recent predictive modeling studies of toxicity employed either 
QSAR or TGX methods alone for model development. It has been demonstrated 
by several recent studies that integrative models employing both chemical 
descriptors from the compound structures and biological descriptors from the 
gene expression change information are advantageous [36, 166]. Specifically, it 
has been shown in predictive studies for hepatotoxicity that models built by using 
combination of chemical and biological descriptors delivered statistically 
significant predictive performance and are potentially useful for prediction of 
hepatotoxicity and prioritization of chemicals [36, 166]. In addition, integrative 
models are likely to provide useful information for mechanistic interpretation of 
the toxicity by investigation of the important chemical features and gene 
signatures.  
 There are two approaches for integrative study of chemical descriptors and 
genomic information as recommended by Rusyn et al [178]. The first approach is 
referred as hybrid method, which is to combine the structural chemical descriptors 
and biological descriptors into a joint descriptor matrix by mapping the two types 
of data. This hybrid data is then used for the modeling process, with similar 
modeling procedure as with QSAR or TGX data alone. This type of data mapping 
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will cause some information loss since there is only QSAR or TGX data available 
for some compounds. And the joint matrix many also cause the increment of the 
data dimension which subsequently will increase the computation time. 
Nevertheless, several recent studies have explored this hybrid study and suggest 
that hybrid descriptors do afford improvement to the accuracy of prediction of 
toxicity [164, 178]. 
 The second approach is consensus (ensemble) method, which is to develop 
independent QSAR and TGX models to predict the same end point and then 
combine the two types of models to build a consensus model. Ensemble modeling 
has been used extensively recently in QSAR studies as well but have not been 
used in TGX modeling much. Although ensemble model will also be built on the 
QSAR, TGX and the hybrid models, the ensemble model of QSAR and TGX 
models is still useful because of its diversity, i.e., including models from different 
feature groups, and flexibility, i.e., no data mapping procedure is needed so it can 
reduce the information loss. The main advantage of ensemble model is that the 
combination of multiple models complementary to each other would result in a 
more robust prediction. The problem is that if the constituent models are not too 
different from each other, the marginal improvement of the prediction 
performance does not worth the added complexity of ensemble modeling [178]. 
Success of consensus prediction depends on the number, performance and 
diversity of the base models as well as the definition of the consensus AD. 
 The main purpose of this study is to investigate whether the addition of 
biological descriptors, such as gene expression levels, could improve the 
prediction performance of classification models than using chemical descriptors 
alone. To achieve this purpose, a comparative study of QSAR, TGX and QSAR 
combined with TGX methods for prediction of drug-induced nephrotoxicity was 
carried out. This chapter only focuses on the model development and performance 
comparison to address the second the issue of the QSAR workflow. Other 
important information for all models will be described in Chapter 8. 
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4.2. Materials and methods 
4.2.1. Data 
The nephrotoxic and non-nephrotoxic compounds as well as the gene expression 
profiles used in this study were collected from the TGX study by Fielden et al. 
[170], in which a set of gene expression signatures was generated to predict the 
drug-induced renal tubular toxicity. The detailed procedures for gene expression 
profiling experiment and the microarray data processing were described in the 
publication.  In general, the kidney samples from three male Sprague-Dawley rats 
were collected on day 5 after exposure of nephrotoxic and non-nephrotoxic 
compounds for subsequent gene expression profile analysis. The signal data for 
all probes were log transformed and normalized, then the Log10 ratios for every 
experimental group was calculated as the difference of the average of the logs of 
the normalized experimental signals and the normalized control signals for each 
gene. The raw and processed microarray data as well as the information of gene 
annotation for all experiments could be downloaded from the corresponding 
NCBI GEO website with Accession ID GSE3210 [170]. This dataset was selected 
for this study instead of others because it is large and diverse compared with other 
renal tubular toxicity studies. This is important for classification studies to obtain 
reliable prediction. Moreover, the original TGX study has developed a predictive 
signature set and shown promising results so a comparison could be made with 
our study. 
 The chemical compounds were curated according to the procedures 
described in Chapter 2. After removing duplicates, inorganic molecules and 
peptides, 13 positive (nephrotoxic) and 55 negative (non-nephrotoxic) compounds 
were used for model development. Specific chemotypes such as aromatic and 
nitro groups were normalized and chemical descriptors were calculated with 
PaDEL-Descriptor 2.17. Constant descriptors were removed and range scaling 
from 0 to 1 was applied.  
 For the genomic data, important genomic features were selected for 
modeling using various filtering feature selection methods. Of all the transcripts 
59 
 
measured, the set of transcripts with sufficient variation across all the compounds 
were extracted according to the procedure in a similar study [36]. Firstly, the 
transcripts with missing values or constant values were excluded. Then for 
transcripts with high correlation, i.e., pairwise r
2
 > 0.95, one of the correlated pair 
was removed randomly. Finally a Welch t-test was carried out on the gene profile 
and only transcripts with p-value less than 0.05 were retained. The remaining 
transcript variables were range scaled to 0 to 1. Only basic preprocessing 
techniques were used for the selection of transcripts because the purpose is not to 
select an important feature set before modeling but to remove redundant 
information to reduce the data’s dimension. A more systematic feature selection 
step was integrated in the modeling step so we want to retain the useful 
information as much as possible before model development. 
4.2.2. Methods 
To obtain a comprehensive study of QSAR and TGX methods, four types of 
models were developed, including: QSAR models, TGX models, hybrid models 
and consensus models. The overview of the model development process is 




Figure 4.1 Overview of model development for nephrotoxicity study. 
 Firstly, multiple QSAR and TGX models were developed using same 
modeling process based on the chemical and genomic data independently. Then 
the chemical and genomic data were joined together to form a large dataset 
according to the name of the drugs. This joint data was used to develop 
classification models (referred as hybrid model in this thesis) using the same 
modeling process. After that, for all three types of models, ensemble model was 
constructed based on the corresponding set of individual QSAR models, TGX 
models and hybrid models. The ensemble models are named as ensemble QSAR 
model, ensemble TGX model and ensemble hybrid model respectively. Lastly, the 
individual QSAR and TGX models were combined together to obtain a large 
model pool and ensemble models were developed based on this new model pool. 
This ensemble model was referred as ensemble consensus model. It should be 
noted that the process for developing “ensemble consensus model” did not 
involve any new individual models.  
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4.2.3. Model development and validation 
The general workflow for the model development and validation process 
assembles the modeling process introduced in Chapter 3 except that the 
modeling algorithms are different. The 5-fold external cross validation method 
described in Chapter 2 was used in this study. For 5-fold external cross 
validation, firstly all 68 compounds are used to build an ensemble model for four 
modeling processes in the first place. Then these 68 compounds were randomly 
partitioned into 5 subsets of nearly equal size. Each subset was paired with the 
remaining four subsets to form a pair of external and modeling sets. The data 
within each modeling set were further divided into multiple pairs of training and 
test sets for internal validation. Although models were built using the training set, 
model selection depended on their performance on both the training and test sets 
(i.e., internal validation) since training set accuracy alone is insufficient to 
establish robust and externally predictive models.  
Support vector machine and naïve Bayes techniques introduced in 
Chapter 2 were used for model development. They were selected because they 
are able to handle high dimension-low sample size data well and the 
computational speed is relatively fast for this problem. The AD was determined 
used the double threshold method described in Chapter 5. For each round of the 
external cross validation process, 100 models were generated for each modeling 
method by varying the number of descriptors using a random selection integrated 
with the forward feature selection process in the internal cross validation. In total 
200 models were generated for each run. 
All individual and ensemble models’ prediction ability were measured by 
the overall accuracy, sensitivity, specificity, AUC and MCC value. The 
performances of the ensemble models generated using all 68 compounds in the 




4.2.4. Ensemble modeling 
All ensemble models were generated using genetic algorithm which will be 
introduced in details in Chapter 6. For each type of models, a filtering process 
was applied on the 200 based models according to two criteria. Firstly, the 
sensitivity, specificity and AUC value of the model on the training set and from 
internal cross validation must be no less than 0.7. This is to avoid selection of a 
weak model which might deteriorate the performance of the ensemble model. 
Secondly, the rate of compounds out of AD should be no bigger than 0.1 for both 
positive and negative class. This is because that the dataset we used is relatively 
small, too many compounds out of the domain will limit the model’s coverage. 
Then genetic algorithm was applied to select a subset of models with high 
majority voting accuracy. The selected models were then pooled together to 
obtain an ensemble model.  
4.3.Results and discussion 
4.3.1. Discussion of models 









100±0 100±0 100±0 1±0 1±0 
TGX 
100±0 100±0 100±0 1±0 1±0 
Hybrid 
100±0 100±0 100±0 1±0 1±0 
Consensus 




85.5±7.8 63.3±30.6 90.9±10 0.565±0.243 0.852±0.121 
TGX 
91.3±8.3 63.3±30.6 98.2±3.6 0.698±0.276 0.918±0.109 
Hybrid 
94.2±5.4 70±26.7 100±0 0.798±0.183 0.948±0.082 
Consensus 
92.7±6.4 63.3±30.6 100±0 0.748±0.213 0.924±0.073 
 
From Table 4.2, we could see that all models have perfect prediction 
performance on training set, i.e., 100% sensitivity and specificity. For 
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performance on validation set, all models achieved high overall accuracy from 
85.5% to 94.2% and specificity from 90.9%~100% as well. The corresponding 
MCC and AUC value are all in the higher level in their own range which suggests 
the good prediction ability of the models on validation set. The sensitivity on the 
validation set is consistently low and variation is high is because there are only 
three positives available in the validation set so the overall accuracy is more 
reliable to represent the model’s performance. These results are higher than the 
original study of the data used in which the overall accuracy is 76%.  
 When comparing the performance measurements of all four models, 
QSAR model shows consistently weaker performances than the other three 
models, which all incorporated TGX information.  This suggests that the genomic 
data could produce better prediction performance than chemical structure data for 
the compounds used in this study, and this result was consistent with a similar 
study in which TGX method was compared with QSAR to predict the 
hepatocarcinogenicity of a group of compounds [36]. Among all three models 
with TGX information, the hybrid model achieved slightly better performance, i.e., 
higher ACC, SE, SP, AUC, MCC and lower variances, than consensus model, and 
the consensus model is slightly better than the model with TGX data alone. 
Although the difference for the overall accuracy values is not that significant (less 
than 5%) which seems like the chemical information added limited useful 
information to the prediction ability of the hybrid and consensus model, it is still 
important for using combined chemical and biological descriptors given the data 
is available. This is because firstly, the limited performance improvement in this 
study might not applicable for other studies. It is highly possible that for some 
other studies, the integrative approach could provide significant performance 
improvement. Secondly, the use of both chemical and biological descriptors could 
enrich the interpretation of the models. The selected chemical descriptors in the 
final model are important for understanding the drug action and the selected 
biological descriptors could be used as predictive biomarker set for toxicity 
assessment. Therefore, the addition of biological descriptors offered improved 
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performance than normal QSAR models and is potentially useful for better 
interpretation of the models, the drug action and toxicity mechanism. 
4.3.2. Discussion of methods 
Compared with QSAR method, the popular computational method for toxicity 
assessment in the last several years, TGX has several advantages. Firstly, it could 
handle a wider spectrum of compounds including metals such as cisplatin or 
macromolecules such as peptides since the measurement of gene expression 
change is not restricted by the structure of the molecules. In addition, changes in 
genomics profiles are thought as sensitive indicators of a potential toxicity and 
could deliver better prediction performance than chemical descriptors. 
Nevertheless, although TGX models achieved better results than QSAR models, 
QSAR method is still very important for predictive toxicology. This is because 
the collection of TGX information requires large-scale gene profiling experiment 
which is still time consuming and labor intensive. QSAR method is still pure in 
silico and does not require extra efforts for experiment so it is cheaper and faster, 
sometimes more accurate. Moreover, QSAR calculates the molecular descriptors 
from chemical structures alone so it offers stronger flexibility and higher 
efficiency in data collection and preprocessing etc.  
For the two types of integration methods of QSAR and TGX, although 
there is no significant difference of their results in this study, careful 
consideration is still needed. The advantages of consensus model is that it does 
not require combination of the two groups of descriptors so avoid high-
dimensional data processing which make it faster in computation. Moreover, since 
the two types of models are developed independently, the distribution of the 
samples, the choice of the modeling methods etc. are not necessary to be the same. 
Theoretically, different sample sets and methods could be used to develop 
different QSAR or TGX models, which is more flexible than the hybrid methods. 
This is quite useful when there are compounds which are metal, macromolecules 
which could not be used in QSAR model. This is because their information could 
still be used to build the TGX model, whereas it will be lost when developing the 
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hybrid model since the samples need to be consistent for QSAR and TGX dataset. 
The advantage of hybrid method is that the combination of the two groups of 
descriptors could explore the inherent relationship of the chemical descriptors and 
the biomarkers, and then provide more information about the mechanism of the 
given toxicity. In summary, the proper choice of using QSAR and TGX methods 
together would be trying both hybrid and consensus model to select the best 
models. 
Nevertheless, despite their potential of the integrative study, there are a 
number of general challenges for application of TGX method in predictive 
toxicology. The major limitation is that the lack of data, which is currently the 
major difficulty for promoting these integrative approaches. In particular, the 
database of toxicity studies is always limited to a small number of chemicals. 
These data sets are both too small in sample size and too limited in structural 
diversity for reliable QSAR analysis [178]. For this study, a lot of the positive 
compounds contain metal atoms so they could not be used for QSAR modeling 
process. Simple removal of these compounds also leads to the imbalance of the 
data set, and affects the performances of the models subsequently. 
4.4. Conclusion 
A comparison study of using computational method to predict nephrotoxicity 
based on chemical and/or genomic information was carried out in this project to 
address the second issue in the QSAR workflow. The results showed that addition 
of TGX information offered better prediction performance than QSAR modeling 
using chemical information alone. Thus, if the TGX data is readily available, they 
could be used together with chemical information to build predictive models by 
expanding the prediction ability of QSAR models. The integrative model could be 
used to evaluate the safety of chemical compounds in early stage of drug 
development. With the development on genomics or other biological technologies, 
more promising results could be obtained for the pharmacological and 
toxicological screening of new potential drugs. 
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Chapter 5 Applicability domain 
This chapter is to address the third issue of the QSAR workflow in Chapter 1: 
lack of AD, by developing a method to determine the AD of QSAR models to 
improve the reliability and generalizability of the models. A simple experiment 
was carried out using a toy data set to investigate the reliability of the method. 
The result demonstrates that the method could identify the reliable prediction 
space for the model and improve the model’s performance on external validation 
set.  
5.1. Introduction 
The increasing use of QSAR models for chemical risk assessment, toxicity 
prediction and regulatory decisions has raised the concern of the reliability of 
model predictions. One of the conditions required for a QSAR model to make 
reliable predictions is the use within its AD. According to the Setubal workshop 
report [179], the AD of a QSAR is defined as “the physicochemical, structural or 
biological space, knowledge or information on which the training set of the model 
has been developed, and for which it is applicable to make predictions for new 
compounds”. For local QSAR models, they are usually built on small dataset with 
low diversity among the training compounds and the AD is usually implicitly 
defined. Over the past several years, a growing number of global QSAR models 
have been developed based on large and diverse datasets. These models are 
usually developed on diverse and sparsely distributed molecular descriptors with 
complex computational algorithms and are expected to be more reliable for 
prediction of unseen compounds with diverse structures than local QSAR models 
[180, 181]. Although these models are advantageous for their ability to provide 
better representation of chemical structures and approximation of SARs, the 
chemical space defined by these models will become more complex and 
fragmented. As a result, the model may not be applicable to certain regions of the 
domain as defined by the information in the training set. For such models, the 
absence of the model AD may cause the unreliable extrapolation of the model in 
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the chemical space and is more likely to produce inaccurate predictions [82]. For 
this reason, a clearly defined AD has been listed as one of the OECD principles 
for the validation of QSAR models for regulatory purposes. Therefore it is 
important to define the AD of a QSAR model before applying it on unseen 
compounds.  
 For the last decade, many studies have been published to address this issue 
in the field of QSAR [182, 183].  Some of them have been carried out to develop 
methods to define AD and a summarized list of AD methods used in recent 
studies is shown in Table 5.1. Only the methods developed using quantitative 
methods based on the molecular descriptors information are included, methods 
based on SAR or mechanistic knowledge such as the expert systems, DEREK for 
Windows [184], is not included.  
Table 5.1 Current AD determination methods 












Calculate the distance of examples 












Calculate the coverage of the convex 
hull covered by training set 
 [118, 185] 
Density based 
method 
Probability density estimation of the 
training set 
High density region with 
Monte Carlo simulation 
[118] 














Analyze the variability of ensemble 
methods in the predictions 
ANN [188] 
Gaussian process, decision 






model  (DM) 
based method 
Combine variability in 
the predictions with distances to the 
training set 
 





Applicability domain estimations for 
kernel based model 
Support vector regression 
and the ranking of a disjoint 
screening data set according 
to the predicted activity 
[192] 
 
Generally, AD determination methods are usually based on some 
manually defined distance of the compound to the training set or model [191]. 
The commonly used AD determination methods are the classical methods used 
for interpolation in the model descriptor space, including range based method, 
distance method, leverage method and probability density based method [193]. 
These methods are easy to implement and the result is also easy to interpret so 
they are very popular in QSAR studies. However, for the approaches based on the 
descriptor space only, the AD is estimated based on the structural information of 
the compounds used to train the model and could only be applied for evaluation of 
the compounds within the compounds’ descriptor space. It does not include the 
information of the performance of the model and the AD would be partially 
defined [194]. To overcome this limitation and to define a more informative AD, 
the response space should be incorporated into the AD.  
Some other methods for determining AD involve computing the similarity 
of the testing compounds to the training set using different types of descriptors 
and distances, and relating the similarity to the prediction error [182, 183]. One of 
the important techniques used for AD evaluation was the degree of fit method and 
modified version of this method was also available [195, 196]. Another popular 
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method is based on the distance to model (DM) value, which is defined as 
“numeric measure calculated solely on the basis of chemical structures or 
prediction values and which increases with a decrease in the reliability of 
classification”. Based on the model performance, a threshold for the DM that 
provides a predefined accuracy of classification could be identified. All 
compounds with DM values below the threshold form a model’s AD. Along with 
the development of ensemble methods in QSAR studies, AD method by analyzing 
the variability of ensemble methods in the predictions was also developed. A 
recent popular method is the combination of DM with ensemble method 
developed by Sushko et al. [190], which demonstrated that DMs computed based 
on ensemble model offered systematically better performance than other DMs. 
These methods are useful and have demonstrated good distinguishing ability for 
prediction ability of samples within and out of AD. Nevertheless, the above 
methods are either tailored for specific type of models (e.g. regression models 
only) or are computationally intensive.  
Moreover, although it is sometimes advantageous that a single AD is 
defined for a training set, there are situations that different ADs are needed for 
different models based on the same training set. For the same training set, 
different models developed using different subset of samples, features or different 
algorithms should have different ADs since the information incorporated and the 
relationship explored from the training set are different. This is especially 
important when ensemble modeling method is used in QSAR studies, in which 
there are large pool of models developed using different descriptor sets and 
diverse modeling algorithms. In this study, an individual model based AD 
determination method using prediction confidence was developed to achieve a 




5.2.1. AD for base model  
The AD of each base model was defined using a double threshold (DT) method 
inspired by the multiple thresholds method proposed by Fumera et al [197]. This 
multiple thresholds method was originally used in pattern recognition to obtain 
the optimal decision and reject regions of classifiers. It has been proved 
mathematically and empirically to have better accuracy and rejection trade-off 
compared with single threshold method [198]. When it was applied in QSAR 
studies to define the AD, it could help to optimize the classification accuracy in 
the decision region (inside AD) and rejection region (out of AD). The multiple 
thresholds are determined by using the confidence value for each prediction 
computed by mathematical algorithms of the modeling methods. Different 
modeling methods have different algorithms to compute this confidence value. 
For example, for the development of a KNN model, the confidence value for 
predicting a sample as positive is computed as the proportion of k nearest 
neighbors of the sample that are positive. Usually in a binary classification 
modeling method, a threshold of 0.5 for the confidence value is used such that if 
the confidence value is bigger than 0.5, the sample will be predicted as positive. 
Otherwise, it will be predicted as negative. When applying the multiple thresholds 
methods on binary classification problem, two thresholds T1 and T2 (T1, T2 ϵ [0, 1] 
and T1<T2) are used such that if the confidence value is greater than the higher 
threshold value T2, the sample is predicted as positive. Conversely, if the 
confidence value is smaller than the lower threshold value T1, the sample will be 
predicted as negative. When the confidence value falls into the range of T1 and T2, 
the sample is considered as out of the AD of the model and its activity is not 
predicted. In this study, the two thresholds T1 and T2 were determined using the 
confidence values of the samples in the testing sets of a 5-fold cross validation. 





Figure 5.1 Workflow of determination of optimal thresholds. 
 Firstly, the confidence values were sorted and those that were found in 
both positive and negative samples or those that indicate a transition between 
positive and negative samples were identified as potential thresholds. All 
combinations of threshold pairs from the pool of potential thresholds were then 
tested. The optimum threshold pair was then identified using three criteria.  
i. The accuracy of the model for those samples identified as out of the AD 
should be minimized.  
 
ii. The precision of the model for those samples identified as within the AD 
should be maximized.  
 
iii. The number of samples identified as out of the AD should be maximized.  
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 The three criteria were applied consecutively. If only one threshold pair 
satisfied the first criterion, the process was stopped and that pair was identified as 
the optimum pair. If more than one threshold pairs satisfied the first criterion, the 
second criterion was applied. The third criterion was used only when more than 
one threshold pairs satisfied the second criterion. Random selection was used if 
there are still more than one threshold pairs available after the third criterion.  
5.2.2. AD for ensemble model 
When ensemble model was developed from the base models, the AD of the 
ensemble model was defined based on the prediction of the base models. 
Compounds were defined to be out of the AD of the ensemble model when all the 
base models identified the compound to be out of their AD, or if there was a tie in 
the predictions (i.e. an equal number of base models predicted the drugs to be 
positive and negative). Otherwise, the compounds were defined to be within the 
AD of the ensemble model and were predicted based on majority voting of the 
base models. The confidence values for the predictions were also computed as the 
ratio of the number of model with the majority vote over the total number of base 
models for the ensemble model. 
5.3. Testing of DT AD method 
The DT AD method has been integrated in the model development process for the 
ADRs and toxicity studies in Chapter 3 and Chapter 4 and it has identified the 
compounds out of the AD successfully in these studies. Nevertheless, due to the 
small number of compounds out of AD, it is not possible to establish a 
comparison of the model’s performance on compounds in and out of AD for these 
studies. Here a simulated dataset was used to show that the DT AD method could 
distinguish the samples in and out of AD successfully. 
5.3.1. Dataset 
To test the DT AD method’s performance in binary classification problem, a 
polynomial classification data (PC) with 5000 samples and 10 attributes was 
generated in using the data generation function of RapidMiner. This data set was 
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chosen because it has small number of attributes and balanced classes of samples 
and also could be well classified by most classification methods. 
5.3.2. Methods 
All the modeling procedure was carried out using RapidMiner. The general 
workflow for model development is shown in Figure 5.2. 
 
Figure 5.2 Workflow for model development. 
 The dataset was firstly split into a training set and validation set with ratio 
8:2. The training set was used to develop binary classification models using 5-fold 
cross validation with three machine learning algorithms including support vector 
machine (SVM), naïve Bayes (NB) and random forest (RF). The reason for 
selecting these algorithms is to avoid the bias of different algorithms. The DT AD 
determination method was used with an internal 5-fold cross validation according 
to the three criteria stated in Figure 5.1. The optimum threshold pair was 
identified for each model. To reduce bias of the modeling method, 30 models 
were generated for each algorithm with a random feature selection followed by 
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forward selection before modeling. Based on the cross validation result, the 
models with any one of the sensitivity, specificity and AUC values less than 0.5 
were removed to ensure the models’ quality and avoid potential errors. Then the 
remaining models were applied on the training and validation set respectively. 
The performances of models on the samples within and out of AD for both 
training and validation set were evaluated. For samples in the AD, the double 
thresholds determined using DT methods were applied while for samples out of 
AD, the regular threshold 0.5 was applied. 
5.3.3. Results and discussion 
The corresponding performance result for the models on the samples within and 
out of AD is shown in Figure 5.3.  
 




(b). Prediction accuracy of NB models 
 
(c). Prediction accuracy of RF models 
Figure 5.3 Prediction accuracy of SVM, NB and RF models on samples within 
and out of AD for training and testing set. T_IN_ACC and T_OUT_ACC are the 
accuracy of the model on samples within and out of AD for training set 
respectively. Similarly, V_IN_ACC and V_OUT_ACC are the accuracy of the 
model on samples within and out of AD for validation set respectively. 
 From Figure 5.3, we could see that for all three modeling algorithms, the 
performances of most of the models on the samples within AD are much higher 
than those out of AD for both training and validation set. For SVM model, the 
mean±standard deviation of the accuracy of models on samples inside AD are 
93.6%±1.8% and 93.8%±1.5% for training and validation set, whereas it is 50.3%
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±0.4% and 59.8%±1.9% for samples out of AD.  Similar pattern was observed 
for NB and RF models. This shows that the models have good prediction accuracy 
for samples inside AD and have nearly random prediction accuracy for samples 
out of AD, i.e., no prediction ability, regardless of the selection of modeling 
algorithm. This situation is consistent with the result of another AD method on the 
benchmarking Ames dataset [190]. There are two RF models (RF1 and RF3) 
which achieved accuracy higher than 70%. However it is found that the 
corresponding sensitivity and specificity values are 1 and 0 respectively which 
means the two models predict all samples out of AD as positive so the accuracy 
merely depends on the portion of the positive samples out of AD and is not 
reliable.  
5.4. Conclusion 
In summary, an AD determination method DT method was developed based on 
the multiple threshold method in this chapter. When applied in a predictive 
modeling study using a toy dataset, DT method managed to identify the reliable 
prediction space for the model and subsequently improved the model’s 
performance on external validation set. Therefore, the DT method is potentially 











Chapter 6 Ensemble modeling  
This chapter is to address the fourth issue of the QSAR workflow in Chapter 1: 
difficulty of model selection for ensemble model development. There are many 
QSAR models for ADR or toxicities developed using different sets of descriptors 
and various modeling algorithms, and it has been demonstrated by several studies 
that the application of ensemble modeling method could improve the overall 
prediction accuracies of the final model for the target endpoints. In this chapter, 
two different model selection methods were introduced and then applied in three 
real studies to combine individual QSAR models to form ensemble model to 
obtain better performance.  
6.1. Introduction 
Ensemble modeling has been frequently employed to reduce the risk of selecting 
an inappropriate model and provide more accurate and reliable predictions. 
Ensemble model has been demonstrated to outperform the single model in a 
number of modeling studies [199, 200].  Recently, ensemble method has also 
been applied in several QSAR studies and ensemble models have shown better 
performances compared to single base model [40-42]. However, a full ensemble 
model including all the base models does not always give better performance than 
individual models, so the best way is to select a subset of models which could 
give the optimal performance. It is always a question of how to select the optimal 
subset of models from a large pool of different models. Suppose m classifiers are 





  (   ) 
 combinations [201]. Usually the ensemble size m is not known or 
hard to determine so the total number combinations of the classifiers is 2
n
-1, 
which is not realistic for large n. A popular method was to select a certain number 
of top performing classifiers, which could give moderate performance 
improvement. Nevertheless it has been demonstrated that a simple collection of 
top performing classifiers does not necessarily produce the optimal performance, 
and it even could not ensure the good performance [201, 202]. The reason is that 
ensemble classifier could only produce improved performance when the 
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constituent classifiers have good performances and are sufficiently different from 
each other [203, 204]. Therefore to achieve the good or optimal performance, a 
good selection method should be able to produce an ensemble which gives better 
performance than the best individual classifier. It is suggested that equivalent or 
similar classifiers do not contribute any information but increase the complexity 
of the ensemble classifier [205]. Besides, models with weak performances are not 
beneficial for the ensemble classifier performance even they are different and 
complementary with each other. Therefore, both individual performance and 
diversity among classifiers should be considered during classifier selection 
process [203]. Furthermore, there are both theoretical and empirical studies which 
showed that a good ensemble classifier should be combined by individual 
classifiers which are both accurate and making different errors [206], especially 
classifiers which are negatively correlated could provide significant improvement 
of performance of the ensemble classifier [204]. These facts promote the need for 
selecting a combination of diverse and reliable classifiers, commonly referred as 
multiple classifier selection (MCS).  
Given a large pool of candidate classifiers, MCS works by searching the 
different combinations of classifiers to find a subset of classifiers that could give 
optimal performance on the validation set. The testing set, selection criterion and 
the search algorithm are all important for the performance of the combination of 
classifiers produced by MCS. When the candidate classifier pool is large, efficient 
search algorithms are required to avoid the combinatorial explosion of classifier 
space [207]. Similar as the feature selection process, different methods have been 
studied for effective multiple classifier selection, including  the clustering and 
selection method which works by clustering the candidate classifiers based on 
their internal relationship and then selecting one classifier from each cluster [208]. 
Besides, heuristic search methods such as evolutionary algorithms are also used 
for classifier selection [209]. For the selection criterion, different measures of 
diversity have been used to select a diverse subset of classifiers [203]. For the 
evaluation of classifier performance, the combination accuracy or classification 
error on validation data was usually used to rank the ensemble classifiers [209]. 
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The common search algorithms used for classifier selection are similar to the 
methods which have been used frequently in feature selection: sequential search 
methods and genetic algorithm. The difference is that the subjects are features in 
feature selection and classifiers in classifiers selection.  
Depending on the requirement of different problems, sequential search 
methods of classifiers could either begin from an empty set or a full set of all 
candidate classifiers. The iterative process operates in the way that for each step, 
only one or a small number of classifiers are added to or removed from the 
selected subset so as to improve the evaluation criterion. The process stops when 
the evaluation criterion is fulfilled or no classifiers could be added or removed. 
The advantage of sequential search methods is that the complexity of search is 
relatively low, so they are computationally efficient even for large-scale problems. 
Sequential search methods are widely used for its simplicity and efficiency. The 
limitation of  sequential search method is that the selected subset of classifiers is 
not guaranteed as the global optimal solution [207]. 
Genetic algorithm is an evolutionary algorithm that aims to find a global 
solution to a given problem by simulating the process of natural evolution, such as 
mutation, crossover, reproduction and natural selection [210]. It is reported that 
genetic algorithm is one of the most suitable approaches which could give 
reasonable balance between computational complexity and the performance [211]. 
When genetic algorithm is applied in classifier selection, a set of classifiers are 
represented by a binary string (referred as the chromosome) with bits 1 and 0 to 
indicate the presence and absence of classifiers. A set of chromosomes (referred 
as the population) evolve from generation to generation using selection, crossover, 
and mutation procedures towards higher fitness. The crossover and mutation 
procedures increase the variation of population in order to reduce the risk of stuck 
at local optima. After a certain number of generations, the chromosome with 
highest fitness among the population was regarded as the solution of classifier 
selection [207]. Genetic algorithm has strong ability to search large space for an 
optimal solution [212] and has been applied in both feature selection and classifier 
selection [209].  
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In this study, a modified sequential selection method and standard genetic 
algorithm were used. The two methods DisEnsemble method and genetic 
algorithm were introduced and applied in QSAR studies and the performances of 
the ensemble models generated were compared with the best performing models. 
6.2. Methods 
In the design of  ensemble models, it is essential to generate  a number of base 
models with a large diversity [213].  This has been achieved by develop a 
considerate number of base models using different feature groups and modeling 
algorithms as described in Chapter 3. The AD of all models was determined 
using the double threshold method introduced in Chapter 5. The modified 
sequential search method DisEnsemble method was applied in SJS/TEN and TdP 
study and genetic algorithm was applied in serious psychiatric ADR study 
respectively. 
6.2.1. DisEnsemble method 
For sequential search methods, different criteria have been used to optimize the 
selection process. Besides the ensemble accuracy or classification error, a 
diversity measure is also important for selecting the subset of models. In this 
study, a novel sequential selection method DisEnsemble method was developed 
for model selection. The principle of this method is to select a diverse set of 
models from the pool with consideration of both individual performance and 
diversity among the models.  
 The first step is to remove models with weak performance from the model 
pool. Among all 300 base models developed using OCSVM, OCLOF and OCPD 
algorithms, two criteria were used to select suitable base models for subsequent 
ensemble modeling. These include cut-off values for sensitivity and specificity 
values such as sensitivity ≥ 0.5 and specificity ≥ 0.5 for both training performance 
and internal CV results and cut-off value for the between training set and internal 
CV, such less than 0.1 to reduce the chance of the base models to be over-fitted. 
Similar selection methods have been used in previous studies and have shown to 
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be useful for filtering models with weak performances [50, 51]. It is important to 
note that these cut-off values might be adjusted for different studies to obtain a 
balance between the number of available candidate models and their 
performances. 
Then the second step was to select a subset of diverse base models from 
the model pool to form ensemble models. A binary output was used to represent 
the prediction results of models, with correct prediction noted as “1” and wrong 
prediction noted as “0”. For computation efficiency and ease of understanding,  a 
common diversity measurement, the disagreement value, which is the ratio 
between the number of samples on which one model is correct and the other is 
incorrect to the total number of samples, was used to measure the diversity 
between two base models [214]. For instance, for a pair of base model i and j, 
suppose N10 is the number of drugs predicted correctly by base model i but 
wrongly by base model j, and vice versa for N01, then the diversity between base 
models i and j could be written as   
Di, j= 
       
               
 ( 6.1) 
The detailed steps for the ensemble process are as follows: 
i. From the model pool, the pair of models with the largest disagreement 
value was selected. 
ii. For each of the remaining base models, the total disagreement value to the 
selected base models was calculated. Then the base model with maximum 
total disagreement value was selected. If there is a tie, the one with largest 
internal CV prediction accuracy was selected.  
iii. Ensemble model (EM) was formed by combining selected models through 
majority voting.  
iv. Repeat step ii and iii until all base models were selected.  
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In the end, suppose there are n base models in the model pool, then ensemble 
models with ensemble size from 3 to n were generated. The best ensemble model 
was determined as the one with the highest majority voting accuracy on the 
testing sets results of internal 5-fold CV. That model was then chosen as the final 
ensemble model. Sometimes a fixed value of number of base models included in 
the ensemble model could also be used and the selection process stops when a 
desired number of models are selected. 
 As described in Chapter 5, the AD of the ensemble model was defined 
based on the prediction of the base models. Drugs were defined to be out of the 
AD of the ensemble model when all the base models identified the drug to be out 
of their AD, or if there was a tie in the predictions. Otherwise, the drugs were 
defined to be within the AD of the ensemble model and were predicted based on 
majority voting of the constituent models.  
6.2.2. Genetic algorithm 
In this study, genetic algorithm was applied to select a subset of the base 
models with high fitness, which is the majority voting accuracy of the prediction 
results of the selected models on the training set. 
Before applying genetic algorithm ensemble method, the base models 
were screened to remove weak models. For all the 300 base models developed 
using OCSVM, OCLOF and OCPD, the same criteria were used to select suitable 
base models for subsequent ensemble modeling.  Out of this pool of models, 
genetic algorithm was then used to select models that had different 
misclassifications so as to construct an ensemble model with a maximum majority 
voting performance.  Selection of parameter is important for the performance of 
the genetic algorithm. For the study of serious psychiatric ADRs, different 
population sizes from 5 to 50 were used but no significant improvement of the 
performances with increased population size was observed, so population size 
was set as 5 for computation efficiency. Similar method was applied to number of 
generation which was set as 100 to make sure the fitness reached plateau. Default 
values were used for the other parameters. 
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6.2.3. Model fusion 
For aggregation of the prediction results of ensemble models, there are a variety 
of fusion methods available such as majority voting, weighted majority voting and 
naïve Bayes combination etc [215]. Majority voting was chosen throughout of the 
studies covered in this thesis because it is popular, easy to implement and could 
obtain comparable performance as other advanced methods [216]. A common 
majority voting method chooses the prediction that is mostly predicted by 
different models [205]. Besides, the majority voting approach used in our study 
took the AD of each model into consideration, so only samples falling into the 
ensemble AD and with major class returned will be predicted.  
6.3. Results 
6.3.1. Base and ensemble model performances for SJS/TEN study 
For the rigorous external CV process, after the ensemble model development, 
number of constituent models for best ensemble models is from 4 to 18. The 
detailed performances of the best base models and corresponding ensemble 
models from the five external CV runs are presented in Table 6.1. Throughout 
this thesis, BMn and EMn are used to indicate the best performing base model and 









Table 6.1 Performances of best base models and best ensemble models for 
SJS/TEN study. 







  71.1 75.5 66.5 0.422 0.708 
BM
2
  69.8 74 65.3 0.395 0.711 
BM
3
  68.3 56.1 81.5 0.387 0.7 
BM
4
  69.3 81.9 55.8 0.391 0.741 
BM
5
  66.9 71.4 62.1 0.337 0.708 






  74.8 80.1 69.1 0.496 0.652 
EM
2
  77.6 88.6 64.5 0.553 0.714 
EM
3
  74.6 74 75.3 0.492 0.778 
EM
4
  74.1 83.3 64.1 0.485 0.777 
EM
5
  76.4 86.7 64.9 0.532 0.786 







  53.5 51 56.3 0.072 0.555 
BM
2
  67.8 68.6 66.7 0.353 0.668 
BM
3
  61.9 46 78.7 0.261 0.648 
BM
4
  55.6 62.8 48 0.108 0.556 
BM
5
  59.2 70.6 46.8 0.179 0.594 






  69.3 71.8 66.7 0.385 0.596 
EM
2
  75 81.8 67.5 0.5 0.667 
EM
3
  80.4 80.4 80.4 0.608 0.852 
EM
4
  80.9 89.8 71.1 0.623 0.836 
EM
5
  67 81.3 51.2 0.341 0.612 
Average 74.5±6.3 81.0±6.4 67.4±10.6 0.491±0.127 0.713±0.123 
6.3.2. Base and ensemble model performances for TdP study 
For the rigorous external CV process, after the ensemble model development, the 
number of constituent models for ensemble models is from 4 to 12 for the five 
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runs. The detailed performances of the best base models and ensemble models 
from the five runs are shown in Table 6.2.  
Table 6.2 Performances of best base models and best ensemble models for TdP 
study. 





BM1  85.4  88.0  83.6  0.706  0.899  
BM2  88.3  88.0  88.5  0.760  0.894  
BM3  74.9  39.5  97.6  0.483  0.801  
BM4  88.0  86.6  88.8  0.749  0.924  
BM5  89.4  82.9  93.7  0.777  0.924  




EM1  91.8  86.2  94.9  0.819  0.909  
EM2  89.3  84.5  92.2  0.772  0.879  
EM3  94.3  91.0  96.3  0.879  0.902  
EM4  90.2  94.7  87.4  0.804  0.927  
EM5  91.0  89.6  91.8  0.810  0.952  





BM1  84.3  79.0  87.5  0.664  0.837  
BM2  78.0  60.0  90.0  0.535  0.697  
BM3  71.2  28.6  100.0  0.439  0.767  
BM4  72.0  70.0  73.3  0.428  0.771  
BM5  78.4  65.0  87.1  0.540  0.846  




EM1  87.2  76.5  93.3  0.720  0.839  
EM2  91.1  85.7  93.5  0.793  0.869  
EM3  81.4  72.2  88.0  0.615  0.700  
EM4  85.7  81.3  88.5  0.697  0.849  
EM5  82.4  76.2  86.7  0.634  0.869  




6.3.3. Base and ensemble model performances for serious psychiatric ADR 
study 
For the rigorous external CV process, after the ensemble model development, the 
number of constituent models for ensemble models is from 4 to 10 for the five 
runs. The detailed performances of the corresponding ensemble models from the 
five CV runs are shown in Table 6.3.  
Table 6.3 Performances of best base models and best ensemble models for serious 
psychiatric ADR study.  
6.4. Discussion 
6.4.1. Model pool size and ensemble size 
The number of candidate models available in the model pool is generally less than 
100 after applying the screening criteria. Although it is possible to search for an 
optimal combination of the candidate base models exhaustively for such a small 
pool, the computational complexity will increase exponentially for large scale 
problems when there are a larger number of candidate models available. Since our 
  Training performance Validation  performance 
Model ACC(%) SE(%) SP(%) ACC(%) SE(%) SP(%) 
BM1 68.8 66.7 71.4 42.9 33.3 50.0 
BM2 78.4 73.7 83.3 37.5 40.0 33.3 
BM3 80.0 78.9 81.3 40.0 100.0 0.0 
BM4 100.0 100.0 100.0 44.4 16.7 100.0 
BM5 81.6 88.5 66.7 56.3 54.5 60.0 
Average 81.7±11.4 81.6±13.0 80.5±12.9 44.2±7.2 48.9±31.6 48.7±36.6 
EM1 74.7 67.7 83.6 60.5 50.0 70.0 
EM2 73.7 77.5 66.7 60.3 68.3 48.1 
EM3 70.4 68.1 75.0 80.0 85.7 66.7 
EM4 74.5 87.2 52.7 66.2 75.0 50.0 
EM5 72.1 84.2 53.6 78.2 87.8 62.1 
Average 73.1±1.8  0.76.9±9.0 66.3±13.4 69±9.5 73.4±15.3 59.4±9.8 
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purpose is to develop and explore methods that can be applied in more versatile 
applications, simple and fast search algorithms are more practical, so the 
DisEnsemble and genetic algorithm methods are investigated in this study.  
 The ensemble sizes of the best ensemble models are generally small 
numbers in the range of 4 to 20. Previous studies have shown that the optimal 
ensemble size is different for different ensemble methods. For example, based on 
some empirical and theoretical studies on ensemble models by Opitz et al.[206], 
the optimal ensemble size is around 20. In another study, the ensemble size for the 
best ensemble model is about several hundred [40, 206]. However, to avoid high 
computational complexity, a smaller ensemble size is preferred for ensemble 
models with comparable performances.  
6.4.2. Performance of best base models and best ensemble models 
For SJS/TEN study, Table 6.1 shows that for five CV runs, all sensitivity values 
are above 0.7 and specificity values are above 0.5 for five ensemble models. In 
contrast, one sensitivity value and two specificity values are less than 0.5 for five 
best base models. Almost all the performance values of ensemble models are 
higher than the values of corresponding best base models, especially for MCC 
values. This suggests that the ensemble models outperform the base models in 
prediction ability. The differences of the MCC values for training and validation 
performance of the base models are much bigger than the ones for the 
corresponding ensemble models, so the generalizability of the base models is not 
as good as ensemble models. That is, the base model is more likely to produce 
weaker performance on external data set compared with the performance on the 
training set. Moreover, the performances of best base models varied widely for 
the different runs. For example, the lowest and highest specificity of the best base 
models on validation set are 46.8% and 78.7% respectively. This is contrary to the 
performances of the ensemble models that are more stable across the runs. The 
high variance could be because that, different training sets, feature groups and 
modeling algorithms were involved in the model development process, so the best 
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performing model for the different runs might have very different characteristics 
which cause the inconsistency of the performance profile. 
 The similar pattern was observed in the result of the studies for TdP and 
serious psychiatric ADR. For TdP study, the result in Table 6.2 shows that the 
performances of the best ensemble model in each of the five runs are generally 
higher than the corresponding performance of the best base model. Moreover, the 
performances of best base models vary widely in the different runs. For instance, 
the lowest and highest sensitivity of the best base models on validation set are 
28.6% and 79.0% respectively. However, the performances of the best ensemble 
models are more stable across the runs. For serious psychiatric ADR study, the 
result in Table 6.3 shows that for best base models for the five CV runs, most of 
the sensitivity and specificity values are lower than 50% which suggests these 
models have weak prediction ability. In contrast, all ensemble models achieved 
ACC, sensitivity and specificity values larger than 50%. Besides, the average 
performances of the ensemble model are also higher than corresponding best base 
models. Once again, the variance of the performances of the best ensemble 
models is lower than the one for best base models.  
 In summary, all results suggest that the application of ensemble method 
improved the model’s prediction ability, generalizability and stability compared 
with the case when only the best performing model was chosen. This is because 
different base models make different errors and ensemble method reduces the 
consensus errors. For both ensemble methods, development of multiple base 
models with different set of features and different modeling algorithms offered 
sufficient diversity and the model selection criteria ensured the good performance 
of the models in the model pool. Then the application of ensemble methods 
managed to select a set of complementary base models which make different 
misclassifications individually but correct classifications when combined together. 
Since the chance of selecting a bad model from the base models is much higher 
than the ensemble models, which will probably lead to poor performance on 
unseen dataset of “optimized” single model obtained from CV, the model 
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selection methods provide a solution to develop ensemble model and ultimately to 
improve the prediction performance, generalization ability and stability for QSAR 
models. This performance improvement may not be significant for well classified 
data and but it is important for studies dealing with small and diverse dataset and 
endpoints with complex mechanisms, in which the base models have limited 
prediction abilities, such as the studies for the three types ADRs in this work. 
6.4.3. Selection of two ensemble methods 
 As exploratory studies of applying ensemble method in QSAR studies for 
ADRs, only DisEnsemble method was developed and applied in SJS/TEN and 
TdP studies. For serious psychiatric ADR study which was carried out in later 
stage, both DisEnsemble method and genetic algorithm were employed and 
ensemble models developed from genetic algorithms showed better performances 
than DisEnsemble method, so genetic algorithm was used for this study. 
Nevertheless, this result could only be regarded as applicable for this particular 
study and does not necessarily mean that genetic algorithm outperformed 
DisEnsemble method. DisEnsemble method is more suitable for large scale 
problems because of its simplicity and efficiency. For the comparison and 
selection of the two methods, an established study which compared the search 
efficiency of sequential search methods and genetic algorithm for classifier 
selection showed that no method could win the other in all cases in terms of 
optimality [207]. Hence, it is recommended that both methods could be tried and 
compared, and should be used with consideration of both efficiency and 
optimality. 
6.5. Conclusion  
This chapter introduced two different model selection methods and investigated 
their applications in three QSAR studies. The result demonstrated the advantage 
of ensemble model over best base model in terms of prediction ability, stability 
and generalizability. Nevertheless, as an exploratory study of using these methods 
in QSAR studies, their performances were not compared systematically. Hence, it 
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is recommended that in future studies, both methods could be tried and the more 





























Chapter 7 Development of model evaluation method 
This chapter is to address the fifth issue of the QSAR workflow in Chapter 1: 
limitation of current model evaluation method. In this chapter, a novel model 
evaluation method ADVal for predictive models with consideration of the 
representativity of the dataset was developed, with the aim to estimate the model’s 
actual performance more accurately and comprehensively. 
7.1. Introduction 
 Currently the common methods available to evaluate the performance of 
predictive models are random split (RS) validation and cross validation (CV). CV 
has been served as a standard technique for performance estimation and model 
selection in modeling studies. A common problem with these validation methods 
is that there is only a weak correlation between the performances estimated by 
these methods with the model’s actual performance [116]. This means that a well-
fitting model does not necessarily ensure comparable prediction on unseen data. 
This results in inaccurate ranking of predictive models, especially models with 
similar performances. This problem arises because the testing sets that are used by 
these methods to assess the model’s performance are usually small and thus may 
not be fully representative of the intended population. This results in extrapolation 
of the model on the novel datasets which may be unreliable. Moreover, the 
performance of a predictive model is usually evaluated by a single measurement, 
such as accuracy, sensitivity and specificity for classification models, cross-
validation R
2
 or root mean squared error for regression models. This is 
insufficient as the model is likely to have different performances for samples that 
are very similar to those in the training set and for samples that are very different 
[217]. As a result, there is a need to develop an evaluation method that can 
estimate the model’s actual performance more accurately and comprehensively. 
 As a subset of the general predictive models, QSAR models are inevitably 
affected by these limitations. It has been confirmed by different groups of 
scientists who have shown that a QSAR model with reasonably high internal 
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fitness (LOO q2 or classification accuracy) does not automatically imply a high 
prediction power of the biological activities of independent validation set [116]. 
Instead, they may have very poor external predictive ability, i.e., low performance 
when making prediction of the target properties of unseen compounds. The most 
common reason for this inconsistency is that compounds in the training sets cover 
only a limited area in the entire chemical space. Hence it is likely that most of the 
future compounds lie outside this limited area, resulting in extrapolation of the 
model, which is inherently unreliable [218]. Therefore before applying a QSAR 
model on unseen compounds, it is important to consider the representativity of the 
samples to the training set, i.e., the AD. For these reasons, a novel validation 
method with consideration of the AD was developed in this study to address the 
limitation of traditional model evaluation methods. 
 The novel evaluation method is supposed to address the limitation of 
conventional evaluation methods used in QSAR models that there is discrepancy 
between the internal and external prediction performance. Based on this approach, 
for any dataset, a universal prediction performance standard could be established, 
and any unseen sample falling into the corresponding AD can be evaluated in a 
much more accurate and reliable manner, both statistically and mechanistically. In 
addition, instead of using the traditional evaluation methods which usually 
compute a single value of the prediction performance of the model on all unseen 
data, model evaluation method will produce a vector of prediction performances 
by considering the association of the unseen data to the data used to build the 
model. This forms a performance profile for a predictive model, which can be 
used to aid in model comparison and selection. 
7.2. Materials and methods 
7.2.1. Data sets and tools 
Three binary classification data sets were used in this study for their large 
data size and different characteristics. The first data set is Ames mutagenicity 
(AM) data, a benchmark data set designed for the evaluation of in silico 
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prediction methods. It includes 6512 chemical compounds together with their 
Ames mutagenicity test results publicly available [34]. The Ames test was a 
biological assay to assess the mutagenic potential of chemical compounds [34]. A 
positive test indicates that the chemical might act as a carcinogen. The curation 
and preprocessing procedure described in Chapter 2 were applied on the dataset 
and PaDEL-Descriptor was used to calculate molecule descriptors. The second is 
the MAGIC gamma telescope data (MAGIC) from the UCI machine learning 
repository which includes 19020 instances and 10 attributes. This binary 
classification data was simulated using a complex Monte Carlo program –
CORSIKA by Heck et al [219]. Briefly, the program approximates the 
development of extensive air showers generated by a high energy cosmic ray 
particle. The two classes are “gamma” and “hadron”, which indicate the signal 
and background respectively. The 10 attributes are numerical parameters for the 
obtained shower image. The detailed description of the dataset is available in the 
original publication. The last data set is a polynomial classification (PC) data 
generated using RapidMiner data generation function. The binary classification 
data with 5000 instances and 5 attributes was generated for verification of the 
validation methods on simple toy data. The experiment was carried out using 
RapidMiner for the whole workflow from data preparation to model evaluation.  
7.2.2. RS and CV method experiment 
Two common model validation methods RS and CV were applied on the same set 
of training, testing and validation set and the corresponding estimated 
performance and true performance results were compared. Linear correlation 
coefficients (commonly denoted as r) were obtained using the following formula 
with two variables X, Y to represent the corresponding vectors of sensitivity, 
specificity values respectively and n as the number of pairs of data:  
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The detailed workflow of the experiment for CV and RS was illustrated in Figure 
7.1. Briefly, the preprocessed real or simulated data was split into a validation set 
and modeling set with ratio 9:1 using stratified sampling. The large proportion for 
the validation set is to ensure that the validation sets to represent the majority of 
the population for the MAGIC and PC datasets. A model was developed using the 
modeling set and then applied on the validation set to obtain the true performance 
result. For the RS method, the modeling set was split into a training set and 
testing set with ratio 6:4. A model was constructed on the training set and then 
applied on the testing set to obtain the estimated performance result for the RS 
method. For the CV method, 5-fold cross validation was carried on the modeling 
set. The prediction results of the five runs were averaged to obtain the estimated 
performance results for the CV method. The entire process of splitting into 
modeling set and validation set, and evaluation using RS and CV method was run 
for 30 times to obtain a comprehensive performance profile (RS performance and 




Figure 7.1 Workflow of CV and RS method.  
7.2.3. ADVal method experiment 
In order to see whether our proposed validation method would achieve better 
correlation than RS and CV methods, an experiment was carried out on the same 
set of training, testing and validation set with application of our novel method. 
Then the correlation coefficients obtained were compared with the ones obtained 
from RS and CV. Using the same set of training, testing and validation sets as the 
RS method, the novel validation method (ADVal) was carried out with 
consideration of AD of the model by dividing the testing and validation set into 
several subsets according to the level of the association of the testing/validation 
data to the coverage region of the training/modeling data used to develop the 




Figure 7.2 Workflow of ADVal. 
 Generally, starting from the same training, testing and validation sets as 
the RS method, the representativity of each sample in the testing set to the 
training set and that for each sample in the validation set to the modeling set was 
determined by statistical method and the samples in the testing set and validation 
set were discretized into 10 different bins according to the level of their 
representativity. A predictive model was then developed using the training set and 
assessed using the discretized testing set to determine the performance of the 
model at each bin. This forms the estimated performance profile of the model. 
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Similarly, a predictive model was developed using the modeling set and assessed 
using the discretized validation set to obtain the external validation profile. The 
correlation coefficient of the estimated performance profile and the external 
validation profile was calculated. Similar as the experiment for CV and RS 
method, the whole process was run for 30 times.  
7.2.4. Determination of representativity 
The representativity of a sample to a dataset was determined using the 
same methods to determine the AD for a model based on the multivariate space 
formed by the training data. As introduced in Chapter 2, there are four main 
approaches available for this purpose: range, distance, geometrical, and 
probability density distribution [118]. The commonly used methods were range 
method, distance method and leverage method for low computational cost and 
easy implementation. Among these methods, range method is the most intuitive 
one but also the most unreliable one since it is based on the assumption that the 
dataset is uniformly distributed, which is not true for most real data. Probability 
density distribution is regarded as the most reliable method since it is the only 
method capable of identifying internal empty regions within the convex hull of a 
dataset. Besides, it also produces a density value which can be considered as an 
intuitive measure of the representativity of a sample to the training set. Therefore, 
the density distribution method was adopted for determination of the 
representativity of the samples to the datasets.  
 The probability density function of a data set can be estimated by 
parametric or non-parametric methods. Parametric methods assume the density 
function with a standard normal distribution while non-parametric methods do not 
make any assumptions of the data. Biomedical and chemical data are rarely 
normally distributed so non-parametric approaches are usually applied in these 
applications. In this study, the non-parametric kernel density estimation method 
was used [220]. Suppose (x1, x2… xn) is an independent and identically distributed 
(i.i.d.) sample drawn from some distribution with an unknown density ƒ. Kernel 
density estimator of the sample is 
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Where K(·) is the kernel function and h is a smoothing parameter referred the 
bandwidth [221]. It's important to choose the most appropriate bandwidth for the 
estimation. In our study, heuristic bandwidth selection algorithm was 
implemented to optimize the bandwidth selection. 
 After generation of the density map of the training/modeling set using 
probability density method, each sample in the testing/validation set was placed 
onto the density map to determine its density value. Basically, the attributes 
information of each sample in the testing/validation set was substituted into the 
same formula used to calculate the corresponding density value in the 
training/modeling set. Once the density values for all the samples in the 
testing/validation set were computed, the testing/validation set was discretized 
into ten bins with equal density intervals (i.e., [0, 0.1), [0.1, 0.2) ,…, [0.9,1] ). 
Then the prediction performance of the model for each density interval could be 
determined. 
7.2.5. Model development 
Three well known and inherently different machine learning methods SVM, KNN 
and ANN were used to develop classification models in order to check whether 
the correlation results obtained from different modeling method are consistent for 
different modeling methods. Since the main purpose of this study is not to 
produce models with optimum prediction performance, default parameters were 
applied otherwise specified for computation efficiency.  
7.2.6. Performance profile comparison 
After all the procedures above, the performance profiles of the models on the 
testing and validation were obtained. For performance profile from RS and CV 
experiment, it was a two dimensional data matrix with AUC, SE and SP values 
for testing and validation set as row and iteration number as column. Hence the 
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correlation coefficients of AUC, SE and SP values were calculated directly. 
Whereas for performance profile for ADVal experiment, since the bin index was 
included, the calculation and comparison method was less straightforward. The 
performance profile was sorted according to the bin index first. For each bin index, 
there was a 30 rows table with AUC, SE and SP values with iteration number 
from 0 to 29 for the 30 runs. Then for each bin, except the ones with more than 
half rows containing undefined values which would be removed for statistical 
insignificance, the correlation coefficients of AUC, SE and SP values for testing 
and validation set were obtained. Finally, a group of correlation coefficients were 
retrieved and were compared. This comparison was to examine the correlation 
inside each bin and also to compare all the correlation coefficients with the RS 
and CV results 
7.3. Results and discussion 
7.3.1. Results of CV and RS validation experiment 
Since there were three datasets and three types of modeling algorithms applied, 
there were nine copies of performance profiles for CV and RS. Here only a 
representative performance profile for AM data with SVM modeling and CV, RS 
validation method is shown Table 7.1. It could be observed that most of the AUC 
values are bigger than 0.6, SE and SP values are from 60% to 80% which could 
be regarded as well predicted. The AUC, SE and SP values for PC and MAGIC 
(not shown) are even higher with most of them falling in range of 70% to 90% 
since they are tailored for predictive modeling experiments. All these result 
suggest that the models developed and the evaluation profiles are qualified for 








Table 7.1 Performance profile of SVM models on testing and validation set for 
AM data from CV and RS experiment. 
  Testing performance Validation performance Testing performance Validation performance 
Iteration AUC SE(%) SP(%) AUC SE(%) SP(%) AUC SE(%) SP(%) AUC SE(%) SP(%) 
0 0.747 73.3 67.1 0.734 64.9 70.8 0.790 72.5 69.3 0.734 64.9 70.8 
1 0.760 58.3 74.3 0.730 67.5 66.8 0.784 70.8 71.4 0.730 67.5 66.8 
2 0.688 53.3 70 0.736 65 70.3 0.689 67.5 62.1 0.736 65 70.3 
3 0.693 53.3 67.1 0.751 58.2 79 0.727 67.5 67.9 0.751 58.2 79 
4 0.693 75 64.3 0.748 68 70.3 0.760 67.5 74.3 0.748 68 70.3 
5 0.739 65 74.3 0.756 69.7 69.6 0.734 69.2 65.7 0.756 69.7 69.6 
6 0.722 73.3 67.1 0.747 58.6 78.4 0.789 64.2 79.3 0.747 58.6 78.4 
7 0.672 63.3 58.6 0.736 71 64.5 0.754 70.8 62.9 0.736 71 64.5 
8 0.738 73.3 64.3 0.754 72.1 66.5 0.731 75.8 59.3 0.754 72.1 66.5 
9 0.697 56.7 64.3 0.731 65.2 69.1 0.737 60.8 71.4 0.731 65.2 69.1 
10 0.839 78.3 70 0.736 65.5 70.5 0.822 78.3 69.3 0.736 65.5 70.5 
11 0.743 66.7 64.3 0.738 64.6 71 0.749 70.8 65 0.738 64.6 71 
12 0.694 70 65.7 0.746 52.7 80.6 0.737 65.8 74.3 0.746 52.7 80.6 
13 0.759 53.3 80 0.755 61.5 76.6 0.744 55.8 78.6 0.755 61.5 76.6 
14 0.749 68.3 68.6 0.737 70.2 65.8 0.726 78.3 61.4 0.737 70.2 65.8 
15 0.678 63.3 57.1 0.753 65.3 73.2 0.686 65.8 55.7 0.753 65.3 73.2 
16 0.722 68.3 68.6 0.750 69.5 69.4 0.753 68.3 78.6 0.750 69.5 69.4 
17 0.683 25 82.9 0.755 61.7 76.4 0.667 64.2 64.3 0.755 61.7 76.4 
18 0.642 65 54.3 0.723 71.6 61.8 0.705 57.5 66.4 0.723 71.6 61.8 
19 0.749 65 75.7 0.751 67.4 70.4 0.790 76.7 65 0.751 67.4 70.4 
20 0.771 58.3 81.4 0.740 58.1 75.7 0.734 52.5 78.6 0.740 58.1 75.7 
21 0.772 81.7 52.9 0.752 63.8 73.8 0.793 67.5 79.3 0.752 63.8 73.8 
22 0.845 76.7 82.9 0.743 61.6 73.7 0.794 72.5 71.4 0.743 61.6 73.7 
23 0.781 60 82.9 0.748 60.4 74.9 0.704 65.8 67.9 0.748 60.4 74.9 
24 0.687 53.3 70 0.739 59.1 74.6 0.756 65.8 72.9 0.739 59.1 74.6 
25 0.743 65 67.1 0.739 62.2 72.7 0.692 44.2 70 0.739 62.2 72.7 
26 0.788 63.3 80 0.763 55.7 79.8 0.800 43.3 91.4 0.763 55.7 79.8 
27 0.721 60 75.7 0.747 62 74.5 0.711 61.7 72.9 0.747 62 74.5 
28 0.744 46.7 87.1 0.757 53.5 80.2 0.735 49.2 81.4 0.757 53.5 80.2 
29 0.738 60 72.9 0.750 68.1 71.2 0.715 68.3 66.4 0.750 68.1 71.2 
 
 Based on the above results, the correlation coefficients of the 30 sets of 
AUC/SE/SP values were determined accordingly for CV and RS experiments for 
all three datasets and shown in Table 7.2. It is to be noted that with a given 
sample size 30, the correlation coefficient that was significantly different from 
zero was around 0.3 for a moderate positive correlation. From Table 7.2 we could 
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see that for KNN and ANN models, almost all of the correlation coefficient values 
of three data sets were below this level. For SVM models, the correlation values 
were still low for PC data but much better for AM and MAGIC data with values 
from 0.271 to 0.547. Thus they were not strong enough to predict the external 
data based on internal performance of the model. All of these results were 
consistent with the conclusion that model with reasonably high internal fitness 
does not automatically imply a high prediction power of the independent 
validation set [116].  
Table 7.2 Correlation coefficients of performance profiles of different models on 
testing and validation sets using CV and RS method. CC_AUC, CC_SE and 
CC_SP indicate the correlation coefficient of AUC, SE and SP values of testing 
and validation performance respectively. 





CC_AUC CC_SE CC_SP CC_AUC CC_SE CC_SP CC_AUC CC_SE CC_SP 
SVM 
CV 0.167 0.280 0.484 -0.010 -0.231 0.086 0.271 0.541 0.271 
RS -0.031 0.547 0.564 -0.465 0.047 0.146 0.490 0.537 0.509 
KNN 
CV 0.143 0.071 0.229 -0.072 -0.475 0.009 0.077 -0.174 0.030 
RS 0.066 -0.195 0.313 -0.076 0.120 -0.041 0.184 0.214 -0.117 
ANN 
CV 0.257 0.158 0.273 0.100 -0.242 -0.075 0.053 -0.095 0.127 
RS 0.241 0.526 0.586 0.285 0.067 0.028 0.003 0.189 0.021 
 
7.3.2. Results of ADVal experiment 
 For the results of ADVal experiment, the prediction performance for both 
internal and external validation were in good level for all three datasets, i.e., most 
of the AUC values are bigger than 0.6, SE and SP values are from 60% to 100%. 
Although the performance is not the best compared with other studies using the 
same dataset, it is still acceptable since the purpose is not to optimize the model’s 
performance per se so the modeling parameters were not optimized for 
computation efficiency. These results suggest that the subsequent correlation 
analysis were reliable. Some of the AUC/SE/SP values were undefined due to 
zero or low sample size and this was especially common in lower level bins (bin 1 
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to 5) which has sample size less than 5 generally. Correlation coefficients of AUC, 
SE and SP values with small sample size could be biased and unreliable so some 
bin groups with more than half members with undefined prediction values were 
removed, for example, bin 2 to 5 were removed for AM and only bin 1, bin 6 to 
10 were retained for later analysis. The evaluation profile of three datasets with 
ADVal and SVM modeling method is shown in Table 1 in Appendix. The 
correlation coefficients of the evaluation profiles for ADVal methods were 
determined and the detailed information is presented in Table 7.3. 
Table 7.3 Correlation coefficients of performance profiles using ADVal method 
for three datasets. CC_AUC, CC_SE and CC_SP indicate the correlation 



















    AM PC MAGIC 
  AD_bin CC_AUC CC_SE CC_SP CC_AUC CC_SE CC_SP CC_AUC CC_SE CC_SP 
SVM 
1 -0.168 0.131 -0.161 - - - - - - 
2 -* - - - - - - - - 
3 - - - 0.161 0.195 0.545 - - - 
4 - - - 0.117 -0.182 0.074 - - - 
5 -0.175 0.304 -0.181 0.096 0.192 0.235 -0.159 0.710 0.449 
6 -0.255 0.242 -0.059 -0.118 -0.050 0.196 0.013 0.507 -0.090 
7 -0.427 0.561 0.042 -0.296 -0.278 0.118 0.139 0.497 -0.196 
8 0.099 0.167 0.389 0.058 0.118 0.003 -0.029 0.621 0.175 
9 0.747 0.543 0.776 0.310 0.221 0.440 0.399 0.805 0.666 
10 -0.191 0.551 0.594 0.824 0.931 0.461 0.273 0.825 0.720 
KNN 
1 -0.161 0.050 -0.049 - - - - - - 
2 - - - - - - - - - 
3 - - - -0.165 0.017 0.256 - - - 
4 - - - 0.062 -0.097 -0.015 - - - 
5 - - - -0.006 0.045 0.249 -0.092 0.137 0.032 
6 - - - 0.092 -0.148 0.109 -0.160 0.375 -0.185 
7 0.195 0.183 0.020 -0.167 -0.125 0.024 0.170 0.101 0.204 
8 0.150 0.153 0.244 0.077 0.042 0.176 0.020 0.469 0.350 
9 0.183 -0.083 0.123 0.214 0.367 0.320 -0.112 0.320 0.312 
10 0.022 0.060 0.174 -0.258 0.667 0.494 0.565 0.304 -0.031 
ANN 
1 -0.411 0.425 -0.144 - - - - - - 
2 - - - - - - - - - 
3 - - - 0.859 0.324 0.027 - - - 
4 - - - -0.251 -0.167 0.003 - - - 
5 - - - -0.133 0.265 0.059 -0.134 0.109 -0.286 
6 - - - -0.022 -0.128 0.103 -0.193 0.044 -0.132 
7 0.052 0.284 0.409 0.278 -0.149 0.205 -0.290 -0.291 -0.133 
8 0.157 0.350 0.382 -0.085 0.166 -0.074 -0.034 0.275 -0.065 
9 0.058 0.619 0.403 0.156 0.249 0.405 -0.069 0.156 0.071 
10 0.019 0.424 0.588 0.281 0.522 -0.378 0.048 0.411 0.469 
*- indicates the value is not available. 
7.3.3. Comparison of the correlation results of three validation methods 
The correlation coefficients for the ten bins, bin 1 to bin 10, from ADVal 






 (a) Complete correlation profile for three datasets using SVM.  





(c) Complete correlation profile for three datasets using ANN. 
Figure 7.3 Correlation coefficients of AUC, SE and SP values for ADVal 
experiments for all datasets. The number 1 to 10 is the bin index. AM_CC_AUC, 
AM_CC_SE and AM_CC_SP indicate the correlation coefficient of AUC, SE and 
SP values of testing and validation performance for AM data set respectively. The 
same notation rule applies for MAGIC and PC dataset. 
  
 For the results in Figure 7.3, we could see that most of the correlation 
values for lower bins of ADVal experiment are not available. As stated in 
previous sections, it is because that the equal density interval discretization 
produced inconsistent sample sizes for the different bins so some of the bins had 
zero or small sample size for the testing sets. This caused the correlation 
coefficients for these bins either not available or not statistically meaningful. 
Other discretization methods such as equal sample size can produce bins with 
equal sample sizes, but it will also cause the inconsistency of the density intervals 
for the bins, which makes it difficult to compare the correlation coefficients for 
the bins fairly. Therefore, equal density interval method was still employed and 
the unreliable results for the low sample size bins were not used for analysis. 
There are also some higher bins with zero to low correlation coefficients values 
from -0.3 to 0.3, which means the model has no or low generalizability for the 
samples falling into these bins. This could be because that the model itself does 
not perform well for samples falling in these bins and the correlation coefficients 
for such bins are not reliable. For the remaining correlation coefficients for higher 
bins of ADVal results, they ranged from the moderate to high level from 0.3 to 
0.8, which suggests the model has good generalizability on these bins. Moreover, 
the correlation coefficients are quite different from bin to bin. This difference 
demonstrates that for the same model, it has different generalizability for samples 
in different bins, i.e., with different levels of representativity. 
 For the comparison of the results of three validation methods, it should be 
noted first that for CV and RS methods, more information was used to train the 
model for CV (80% of the modeling set) than RS (60% of the modeling set). For 
RS and ADVal experiment, the models are the same and the only difference is 
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that the testing/validation sets for the ten bins for ADVal experiment were subsets 
of the testing/validation set used for RS experiment. Hence the correlations for the 
bins are supposed to be similar to RS and slightly lower than CV. Nevertheless, 
for all three datasets, the correlation coefficients of SE/SP for RS were either 
slightly higher or around the same level as CV, which were all in low to moderate 
correlation with value from -0.3 to 0.5. This means the additional information 
included in the training set for the model produced from CV did not add value to 
the model’s generalizability. For ADVal, although the correlation coefficients of 
SE/SP were either not available or around low level for the lower bins (bin 1 to 5) 
it became large for high level bins (bin 8 to 10) and even higher than both CV and 
RS values. Actually, since the models and the data sets which the 
testing/validation sets were selected from were the same for RS and ADVal 
experiment, the total number of correct and wrong predictions are the same. If the 
testing/validation set was discretized into ten equal bins randomly for ADVal, the 
correlation result should not be too different from those generated from RS 
experiment. However this is not the case. The correlation result from ADVal had 
both higher and lower values than the one from RS. This is important since it 
demonstrated that ADVal methods could not only differentiate the 
testing/validation test with different association levels with the training set of the 
model, but also exhibit better correlation for the estimated performance and true 
performance for the samples with better association. These results suggest the 
potential of ADVal method for model evaluation. That is, given a large and 
diverse enough benchmark dataset, instead of using a fixed borderline of the AD 
for a specific model and using a single measurement (SE, SP etc) for all the 
samples in the AD, our approach could provide a comprehensive profile of the 
model’s performance on any unseen dataset.  
 However, most of the correlation coefficient values are in low to moderate 
level which means the correlation is not very strong between the testing and 
validation sets. There are several possible reasons for this situation. Firstly, the 
sample size for different bins varied widely which is especially common for real 
datasets. This inconsistency made it difficult to ensure all the testing sets were 
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balanced and comparable with each other, which caused bias in the performance 
measurements and subsequently affect the final correlation results. Moreover, 
probability density method was used to generate the distribution of the datasets 
and then divide the datasets into different bins. However, it might not be able to 
discretize the data well according to the representativity of the data. Some other 
methods used for data categorization such as clustering could also be considered 
in the future.  
7.4. Conclusion 
In this chapter a novel model evaluation method ADVal was developed by using 
probability density estimation and discretization methods to address the 
applicability issue of predictive models. The consideration of association level of 
testing samples with the training data and the AD concept provide the method 
with additional value for model evaluation. Through comparative experiments of 
three evaluation methods RS, CVand ADVal with both real and simulated 
datasets, the results demonstrated that ADVal method is capable of producing a 
more reliable and comprehensive performance profile than RS and CV methods. 
It is possible to use the method in predictive modeling studies given a large 
validation set is available. Nevertheless, the result is still quite preliminary and 



























Chapter 8 Summary of Models 
This chapter focuses on the important information related to the four final models 
developed for three types of ADRs and nephrotoxicity in previous chapters. It 
discusses the samples and features of the data, the AD of the model and the actual 
performance of model. In the end, the final models for all three types of ADRs and 
chemical structure files for all drugs are made available for download at 
http://padel.nus.edu.sg/software/padelddpredictor.  
8.1. Introduction 
Predictive models for three types of ADRs (SJS/TEN, TdP and serious psychiatric 
ADR) and nephrotoxicity were developed by using the methods discussed in 
previous chapters. To our best knowledge, they are the first models developed on 
these endpoints with determination of AD. Besides the four final models, there are 
some important information related to these models, including the samples (e.g. 
classification of drugs) and features (e.g. important descriptors, fingerprints or 
genomic transcripts) of the data, the AD of the model and the actual performance 
of model on external validation set (if applicable). These information could help 
us to better understand and utilize these models. Since the methodologies used for 
development of these final models are similar, they are discussed together in this 
chapter. 
8.2. SJS/TEN model 
For the model development process using entire dataset, 33 out of 300 base 
models were selected as suitable candidate models for ensemble modeling. A total 
of 31 ensemble models with ensemble size from 3 to 33 were developed and the 
final ensemble model EMall was determined by the overall majority voting 




8.2.1.1. Performance of final model 
The performances of the final model EMall were summarized in Table 8.1. The 
three performance groups in the first column are the performances of model 
EMall on the entire dataset, using external 5-fold CV and on the external positive 
set. The external data set will be introduced in section 8.1.3.4. 
Table 8.1 Performances of the final ensemble model EMall. 
Performance ACC(%) SE(%) SP(%) MCC AUC 
On entire data set 75.0 83.4 65.9 0.503 0.749 





 - - 
 “*” indicates the value is not available 
8.2.1.2. Visualization of drugs out of AD of EMall 
In total 28 descriptors were collected from the union of the sets of descriptors for 
all four constituent models of final model EMall. Then principal component 
analysis (PCA) was carried out on all drugs with the selected 28 descriptors using 
statistical software JMP 8 to investigate the characteristics of the drugs out of AD 
of EMall [222]. The first two principal components (PC) were used to plot the 




8.2.1.3. Potential important substructures 
To identify the important substructures related to SJS/TEN, fingerprints for the 
4840 chemical substructures identified by Klekota and Roth were calculated to 
identify potential structural alerts for SJS/TEN [223]. The detailed information of 
molecular descriptors and fingerprints substructures is available on the PaDEL-
Descriptor website. The substructures which were significantly different for ST
+
 




 drugs are 
shown with black and grey dots respectively. Drugs outside the AD of EMall are marked with “x”. 





 class were obtained by t-test with p-value less than 0.05. Then to further 
explore the substructures potentially important for SJS/TEN inducing mechanism, 




 class. The score was 
calculated as follows: if the occurrence of the substructure in ST
-
 class is 0 then 
the score is equal to the number of the occurrence in ST
+
 class; if it is not 0, then 
the ratio of the occurrence of the substructure in ST
+
 class to ST
-
 class was used. 
All substructures were ranked descendent according their scores. After that, it was 
observed that for the top 13 substructures, some of them had similar fragments so 
they were selected to represent the important substructures related to SJS/TEN 
and are shown in Table 8.2. These structures might be potentially useful for 
predicting drugs with SJS/TEN-causing potentials as well as for understanding the 
drug action and mechanisms. 
Table 8.2 Top 13 potential important SMARTS substructures related to SJS/TEN. 
ID Structure
 *












































 [!#1] is any atom not with atomic number of 1. 
8.2.2. Discussion 
8.2.2.1. Drugs out of AD 
Drugs are defined to be out of the AD of the ensemble model when all the 
base models identify the drug to be out of their AD, or if there is a tie in the 
predictions. For model EMall, 94 drugs were defined as out of AD based on 
internal CV prediction result. PCA score plot in Figure 8.1. illustrates the 
distributions of all 494 drugs in two-dimensional space. It was observed that some 
drugs such as nitrofurantoin and rifampicin were near the boundary or in the 
sparse region of the feature space formed by the two principle components. Thus 
they might be outside the information space of the current descriptors, leading to 
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potential extrapolation of the model. Some drugs such as vinblastine had nearby 
neighbours with the opposite class, so the model might not be confident with its 
prediction. Although not all of the drugs out of AD could be clearly explained due 
to the complexity of the chemical space, the above observations suggest that the 
AD method used in this study could not only identify drugs falling outside the AD 
defined by the descriptors but also drugs that the model is not confident of 
providing a prediction.  
8.2.2.2. Final Model 
For final model EMall, the combination of base models with different set 
of attributes and from different modeling algorithms ensures the diversity of the 
base models. From Table 8.1, the similar performance of EMall on the entire 
dataset and rigorous validation suggests that the model has low risk of overfitting. 
The estimated performance from the rigorous validation process gave a false 
positive rate of 33.6%. There are two possible reasons for the relatively high false 
positive rate.  Firstly, QSAR models usually predict drugs with similar chemical 
structures as belonging to the same class, even though they may belong to 
opposite classes. For example, penicillin drugs are regarded as one of the main 
types of drugs causing SJS/TEN. There are 12 penicillin drugs in the entire 
dataset, of which eight were ST
+
 and four were ST
-
. This may cause a tendency of 
the model to predict ST
-
 penicillin drugs as ST
+
 as some studies had shown that 
QSAR models could not differentiate drugs with similar structures but different 
classes very well [40]. This inability to differentiate drugs with similar structures 
is related to the fundamental principle of QSAR which assumes that similar 
molecules have similar activities. The second reason might be that some of the 
“false positives” are actually “real positives” but their toxic potential has not been 
found yet, so the actual false positive rate may be lower than the above value. 
Although we have used several criteria to identify the ST
-
 drugs, it still could not 
eliminate the possibility that they will cause SJS/TEN in the future. This also 
demonstrates the necessity and importance of using OCC method to develop the 
model when the information for the negatives may not be reliable.  
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To the best of our knowledge, currently there are no available QSAR 
models for predicting the SJS/TEN-causing potential of drugs, so it is not possible 
to compare the performance of the ensemble model developed in this study with a 
similar study. Nonetheless, a tentative comparison could be made with 
computational models developed for other toxicological properties such as 
genotoxicity and hepatotoxicity [40, 121]. Although the final model’s 
performance with an overall accuracy of approximately 74.5% was lower than 
models for these well studied properties, it could still be considered as useful 
model. It is because SJS/TEN is a very complex disease with multiple 
mechanisms affecting its occurrence [224] and currently there are no 
computational models available for prediction of SJS/TEN to our best knowledge. 
Therefore, the various approaches introduced in this study have been successful in 
the development of the QSAR model for SJS/TEN causing potential. The final 
model achieved promising performance and is potentially useful for prediction of 
SJS/TEN causing potential of new drug candidates. 
8.2.2.3. Potential important substructures 
For the 13 structures listed in Table 8.2, some of them share similar 
fragments. Five of them (KR2034, KR2035, KR3200, KR3625, KR4275) share 
thiazole fragment, three of them (KR3548, KR3586, KR4067) share 
fluorobenzene fragment, two of them (KR1724, KR2886) share 
bezenesulphonamide fragment, and another two of them (KR3452, KR4834) 
share oxime group. KR2988 is part of the penicillin core structure. Some drugs 
contain these fragments such as sulphonamides, fluoroquinolones and penicillins 
have been observed as causing SJS/TEN [225, 226]. It is useful for decision 
making since it is likely that drugs sharing similar fragments but without any case 
report yet have SJS/TEN causing potential. Moreover, these important structures 
could help to better interpret the complex QSAR model [227]. 
8.2.2.4. External validation 
After the data collection of this study, some more drugs have been found 
as associated with SJS/TEN in recent case reports such as rufinamide and 
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vandetanib [228, 229]. And there are also some drugs have been reported but not 
updated in Micromedex database yet such as nimesulide [230]. Hence to 
investigate the final model’s actual performance on external data, a set of 14 
drugs were collected from literatures with recent SJS/TEN case reports. The drug 
information is shown in Table 8.3 and the performance of the final model on this 
dataset is shown in Table 8.1.  Since only ST
+
 drugs were evaluated, only 
accuracy and sensitivity values were provided. The sensitivity value of 66.7% 
suggests the model could identify two out of three of the real positive drugs, 
which is a promising result. Fingerprints analysis also shows that most of these 
drugs contain one or more of the fragments in Table 8.2. For example, 
ceftriaxone and mastinib contain the thiazole fragment; rufinamide, vandetanib 
and linezolid contain the fluorobenzene fragments and etoricoxib contains the 
sulphonamide fragment. This supports the statement that the identified 
substructures could help to identify drugs with SJS/TEN-causing potential in the 
future. Nevertheless, more studies should be carried out to explore the 
relationship of the fragments and the SJS/TEN-causing potential of compounds as 
the mechanism of SJS/TEN is quite complicated and multiple factors like genetics 












Table 8.3 Compounds collected from literatures with recent SJS/TEN case reports. 
Name Class Prediction Fragments contained 
Adefovir dipivoxil[233] Positive Positive  
Aripiprazole[234] Positive Negative  
Ceftriaxone[235] Positive Positive Thiazole 
Duloxetine[236] Positive Negative  
Etoricoxib[235] Positive Positive Sulphonamide 
Linezolid[237] Positive Positive Fluorobenzene 
Lisinopril[22] Positive Positive  
Masitinib[238] Positive Negative Thiazole 
Nimesulide[230] Positive Positive  
Roxithromycin[239] Positive Out of AD  
Rufinamide[228] Positive Positive Fluorobenzene 
Stavudine[240] Positive Positive  
Tigecycline[241] Positive Out of AD  
Vandetanib[229] Positive Negative Fluorobenzene 
 
8.3. TdP model 
Out of 300 base models developed using three one-class machine learning 
algorithms on the entire dataset, 61 models were selected as suitable candidate 
models for ensemble modeling. A total of 59 ensemble models with ensemble size 
from 3 to 61 were developed and the final ensemble model (EMall) was 
determined by the overall MV accuracy from cross validation results. EMall 




8.3.1.1. Performance of final model 
The training and validation performances of EMall determined using the entire 
dataset and rigorous validation process are given in Table 8.4. 
Table 8.4 Performance of the final ensemble model EMall. 
 ACC(%) SE(%) SP(%) MCC AUC 
Entire data set 91.2 88.9 92.8 0.817 0.932 
Rigorous 
validation 
85.6 78.4 90 0.692 0.825 
  
8.3.1.2. Selected descriptors in final model  
The eight base models contained in EMall have different number of descriptors, 
ranging from 11 to 28. Together, a total of 75 unique descriptors were found to be 
important. None of these descriptors appeared in all eight base models but some 
of them had higher frequencies than others. The detailed categories and 
frequencies of these descriptors are provided in the supporting information of the 
publication [89]. 
8.3.1.3. Potential important substructures 
The same substructure identification method in SJS/TEN study was used to obtain 
the representative set of substructures related to TdP. A total of 238 substructures 
had p-value less than 0.05 for t-test. The score for all these substructures was from 
0 to 11. For simplicity, the top 10 significant substructures that occurred more 
frequently in TdP
+
 drugs than TdP
-
 drugs are shown in Table 8.5. These 
structures might be potentially useful for predicting drugs with TdP-causing 




Table 8.5 Top 10 potential important SMARTS substructures related to TdP. 
No. ID SMARTS Category Structure Score 




























































8.3.2.1. Final model 
In Table 8.4, similar performance results of EMall determined using the entire 
data set and rigorous validation suggests that the final ensemble model is less 
likely to be over-fitted. There are several computational models that have been 
developed for the prediction of hERG K
+
 channel blockers or drugs with long QT 
prolongation causing potentials [242]. However, very few models were developed 
specifically for determination of TdP causing potentials. Moreover, these models 
were developed long time ago thus did not consider the AD which was a 
requirement for QSAR models nowadays. Our final ensemble model with an 
overall accuracy of approximately 85.6% is comparable with the results of 
previous studies. In addition, the model was rigorously validated and the AD was 
well determined and so the model’s performance is expected to be more reliable 
than previous models. 
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8.3.2.2. The descriptors 
 For the 75 unique descriptors for model EMall, the descriptors with higher 
frequency were mainly atom type E-state descriptors and counts of rings. E-State 
descriptors encode both electronic and topological information of the compounds. 
It had been used extensively in QSAR studies because of its straightforward 
calculation, ability to unify both electronic and topological description and 
potential to examine the contribution of sub-molecular features towards 
intermolecular effects for investigation of molecular mechanism of action [243]. 
The large proportion of the E-state descriptors in the final ensemble model is 
consistent with the previous study using recursive feature elimination feature 
selection algorithm, where it was believed that the E-state descriptors encode the 
electron accessibility for each atom, that is, the potential for non-covalent 
intermolecular interaction and possibly describe binding to certain types of 
proteins [244]. The second type of high frequency descriptors was ring counts, 
which includes 4, 6, 8, 9, and 12-membered rings. These rings are common in 
drugs with penicillin core structure or aromatic structure such as piperidine, which 
might be responsible for the binding activity as well. 
8.3.2.3. Potential important substructures  
 The 10 substructures listed in Table 8.5 can be categorized into 
fluorophenyl/trifluoromethylbenzene fragment (4, 7, 9, 10; 1 and 2 could be 
considered as a substructure of 10), phenothiazine fragment (3 and 6), 
phenylpiperazine fragment (5) and piperidine fragment (8). Most of these 
fragments contained aromatic rings which was consistent with the study that the 
presence of aromatic ring is important for hERG K
+ 
 channel blocking activity 
[245]. The identification of fluorophenyl fragments is consistent with the previous 
study where it was selected as the top discriminating fragment for TdP
+
 drugs 
[246]. Both fluorophenyl and trifluoromethylbenzene fragments have 
electronegative fluorine attached to carbon, which may interact with the polar 
amino acid residues of the binding site [247]. It has also been shown recently that 
there is an association between α1-adrenoceptor affinities, hERG K+-antagonistic 
properties and antiarrhythmic activities for a series of phenylpiperazine 
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derivatives [248]. Therefore, it is very likely that compounds containing one or 
more of these substructures but without any case report yet have TdP-causing 
potential. Hence careful attention should be paid when these compounds are used 
during drug development or clinical trials.  
8.4. Serious psychiatric ADR model 
8.4.1. Data summary 
There are 25 critical terms listed in WHO-ART under code 0500 
(psychiatric disorders) for the system-organ class. Out of the 1127 marketed drugs 
used for screening, 330 drugs were found to cause one or more of these 25 serious 
psychiatric ADRs. The number of drugs causing each serious psychiatric ADR 
and the percentage based on all 1127 drugs were listed in Table 8.6. Depression is 
the most common serious psychiatric ADR and is caused by nearly 16% of 
marketed drugs. This is followed by hallucination and psychosis, with each 


















Table 8.6 List of 25 critical terms listed in WHO-ART under code 0500 
(psychiatric disorders) for the system-organ class.  
Critical term Number of drugs Percentage (%) 
Depression 182 16.1 
Hallucination 120 10.6 
Psychosis 119 10.6 
Aggressive reaction 85 7.5 
Suicide attempt 70 6.2 
Delirium 64 5.7 
Manic reaction 60 5.3 
Amnesia 47 4.2 
Delusion 29 2.6 
Catatonic reaction 13 1.2 
Paranoid reaction 13 1.2 
Schizophrenic reaction 9 0.8 
Neurosis 2 0.2 
Psychosis manic-depressive 2 0.2 
Anorexia nervosa 1 0.1 
Drug abuse 1 0.1 
Drug dependence 1 0.1 
Illusion 1 0.1 
Alzheimer's disease 0 0.0 
Asperger's disorder 0 0.0 
Autism 0 0.0 
Autistic disorder 0 0.0 
Childhood disintegrative disorder 0 0.0 
Narcolepsy 0 0.0 
Psychosis alcoholic 0 0.0 
 
 From Table 8.6, only seven serious psychiatric ADRs had more than 50 
drugs that are known to cause them. The total number of drugs associated with 
these seven serious psychiatric ADRs is 321. Of these, 51 drugs were marketed 
after 1999. These will be kept aside to validate the final QSAR model. The 
remaining 270 drugs marketed before 1999 will be used to develop the models. A 
total of 173 drugs with no serious psychiatric ADRs were identified based on our 
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criteria. None of these were marketed after 1999 so all these will be used to assess 
the performance of the models during the model development and rigorous 





 drugs is 262 and 169 respectively. The number of drugs in the prospective 
validation set remains at 51.   
8.4.2. Results 
The 300 models developed on the entire modeling set were screened and 
four of them were finally selected by the genetic algorithm to form the final 
ensemble model EMall. The performances of this final ensemble model, 
determined using the dataset and the two validation methods were given in Table 
8.7. 
Table 8.7 Performance of final EMall model for serious psychiatric ADR study. 
Validation 
method 
ACC (%) SE (%) SP (%) 
Entire dataset 77.3 77.9 76.3 
External 5-fold 
CV 
69.0±9.5 73.4±15.3 59.4±9.8 
Prospective 
validation set 
65.2 65.2 - 
The results show that the model has sensitivity of 77.9% and 73.4%, and 
specificity of 76.3% and 59.4% for training set (entire data set) and rigorous 
validation. For the prospective validation set, 28 drugs were determined by the 
model to be outside its AD and thus only 23 drugs were predicted. The detailed 
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8.4.3. Discussion 
8.4.3.1. The data 
Our study found that approximately 29.3% of marketed drugs were 
associated with at least one serious psychiatric ADR. Since it is commonly 
accepted that drugs used to treat neurological and mental disorders have a higher 
chance of causing psychiatric ADRs, it is interesting to determine the proportion 
of marketed drugs that cause serious psychiatric ADRs but are not used to treat 
neurological and mental disorders. To obtain a better understanding of the 
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therapeutic usage of these drugs, the anatomical therapeutic chemical (ATC) 
classification system [249] was used to divide drugs into different anatomical 
groups according to the organ or system on which they act (1st level).  Since a 
drug can belong to more than one therapeutic group, the number of drugs under 
each therapeutic group was counted and the percentage of the number of drugs for 
each group over the total number of 321 drugs known to cause the top seven 
serious psychiatric ADRs was calculated and summarized in Table 8.9.  
Table 8.9 Distribution of therapeutic groups of the 321 drugs that cause top seven 








N 40.5 130 Nervous system 
C 14.3 46 Cardiovascular system 
J 10.6 34 Antiinfectives for systemic use 
A 10.0 32 Alimentary tract and metabolism 
L 7.8 25 Antineoplastic and immunomodulating agents 
R 7.5 24 Respiratory system 
S 6.9 22 Sensory organs 
G 6.5 21 Genito-urinary system and sex hormones 
D 6.2 20 Dermatologicals 
M 5.3 17 Musculo-skeletal system 
H 4.0 13 
Systemic hormonal preparations, excluding sex 
hormones and insulins 
P 2.8 9 Antiparasitic products, insecticides and repellents 
V 1.2 4 Various 
B 0.9 3 Blood and blood forming organs 
 
From Table 8.9, we could observe that only 130 out of all 321 drugs are 
used to treat neurological and mental disorders. The remaining 191 (59.5%) drugs 
were used to treat other disorders. Hence, there is a relatively large proportion of 
drugs used for treatment of non-neurological and mental disorders which may 
potentially cause serious psychiatric ADRs. This suggests the need to encourage 
patients and clinicians to look out for such ADRs, especially for newly marketed 
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drugs, regardless of whether they are used to treat neurological and mental 
disorders or not. 
8.4.3.2. Final model 
The overall accuracy of our model ranges from 65.2% to 77.3%. The 
relatively broad range for the accuracy is due to an inherent nature of QSAR 
models. QSAR models tend to have better accuracies for drugs with structures 
which were very similar to those used to develop the model and have poorer 
accuracies for drugs with very different structures from those used to develop the 
model. Thus, our final QSAR model have poorer performance on the prospective 
validation set compared to that of the dataset because the prospective validation 
set comprises of drugs which were marketed later and thus some of these are 
expected to have very different structures from those that had been marketed 
much earlier. 
Since there are no similar QSAR models for serious psychiatric ADRs, a 
tentative comparison of the model were made with QSAR models for SJS/TEN 
and TdP. TdP model achieved an overall accuracy of 85.6% through rigorous 5-
fold cross-validation and the corresponding value for SJS/TEN model is 74.5%. 
The SJS/TEN model also has an overall accuracy of 66.7% on a validation set. 
These show that the performance of our current psychiatric model is slightly 
poorer than the other two models. A possible reason could be the larger number of 
ADRs that were modeled in this study. In the torsade and SJS/TEN studies, the 
numbers of ADRs were one and two respectively. In this study, we modeled 
seven ADRs. Thus, the number of mechanisms causing these ADRs will be 
greater and hence it is more complex to develop a single model for so many 
ADRs. Future studies could consider developing QSAR models only for single 
serious psychiatric ADR.   
8.5. Model for nephrotoxicity 
This section presented the information obtained from the predictive model 
developed for nephrotoxicity in Chapter 4. In addition to look at the 
performances of models, we also tried to better interpret of the models by 
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generating a set of important descriptors. These descriptors will be useful for the 
understanding the chemical structural features and biological mechanisms related 
to nephrotoxicity.  
8.5.1. Important features 
Since the hybrid model achieved highest performance among all four models, the 
set of features (both chemical descriptors and genomic features) of the hybrid 
model were collected and analyzed. The final ensemble model contained 33 base 
models and 820 attributes in total. However, only few of the features appeared 
more frequently than the remaining descriptors/transcripts. These top ranking 
features (with frequency greater than 5) were collected and summarized in Table 
8.10. 










AI407482 10 AA799358 6 nHAvin 10 
X60822 9 AA799691 6 ATSc4 8 
AA799550 8 AA799789 6 nsSH 8 
AA818947 8 AA800258 6 nF6Ring 7 
AA851302 8 AA800665 6 nHsSH 7 
AA998971 8 AA818197 6 SsSH 7 
AA799614 7 AA850505 6 ATSc2 6 
AA799700 7 AA850740 6 nwHBd 6 
AA800763 7 AA851370 6 SCH-3 6 
AA800782 7 AA859508 6 SHsSH 6 
AA818203 7 AA892339 6 VCH-3 6 
AA848821 7 AA894080 6 
  AA849731 7 AA899704 6 
  AA849752 7 AA945099 6 
  AA849975 7 AB000216 6 
  AA892300 7 AF010131 6 
  AA925922 7 AF134054 6 
  AA943126 7 AF214733 6 
  AW915692 7 AF237778 6     
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 Compared with previous study by Freidman et al., the descriptor set of our 
model has 10 overlapping genes with their biomarker set containing 35 genes. 
This suggests some new and important genes are discovered in our study. 
Nevertheless, since the ensemble model provided a big number of predictive 
transcripts, further examination is still needed to identify an effective biomarker 
set. Although the genomic signatures were not deemed suitable for use in 
regulatory settings, they are still potentially useful for toxicity assessment of drug 
candidates to assist decision making in the early stages of drug development. In 
addition to find the important gene set that were predictive and highly relevant to 
the mechanisms of drug-induced renal toxicity, chemical structural descriptors 
were also identified. These results suggest that in spite of providing models 
capable of accurate prediction of nephrotoxicity from chemical structures and 
short-term assay results, the concurrent exploration of the chemical features and 
drug-induced gene expressions variations could enrich the mechanistic 
understanding of drug-induced renal toxicity. 
8.6. Conclusion 
The relevant information of the QSAR models for predicting drugs’ 
potential to cause SJS/TEN, TdP and serious psychiatric ADRs and the integrative 
model for nephrotoxicity were presented in this chapter. To our best knowledge, 
they are amongst the first of models developed for the ADRs with AD 
determination and rigorous validation. Besides, the substructures identified 
through a simple analysis of the chemical fingerprints of the drugs also provide us 
with information to better understand the mechanisms of ADRs or toxicity 
inducing process. For the study of serious psychiatric ADR, a list of marketed 
drugs causing serious psychiatric ADRs was compiled, from which it was 
observed that the majority of such drugs are used to treat non-neurological and 
mental disorders. This information will be of interest for other clinical 
professional doing research about psychiatric disorders. Most importantly, all 
these models are not only important for the risk assessment and safety 
investigation of chemical compounds as general QSAR models, they are also 
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potentially useful for both clinical and regulatory setting to provide additional 
information regarding possible risks of drugs. This will enable clinicians and 
regulators to more closely monitor drugs with possible ADRs and thus potentially 
reducing the potential harm of the drugs to patients. In the clinical setting, these 
models can help to identify newly marketed drugs with the potential to cause the 
related ADRs. This will enable clinicians to better evaluate whether such drugs 
should be used in patients with the ADRs. Clinicians and patients will also be 
forewarned to actively look out for such ADRs and thus potentially reduce the 
potential harm to the patient. For regulatory work, the model could help 
regulatory professions better understand the potential risks of a new drug. This 
additional information can then be viewed in the context of other risks and 
benefits of the drug to aid in the drug approval process or risk management of a 
drug.  For the integrative model for nephrotoxicity, with the development of the 
gene profiling technologies, there is a great opportunity to employ TGX method 
for assessment of preclinical safety and understanding of underlying mechanisms 
by establishing the relationship of gene expression profile information with the 
biological properties for a group of compounds, as well as to identify the effective 































Chapter 9 Tool for model deployment 
This chapter is to address the last issue of the QSAR workflow, the lack of 
independent tool for model deployment. A software program, PaDEL-
DDPredictor was developed for rapid prediction of calculate pharmacodynamics, 
pharmacokinetics and toxicological properties (PD-PK-T) of compounds from 
their structures. It is completely free and open-source, has both graphical user 
interface and command line interface, can work on all major platforms (Windows, 
Linux, MacOS) and supports more than 90 different molecular file formats. The 
molecular descriptors are calculated by the PaDEL-Descriptor plug-in and the 
corresponding endpoints of the compounds are predicted and output in a result 
file.The software can be downloaded from 
http://padel.nus.edu.sg/software/padelddpredictor.   
9.1. Introduction 
The term PD-PK-T is used to express the overall profiling of 
pharmacodynamics, pharmacokinetic properties and toxic effects of a substance. 
The determination of the PD-PK-T, especially PK-T properties (commonly 
abbreviated as ADMET) plays an important role in the drug design process. It is 
reported that poor ADMET properties contribute for the failure of about 60% of 
NCE in the clinical stages [3]. Currently, many QSAR models for prediction of 
ADMET properties are published in the scientific literature every year [250]. The 
original purpose for the development of all these models is to perform predictions 
for new data. However, not all of them are suitable for such applications. This is 
because the models may not always fully conform to the validation principles for 
QSAR models laid out by OECD [37]. In addition, for most models, a publication 
usually means the end of their life cycle and very few of them could actually be 
reused due to lack of development of user-friendly tools. Thus, after putting 
substantial efforts in data collection, model development and preparation for 
publication, it is hard to put these models into practical use to benefit larger 
population [44]. Therefore, to address the above problems, development of tools 
which provide well validated models with ease of use is necessary.  
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 Nowadays there are many commercial or free in silico tools for predicting 
various physicochemical properties, toxicological endpoints and other biological 
effects of chemical compounds. Comprehensive lists of in silico tools are 
available in review articles [4, 251, 252]. Different tools have different driving 
sources, development structures and functional specialties. They originate from 
different sources, including commercial companies and academic institutions. 
They are developed as standalone software for use on personal computers or as 
server-client applications for online modeling. They are based on either expert 
systems or statistical modeling for prediction approaches. Some of them predict 
only one specific endpoint, while others predict multiple properties. Some are 
even extendable, allowing the user to develop new models or include new 
information. Some of them are developed mainly or solely for the PD-PK-T 
predictions while others are integrated software which had the function as one of 
their features. Nevertheless, among all these software, very few of them are freely 
available with all datasets, models and source code, which restricts the 
independent validation of the models. Free and open source tools allows users to 
download a program directly and are easily customizable without any license fees, 
so they are more preferred by some users [253].  
Table 9.1 lists some common free and/or open-source software or 
platforms for PD-PK-T predictions and their corresponding characteristics. Some 
of them have been used by a large number of users and even for regulatory 
purposes. However, there are still several limitations for these tools. We proposed 
that a good PD-PK-T property prediction tool should possess most of the 
following features: 
 
1. Availability: free and open-source so that it is available for all interested 
users. 
2. User-friendliness: provide both graphical user interface (GUI) for easy 
usage and a command line interface to allow the software to run in 
computer clusters through a software job scheduler.  
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3. Compatibility: able to work on multiple platforms (e.g. Windows, Mac OS, 
Linux, etc.) and accepts multiple molecular file formats (e.g. MDL MOL, 
SMILES, PDB, etc). 
4. Flexibility:  users should be able to develop their own models using their 
own modeling procedures. 
5. Stability: models should be stable across multiple versions of the software 
and older models should coexist with newer models of the same endpoint 
to facilitate independent comparison. 
6. Reliability: well developed and validated models with diverse endpoints 
and reliable performance  
  
It can be concluded that none of the currently available in silico tools in Table 9.1 
possesses all these features. Therefore, a completely free and open-source 
software package which is dedicated for PD-PK-T predictions is developed in this 
study. All the datasets, and models are made available online and all the models 




















√ √ √ √ √ 10 
http://padel.nus.edu.sg/software/padeldd
predictor/ 
CEASAR [254] √  √  √ √ 5 http://www.caesar-project.eu/software/ 
CHEMBENCH [255] √  √  √  14
*
 http://chembench.mml.unc.edu/ 
CORrelation And Logic 
(CORAL) [256]  
√ √    7 http://www.insilico.eu/coral/ 
DemQSAR [257] √ √ √  √  2 
http://agknapp.chemie.fu-
berlin.de/dempred/ 
EPI Suite [258] 
 
√ √   √ 17 
http://www.epa.gov/opptintr/exposure/p
ubs/episuite.htm 
Lazar √  √  √ √ 4 http://lazar.in-silico.de/predict 





√ √   √ 1 
http://www.epa.gov/oppt/sf/pubs/oncolo
gic.htm 





√ √  √ √ 14 
http://www.epa.gov/nrmrl/std/qsar/qsar.
html#TEST 
The OECD QSAR 
Toolbox 
√ √ √  √ √ 7 www.qsartoolbox.org 
Toxtree [262] √ √ √  √ √ 7 http://toxtree.sourceforge.net/ 
VirtualToxLab [263] √  √  √ √ 3 www.biograf.ch  
* 
The online platforms provide sharing of models among users so the exact number of properties is user-specific. (Accessed at 17 Aug 2012)
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9.2. Materials and methods 
9.2.1. Design choices 
 In order to produce a tool for PD-PK-T predictions that is free and open 
source, we had decided to use only freely available software or libraries. 
Commercial software or libraries were avoided unless they allow free 
redistribution, like the JIDE packages which support open source software [264]. 
Although it is attractive to produce an online application as it has the advantage of 
no maintenance for the users, some users may not be comfortable or willing to 
submit their compounds to online servers for processing. In addition, online 
software may have down times due to maintenance or server overload issues, 
which will lead to frustrations for the users. Hence, we decided to develop a 
standalone application instead. We chose Java as the development language for 
the software because it is widely available for multiple platforms (e.g. Windows, 
Mac OS, Linux, etc). Since the software is intended for use by users who may or 
may not be familiar with computers and/or modeling, a user friendly GUI was 
created using JIDE components to allow most users to interact easily with the 
software. For advanced users who wish to run the software using computer 
clusters, we also created a command line interface to facilitate this. 
 Software for PD-PK-T predictions will require two major components. 
The first is a descriptor calculation component to calculate chemical descriptors 
for the components. This component is necessary to facilitate ease of use by the 
users. Otherwise, the users will have to calculate their own descriptors, which 
may be inconvenient or impossible due to the lack of the appropriate descriptor 
calculation software. One reason why many published models were not usable is 
because the descriptor software may not be available for the users. The second 
component is a modeling platform, which will facilitate the use of the models on 
the compounds provided by the users. 
 In our PD-PK-T software, PaDEL-Descriptor, which was developed in our 
laboratory, was chosen as the descriptor calculation component. PaDEL-
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Descriptor is freely available open source software to calculate chemical 
descriptors and fingerprints. Currently, it can calculate 905 descriptors and 10 
types of fingerprints. This choice of the descriptor software is a debatable issue. 
Although a popular choice for descriptor software among PD-PK-T modelers is 
DRAGON, it is commercial software and thus is not freely available [265]. This 
prevents the use of DRAGON in our software as we do not have the license to 
redistribute it with the PD-PK-T software. Among the free descriptor calculation 
software, PaDEL-Descriptor is the best choice because it has a user-friendly 
interface and can run on all major platforms, which makes it easy for modelers to 
calculate descriptors during their model development. It can also calculate a large 
set of descriptors and fingerprints, and is designed to be easily integrated into 
other software.  
 For the modeling platform, open source software RapidMiner was used to 
provide flexibility for the users to develop their own models using their own 
modeling procedures [150]. RapidMiner is a Java-based, freely available open 
source data mining and analysis system. It contains many algorithms for data 
preparation, modeling and validation and is integrated with the machine learning 
library WEKA [266]. It also has a simple extension mechanism which allows 
users to add in their own algorithms. Hence, we believe most users would be able 
to replicate their modeling procedure inside RapidMiner.  
  A potential problem with PD-PK-T models is that with updates in the 
descriptor calculation software or modeling platform, the predictions for some 
compounds may change due to changes in either descriptor values or modeling 
algorithm. Although some of these software updates may be to fix bugs in earlier 
versions, such changes will result in inconsistency in the predictions provided by 
the models. Hence, to address this issue of model stability, multiple versions of 
PaDEL-Descriptor and RapidMiner in our PD-PK-T software are necessary. Both 
PaDEL-Descriptor and RapidMiner will be modified into single jar files so that 
they can act as plugins with different versions made available. This will allow 
models to be able to consistently use the same versions which they were 
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developed with, regardless of software updates to PaDEL-Descriptor, RapidMiner 
and/or our PD-PK-T software. 
9.2.2. Implementation details 
 Since it is possible for the user to select several PD-PK-T properties to be 
predicted for the compounds, prediction of the properties will be performed in 
parallel by using a Master/Worker pattern, which consists of a Master thread and 
one or more worker threads. The advantage of the Master/Worker pattern is that it 
makes efficient use of the multiple CPU cores that are present in most modern 
computers to speed up the calculation of chemical descriptors and the prediction 
process. The Master thread starts the calculation process by determining the PD-
PK-T properties to be predicted and creates a job description for each property. A 
job description consists of the property to be predicted, the correct versions of 
PaDEL-Descriptor and RapidMiner to use for the prediction, the structures of the 
compounds and the types of descriptors and fingerprints to calculate. The jobs are 
added to a shared job queue and each worker thread will retrieve a job from the 
shared queue. The worker thread will check the job description and use the correct 
version of PaDEL-Descriptor to calculate the necessary chemical descriptors. The 
calculated descriptors will then be sent to the correct version of RapidMiner to 
apply the model on the compounds to get the predicted property values. All the 
predicted property values from the various worker threads are then placed in a 
shared results queue where it will be retrieved by the Master thread to be stored in 
a results file in comma-separated value (CSV) format. The first row of the results 
file is the header row, which provides a description of the various columns. 
Subsequent rows will contain the predicted PD-PK-T properties for one 
compound per row. The first column is the compound's name, which is either 
obtained either from the structural file or autogenerated (will be prefixed with 
AUTOGEN_ followed by the file name). Subsequent columns are the PD-PK-T 
properties for the compounds. 
The GUI, which is shown in and Figure 9.1 and Figure 9.2, was 
implemented using property sheets style. There is a “Settings” page (Figure 9.1) 
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which allows the user to easily provide the location where the structures of the 
compounds are stored and the location where the results file should be stored. 
There is also a “Models” page (Figure 9.2), which allows the user to easily 
manage the various PD-PK-T models, such as checking for new models, installing 
new models or uninstalling existing models, viewing their properties, providing 
links to online resources which provide more detailed description of the models, 
and selecting them for properties prediction. The models are grouped according to 
their type of property (i.e. pharmacodynamic, pharmacokinetic and toxicity). The 
list of models is also sortable, which will help to users to find the desired 
properties. All the file locations and selection of models can be saved to a 
configuration file, which can be used to configure the software automatically or 
manually when the software is run the next time. This configuration file will also 




Figure 9.1 Screenshot of PaDEL-DDPredictor interface: Setting page 
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Figure 9.2 Screenshot of PaDEL-DDPredictor interface: Models page 
Only a single argument is required for the command line interface, which 
is the location of the configuration file. This feature allows our PD-PK-T software 
to be used in computer clusters where users have to submit jobs through a 




To have a general overview of the computation time of the software, experiments 
for determining the computation time of predictions on available models were 
performed on a Dell Acer Veriton M670G system with two Intel Core 2 Quad 
Q9550 2.83 GHz processors and 8GB RAM. A total of 1000 compounds with 
median molecular weight of 199 (range 83–253) were used for the descriptor 
calculations. Four available models were applied individually and then together 
and the corresponding computation time for five experiments is shown in Figure 
9.3.  
 
Figure 9.3 Computation time of prediction on 1000 compounds. 
9.3. Results and discussion 
9.3.1. Currently available models 
 In this work, a software program PaDEL-DDPredictor,  was designed and 
developed for the prediction of PD-PK-T properties of compounds. The software, 
currently contains 10 models for different PD-PK-T properties: (1) influenza virus 
neuraminidase N1 inhibitors [267]; (2) human pancreatic cancer cell (PaCa2) 
cellular uptake [268]; (3) human hepatotoxicity [40];  (4) reactive metabolite 
formation [269], (5) Severe skin disorder (SJS/TEN) [88], (6) Torsade de Pointes 
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[89],  (7) Serious eye irritation, (8) Serious eye damage, (9) Skin irritation and (10) 
Eye/Skin corrosion [270]. Among all the models, two PKPD properties were 
covered in PaDEL-DDPredictor, including the human pancreatic cancer cell 
(PaCa2) cellular uptake of nanoparticles and influenza virus neuraminidase N1 
inhibition [267]. The remaining eight models are for different toxic endpoints. 
The general information of the performance of the models is shown in Table 9.2. 
The one-page online summary is organized under five sections: Endpoint, 
Algorithm, Applicability domain, Model performance, and Model outputs. The 
first four sections are to provide information about the model based on OECD 
guidelines and the last section is to help the user to understand the values given in 
the results file. The detailed methods of the model development and validation 
could be obtained from corresponding publication. 






Training Performance Validation Performance 
SE (%) SP (%) SE (%) SP (%) 
Paca2uptake 105 98.2 76.6 86.7 67.3 
Neuroinimidase 1190 97.7 99.5 88.2 99.2 
Reactive 
Metabolites 
1479 67.4 93.4 70.1 ± 5.5 91.4 ± 2.2 







396 83.4 65.9 80.9 63.8 
Cardiotoxicity 
(TdP) 
260 88.9 92.8 78.4 90 
Serious eye 
irritation 
1707 100 90.6 56.4 82.4 
Serious eye 
damage 
1707 96.9 83.9 60.9 79.2 
Skin irritation 1707 94.3 84.7 55.2 82.9 
Eye/Skin 
corrosion 




Another three models will be released after they have completed the peer-review 
process. These include properties such as c-jun N-terminal kinases (JNK) 
inhibitors, serious psychiatric ADR and nephrotoxicity. 
9.3.2. Comparison with other in silico PD-PK-T tools 
PaDEL-DDPredictor is a free and open-source software program 
dedicated for PD-PK-T predictions. Therefore, we only compare it with other 
similar open-access and dedicated software instead of commercial or general drug 
discovery software with physiochemical activity or toxicity prediction as an 
integrated feature. Compared to other in silico tools, PaDEL-DDPredictor are 
more advantageous in the following aspects.  
Firstly, it is completely free and open-source for all users, irrespectively of 
whether they are academic, government, commercial or personal users. For the 
tools listed in Table 9.1, not all the datasets, models or source codes are free to all 
users. Some of them could only be accessed through online platform so the 
models could be used online but not offline. Some only provide limited access of 
the models, datasets and source codes for the public version. And some are only 
free to registered or specific group of users. For PaDEL-DDPredictor, all the 
models and source code could be downloaded without any restrictions, which 
could increase the availability of the software to users. This also allows users to 
freely inspect the code and modify it to suit their needs. Moreover, this could 
potentially improve the detection of bugs and increase the number of features in 
the software.  
Secondly, PaDEL-DDPredictor provides both user-friendly GUI and 
command line interfaces. Although almost all the free and/or open-source 
software packages have a GUI, none of them have a command line interface. The 
command line interface is important as some users may wish to speed up the 
predictions, especially for large datasets, by running the software in computer 
clusters through a software job scheduler. In the GUI of the software, the settings 
of configurations could be saved in an XML file. This XML file can then be used 
in the command line version and to run the prediction on any computers clusters 
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where users have to submit jobs through a software job scheduler. This function 
allows users to use the software on computer systems without GUI option and 
also fully utilize available computer resources by submitting commands. 
Thirdly, PaDEL-DDPredictor is multithreaded so the speed for prediction 
of properties is fast. The Master/Worker pattern separates the prediction of 
different properties into different threads, thus speed up the calculations. This is in 
addition to the multithreaded PaDEL-Descriptor which is used for the descriptor 
calculations. Generally, the amount of speedup increases with the number of 
worker threads used.  
The fourth advantage of PaDEL-DDPredictor is that it supports multiple 
platforms and multiple molecular file formats. It can work on any platform that 
supports Java, which includes the three major platforms, Windows, MacOS, and 
Linux, unlike some standalone software, which supports either one or two 
platforms only. It also supports more than 90 different molecular file formats 
while some other software restricted to only MDL SDF and SMILES format. The 
ability to support more file formats will remove the extra conversion step that 
users need to do when their molecular files are not in the desired format.  
The fifth advantage is model stability. Different versions of PaDEL-
Descriptor and RapidMiner were created as plugins to PaDEL-DDPredictor. This 
allows PaDEL-DDPredictor to use the correct version of corresponding software 
for each model. This prevents possible changes in the predictions provided by the 
models due to updates in PaDEL-Descriptor or RapidMiner. Usually, for some 
PD-PK-T prediction tools, the models will be constructed using external 
commercial or open-source packages. When these packages are updated, the 
software or platforms need to synchronize the updates, so the models developed 
based on older versions either could not be used anymore or the performances 
might be altered.  
Lastly, models in PaDEL-DDPredictor could be created and customized 
by users. Besides the existing models provided by PaDEL-DDPredictor, users 
could choose to use integrate their own models into the application. Some 
software packages or online platforms provide a standard protocol to allow users 
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to develop models using their own datasets, which is fast and convenient for 
general needs. However, some users may wish to use their own protocols for 
model development or to add in some specific component for their models. 
PaDEL-DDPredictor does not restrict the modeling protocol so users could 
develop their own models using any protocols. The only restriction is that the 
protocol must be developed using RapidMiner and the chemical descriptors must 
be calculated using PaDEL-Descriptor. However, both software packages are free 
and open-source so they are readily available. Once users have developed their 
own models, they can easily add them to PaDEL-DDPredictor. Since PaDEL-
DDPredictor is a standalone computer program, the models created by the users 
can remain private for their own use, or they could share them with other people 
by publishing their models for others to download.  
9.3.3. Experiments for computation time 
The results in Figure 9.3 show that the computation time is less than 100 
seconds for all models except the hepatotoxicity model which took more than 4 
minutes. Considering the complexity of the models, the speed is acceptable. The 
computation time for four models together is approximately the sum of the time 
for four models. Hepatotoxicity model took longer time than the other three 
models might be because there are 617 models in the final ensemble model while 
there are only 5, 10 and 13 models in the final models for the other three 
endpoints respectively, so more time is needed to read the models and to do 
prediction. The computation time of the models depends on the number of 
compounds, the number of base models in the final model and the processing 
speed of computer. Prediction of a small number of compounds using a simpler 
model will significantly reduce the computation time. 
9.4. Conclusion 
 A software program, PaDEL-DDPredictor, was developed for rapid 
prediction of PD-PK-T properties. It is more advantageous than other similar 
software programs. It is completely free and open-source, with the combination of 
free descriptor calculation software PaDEL-Descriptor and the data mining 
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software RapidMiner. It provides both GUI and command line options for the 
ease of use of both computational experts and new users. In addition of its 
potential in application of the QSAR models available, it is also hoped that, there 
will be users who are willing to contribute to this effort of making their models 






























Chapter 10 Conclusions 
In this thesis, various strategies have been investigated to improve the 
development and application of QSAR models. Their applications on QSAR 
related studies for the prediction of three types of ADRs and one toxicity endpoint 
have demonstrated the advantages and potential of these methods. Besides, the 
QSAR models developed throughout the studies are useful for the determination 
of the drug candidates’ potential to cause specific ADR or toxicity. Lastly, a 
software program was developed for the future application of the models. This 
last chapter summarizes the major findings and contributions of this study. 
Limitations of the study and potential future studies are also discussed.  
10.1.  Major findings and contributions 
10.1.1. Findings of methods 
Several computational methods have been developed or improved to facilitate the 
development of QSAR models. The exploration of OCC methods described in 
Chapter 3 addressed the problem when negative data is not available. The 
application of the methods in real studies for three types of ADRs produced 
promising results. Therefore, it is of significant potential for modeling studies 
when the negative data is not available or difficult to obtain. The addition of the 
biological information in the nephrotoxicity in Chapter 4 demonstrated the 
potential of adding TGX information to improve the performance of QSAR 
models of using chemical information only. The exploratory study demonstrated 
the advantage of using additional genomic or general biological descriptors to 
QSAR studies given the information is available. The double threshold method 
applied in Chapter 5 offered an efficient and reliable solution for AD estimation 
for classification models. It could be applied on classification problems not only 
in QSAR studies but the general predictive modeling other than pharmaceutical 
area. The DisEnsemble and genetic algorithm methods introduced in Chapter 6 
provided solutions for efficient multiple model selection for ensemble QSAR 
model. The DisEnsemble method is more suitable for large scale problems when 
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there are a large number of the candidate models because of its efficiency. Lastly, 
the model evaluation method developed in Chapter 7 gave an option to generate 
reliable and comprehensive performance profile for QSAR models.  
10.1.2. Findings of models 
Four models for three types of ADR and one toxicity were developed using 
methods from Chapter 3 to Chapter 6 and the information of the final models 
were presented together in Chapter 8. All of them were well validated and are 
applicable for prediction of the given endpoints for new compounds given the 
required information. The models developed for TdP, SJS/TEN and serious 
psychiatric ADR are amongst the first to address the rare and/or serious ADRs 
that have not been paid sufficient attention before. They could be used to 
determine the potential of drug candidates for causing these ADRs and help the 
decision making process for clinicians and regulatory professionals. The 
categorization of the ATC classes for serious psychiatric ADR-inducing drugs 
presented another angle to investigate the distribution of the drugs other than from 
chemical structures. The information will be of interest for clinical experts. The 
nephrotoxicity model could be used for nephrotoxicity assessment and screening 
much earlier before the observation of the onset via conventional clinical 
histopathology methods. The identified important gene signatures and chemical 
descriptors are potentially useful for predictive biomarkers for the drug-induced 
renal tubular toxicity as well as the understanding of the drug action and 
mechanisms. 
10.1.3. Findings of tools 
The open source tool PaDEL-DDPredictor was developed for QSAR model 
application. Based on our information this is the first completely free and open 
source tool for PD-PK-T properties prediction. It successfully integrated the free 
molecular descriptor software PaDEL-Descriptor and the data mining software 
RapidMiner and has many advantages over other similar tools. There are ten peer 
reviewed models available for prediction now and more will be provided to cover 
a wide range of ADMET properties. With this tool, users could prepare their 
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compounds and then use the available models to obtain the prediction results for 
the endpoints of interest for analysis in a convenient and efficient manner. 
10.2.  Limitations and suggestions for future studies 
10.2.1. Limitations and suggestions of data  
The first limitation in this study is the selection criteria for negative drugs. The 
two criteria that the drug must be in market for at least 30 years and used for the 
treatment of common diseases, were used to select the drugs that has been used in 
a large number of population, so as to minimize the possibility that the drug could 
be potential positives. Since actual drug usage data is not readily available, the 
use of these two criteria is a reasonable substitute. However, it is possible for a 
drug to fulfil these two criteria and yet is not used in a large number of patients. 
This problem could arise for drugs which are not the drug of choice but are used 
as second or third-line treatment. Hence more information should be included for 
the selection criteria of “negative” data.  
 For computational toxicities studies, including integrative QSAR&TGX 
study, the major bottle neck is the limited availability of data. Although a public 
genomic data was used for the nephrotoxicity study in this work, there are very 
limited toxicity data, especially human toxicogenomics data. With the 
development of “omics” technology in life sciences area and the generation of 
high-throughput omics data, integrative study with other biological data is highly 
desirable. Fortunately, there are more and more toxicity related datasets and 
databases released to public recently, so future toxicities studies could consider to 
use integrative approaches instead of QSAR alone. Besides the omics information, 
other biological information and even clinical data could also be considered to 
increase the information used to train and to interpret the model. 
10.2.2. Limitations and suggestions of methods 
Different strategies were proposed in this thesis while not of all them were 
explored in depth due to lack of relevant resource and limited time. Although they 
have demonstrated to be able to produce promising result either via the QSAR 
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studies or through some designed experiments using benchmark or simulated 
datasets, they still could not be claimed as superior than all of the other methods 
without rigorous comparative studies. 
 For the DT method used for determination of AD, the major limitation is it 
is only applicable for classification problems, not for regressions problems which 
are popular for QSAR studies. Moreover, although the theory for the DT method 
has been proved empirically and theoretically by the original developer, it has not 
been compared with other AD methods used for QSAR studies. The comparison 
of different AD methods is difficult because the concepts and methods are 
different. It is hopeful that a more intensive and systematic study could be carried 
out to compare these methods in a fair and efficient manner in the future. Lastly, 
the simple majority voting method was used to determine the AD of ensemble 
models, a more systematic method should be developed for ensemble AD 
determination.  
 For the model selection methods for ensemble modeling, they are fast and 
could produce a good subset of models to produce ensemble model with better 
performance than the best performing model. Nevertheless, the resulted subset of 
models is not guaranteed to be the optimal solution for the model pool. 
Generation of an optimal solution will become computationally intensive when 
there are a large number of base models while the margin for performance 
improvement might not be significant. Future study could be applying these 
methods on studies with large model pool and comparing with other available 
model selection methods. For the DisEnsemble method, the disagreement value 
was selected as the diversity measurement. However, there are other more 
sophisticated measurements available, which could be explored in future studies.  
 For the model evaluation method, some interesting result was obtained 
whereas it is not enough to make a confirmatory conclusion that the advantage of 
ADVal method is more significant than RS and CV. Moreover, the method is 
more suitable for large dataset that can produce a proper discretization of bins, so 
it was not applicable for the ADR and toxicity studies in this work. Future studies 
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could be exploration of new AD determination method other than probability 
density method as well as applying the ADVal method on different types of 
predictive modeling studies such as regression problems. 
10.2.3. Limitations and suggestions of models  
Models for three types of ADRs and one toxicity endpoint were developed in this 
work, however it is important to understand that they have inherent limitations so 
that the information that they provide should be evaluated in the right context.  
For all models, they are more suitable for general assessment as complementary 
methods, not for mechanisms interpretation solely. The other limitations and 
suggestions for future studies are presented in details as below. 
 Firstly, the performances of the QSAR models in this study are limited. 
The performance such as accuracy, sensitivity and specificity of all the QSAR 
models are around 60% to 80% which is relatively lower than some well-studied 
toxicities. Machine learning methods depend highly on the diversity of samples 
and the appropriateness of features. However the sizes of the dataset used in this 
work are generally small and mechanisms of the endpoints are complex so the 
datasets used in this work could not fully represent the SARs. All these factors 
affect the prediction performance of the models.  
Secondly, the applicability of the QSAR models is limited. For all the 
QSAR models in this study, due to the limitation of the software used to calculate 
the molecular descriptors of the compounds, compounds with contain inorganic 
atoms, are peptides or with molecular weight greater than 5,000 cannot be 
predicted using these models. Moreover, the models are not able to identify which 
patients will experience the serious ADRs. The models are also not able to 
provide the incidence rates of causing the serious ADRs for a drug candidate. In 
order to achieve these, information about a patient and the incidence rates for 
existing drugs will need to be available during the model development. 
Unfortunately, such information is not easily obtainable and thus not available in 
this study. In addition, for models for serious psychiatric ADRs, it identified 
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drugs with potential to cause any of the seven serious psychiatric ADRs modelled 
in this study. Other serious psychiatric ADRs were not modelled and thus will not 
be predictable by the model. The model is also unable to identify which of the 
seven serious psychiatric ADRs may be caused by a drug. For the production of 
nephrotoxicity model, it is more used as an exploratory study of the integrative 
QSAR and TGX method. The QSAR model developed in the study could be used 
as other QSAR models for toxicities while the TGX related models should be 
used with care since extra experiment is needed to obtain the genomic information. 
 For future work, many more endpoints can be explored to produce a 
comprehensive ADR/toxicity profile such as drug-induced blood disorders, drug-
induced musculoskeletal disorders etc. For the model for serious psychiatric 
ADRs, in order to overcome the aforementioned limitations, future studies will 
need to develop models for a single serious psychiatric ADR only such as 
depression, suicide thoughts etc. For all of the models for ADRs in this work, they 
could be updated with new training data or validated with additional data when 
new information becomes available. For nephrotoxicity model, the selected 
transcripts could be further examined to identify a predictive set of biomarkers. 
Moreover, methods such as gene set enrichment analysis could facilitate the 
understanding of the underlying mechanism associated with the toxicity.  
10.2.4. Limitations and suggestions about tools 
Currently there are ten models available for ten types of PD-PK-T properties in 
PaDEL-DDPredictor. Scientists have proposed a set of ADMET endpoints 
required in drug discovery including the primary models and the secondary 
models depending on the mechanism of the endpoints [271]. However, not all of 
them are available in PaDEL-DDPredictor yet due to either lack of good 
experimental data or limitation of time. These will be made available in the future. 
 For the software, future upgrades might provide options for users to easily 
contribute and share their datasets and models with one another. Such sharing 
system has become a trend in the construction of various bioinformatics and 
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cheminformatics tools. This would fully utilize the resources and maximize the 
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Table 1 Detailed performance profile of AM, PC, MGIC data with SVM 
modeling method.  
 
(a) Performance profile of AM dataset. 
 
    Testing performance Validation performance 
Iteration Bin AUC SE(%) SP(%) AUC SE(%) SP(%) 
0 1 0.583 83.3 50.0 0.796 73.0 71.9 
1 1 0.000 100.0 0.0 0.673 92.3 32.7 
2 1 0.400 100.0 25.0 0.711 69.3 56.9 
3 1 0.725 80.0 25.0 0.725 71.4 65.7 
4 1 0.500 25.0 50.0 0.699 84.3 42.4 
5 1 0.900 100.0 50.0 0.597 83.8 31.7 
6 1 0.476 100.0 16.7 0.817 77.8 68.9 
7 1 0.786 71.4 50.0 0.648 93.2 21.7 
8 1 0.278 50.0 33.3 0.697 75.3 51.6 
9 1 0.600 60.0 16.7 0.660 69.9 41.3 
10 1 1.000 100.0 0.0 0.698 74.8 54.5 
11 1 0.917 75.0 66.7 0.737 80.4 51.2 
12 1 0.455 81.8 0.0 0.729 87.7 40.2 
13 1 0.375 75.0 28.6 0.747 91.0 39.6 
14 1 1.000 90.9 100.0 0.725 89.5 41.2 
15 1 0.556 66.7 66.7 0.797 78.3 61.3 
16 1 0.781 100.0 50.0 0.666 90.7 29.7 
17 1 0.688 100.0 50.0 0.740 90.0 43.4 
18 1 0.607 87.5 28.6 0.655 61.6 58.4 
19 1 0.800 100.0 20.0 0.694 85.6 38.5 
20 1 0.571 71.4 50.0 0.709 81.3 49.3 
21 1 0.875 87.5 66.7 0.756 79.1 51.0 
22 1 0.650 90.0 0.0 0.678 73.1 56.7 
23 1 0.679 85.7 25.0 0.716 70.8 57.1 
24 1 0.778 83.3 0.0 0.648 68.5 51.2 
25 1 0.438 37.5 50.0 0.733 74.2 57.1 
26 1 0.667 75.0 66.7 0.758 79.7 44.4 
27 1 0.486 57.1 20.0 0.723 80.0 58.1 
28 1 0.650 75.0 60.0 0.684 81.0 30.0 
29 1 0.556 66.7 33.3 0.759 67.1 67.1 
0 6 1.000 100.0 100.0 0.667 60.0 65.5 
1 6 1.000 100.0 0.0 0.694 90.6 46.7 
3 6 - 100.0 - 0.806 52.4 85.7 
4 6 1.000 100.0 100.0 0.709 59.2 66.7 
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5 6 0.750 75.0 100.0 0.643 74.3 50.0 
6 6 1.000 100.0 100.0 0.514 52.6 60.0 
7 6 - 100.0 - 0.723 77.4 73.3 
8 6 - - 100.0 0.785 62.2 78.6 
9 6 0.125 0.0 50.0 0.591 44.1 52.2 
10 6 0.000 0.0 0.0 0.765 49.1 81.8 
11 6 0.556 33.3 66.7 0.720 67.5 74.1 
12 6 0.667 77.8 50.0 0.601 50.0 62.7 
13 6 1.000 100.0 100.0 0.710 85.0 37.0 
14 6 - 100.0 - 0.618 65.4 60.5 
15 6 0.700 40.0 50.0 0.646 55.9 65.1 
16 6 - 75.0 - 0.544 56.8 48.3 
17 6 0.500 25.0 50.0 0.579 81.6 25.0 
19 6 0.500 50.0 33.3 0.766 60.7 76.5 
20 6 0.500 0.0 100.0 0.588 48.9 55.4 
21 6 0.000 0.0 66.7 0.692 72.1 63.0 
22 6 0.444 33.3 66.7 0.697 52.9 68.6 
23 6 0.500 50.0 66.7 0.709 57.1 76.1 
24 6 0.500 100.0 50.0 0.706 76.7 59.3 
25 6 0.667 0.0 66.7 0.656 70.6 62.5 
26 6 0.333 100.0 0.0 0.781 81.4 66.7 
27 6 0.500 - 100.0 0.606 65.0 50.0 
28 6 1.000 66.7 100.0 0.667 73.6 50.6 
29 6 0.000 100.0 0.0 0.647 55.6 63.4 
3 7 0.656 50.0 75.0 0.663 50.5 67.4 
4 7 0.762 71.4 66.7 0.669 57.7 68.3 
8 7 0.409 63.6 50.0 0.634 59.6 61.9 
9 7 0.667 40.0 66.7 0.694 55.6 67.4 
10 7 0.833 83.3 50.0 0.617 51.8 66.3 
11 7 0.750 40.0 75.0 0.654 59.1 68.2 
12 7 0.361 33.3 33.3 0.728 66.9 66.2 
13 7 0.775 75.0 60.0 0.805 82.7 69.8 
14 7 0.700 100.0 33.3 0.594 63.2 54.8 
15 7 0.833 66.7 50.0 0.685 62.4 65.2 
16 7 0.583 33.3 62.5 0.760 62.7 75.6 
17 7 0.917 83.3 100.0 0.679 81.6 33.3 
19 7 0.691 70.0 63.6 0.662 57.0 56.0 
20 7 0.667 50.0 66.7 0.728 60.2 68.1 
22 7 1.000 75.0 100.0 0.663 58.6 69.3 
23 7 0.429 42.9 28.6 0.753 67.2 72.5 
24 7 0.778 66.7 100.0 0.733 77.3 66.7 
25 7 0.571 0.0 100.0 0.708 56.1 76.7 
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26 7 1.000 66.7 100.0 0.620 63.9 50.6 
28 7 0.691 55.6 66.7 0.710 68.5 62.7 
29 7 0.429 57.1 0.0 0.655 74.8 55.1 
0 8 0.722 55.6 66.7 0.700 58.7 73.6 
1 8 0.625 70.0 50.0 0.662 72.0 51.2 
2 8 0.914 40.0 100.0 0.679 61.9 66.0 
3 8 0.345 42.9 41.7 0.737 53.8 80.0 
4 8 0.704 33.3 83.3 0.724 57.4 75.8 
5 8 0.875 62.5 85.7 0.690 74.2 52.0 
6 8 0.661 71.4 62.5 0.699 61.1 68.7 
7 8 0.688 81.8 56.3 0.731 72.2 64.4 
8 8 0.711 68.8 52.4 0.728 66.8 68.7 
9 8 0.681 55.6 60.0 0.709 59.4 72.1 
10 8 0.673 40.0 81.8 0.721 59.3 75.8 
11 8 0.838 85.7 60.0 0.703 62.7 69.5 
12 8 0.921 76.9 86.1 0.701 54.3 76.0 
13 8 0.882 44.4 93.8 0.654 71.9 54.7 
14 8 0.795 62.5 72.7 0.666 67.8 60.9 
15 8 0.742 54.5 52.6 0.696 61.5 68.4 
16 8 0.540 55.6 64.3 0.706 64.9 65.5 
17 8 0.692 83.3 70.0 0.696 70.6 60.7 
18 8 0.548 16.7 78.6 0.731 58.1 71.4 
19 8 0.708 77.8 62.5 0.719 66.4 69.9 
20 8 0.663 43.8 60.0 0.699 53.1 74.8 
21 8 0.881 71.4 83.3 0.665 62.3 64.1 
22 8 0.776 57.1 78.6 0.713 57.9 75.2 
23 8 0.693 66.7 63.6 0.730 58.0 77.7 
24 8 0.567 90.0 33.3 0.683 67.6 57.7 
25 8 0.649 18.8 83.3 0.680 54.4 69.1 
26 8 0.750 66.7 100.0 0.735 66.9 69.6 
27 8 0.667 33.3 60.0 0.705 55.9 70.3 
28 8 0.698 31.3 94.4 0.735 55.6 76.8 
29 8 0.679 66.7 61.1 0.733 68.2 69.2 
0 9 0.671 60.0 63.9 0.691 59.5 68.2 
1 9 0.707 64.5 60.7 0.678 61.1 61.0 
2 9 0.746 46.2 74.1 0.730 56.7 74.7 
3 9 0.733 65.5 65.9 0.749 42.6 85.0 
4 9 0.852 75.0 83.7 0.758 49.4 83.8 
5 9 0.795 80.6 65.8 0.745 60.3 73.9 
6 9 0.778 65.0 82.5 0.728 52.5 78.4 
7 9 0.795 61.9 75.9 0.708 58.6 69.4 
8 9 0.791 67.9 76.5 0.756 60.4 77.4 
9 9 0.770 51.7 83.7 0.719 60.0 72.6 
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10 9 0.825 61.5 89.5 0.739 52.8 80.2 
11 9 0.781 73.3 69.8 0.727 53.4 76.2 
12 9 0.709 51.6 80.8 0.754 41.5 87.3 
13 9 0.797 33.3 90.2 0.713 64.1 70.2 
14 9 0.691 70.8 65.9 0.738 61.0 72.7 
15 9 0.677 59.4 65.0 0.754 52.2 78.8 
16 9 0.665 42.3 82.5 0.707 62.5 69.0 
17 9 0.606 31.3 71.7 0.735 55.7 76.9 
18 9 0.725 42.9 74.1 0.705 60.1 70.7 
19 9 0.885 71.0 85.1 0.749 58.5 76.8 
20 9 0.769 44.0 89.1 0.732 43.6 83.2 
21 9 0.841 44.0 91.5 0.730 53.4 78.6 
22 9 0.809 64.0 78.0 0.746 48.6 80.0 
23 9 0.669 48.7 73.4 0.764 47.0 82.8 
24 9 0.685 31.8 86.2 0.735 51.0 78.1 
25 9 0.787 47.6 81.1 0.718 44.8 81.5 
26 9 0.817 30.8 91.7 0.767 49.8 82.9 
27 9 0.702 50.0 74.2 0.715 54.0 76.0 
28 9 0.676 33.3 86.3 0.776 43.7 86.9 
29 9 0.656 60.0 70.0 0.757 58.5 79.4 
0 10 0.834 75.7 71.3 0.758 67.3 71.6 
1 10 0.817 72.9 76.9 0.761 65.7 72.8 
2 10 0.683 75.0 57.0 0.748 67.7 69.7 
3 10 0.782 69.8 76.4 0.772 65.8 76.6 
4 10 0.777 74.3 68.6 0.764 77.8 63.7 
5 10 0.678 60.3 67.1 0.771 71.3 70.6 
6 10 0.819 58.2 84.3 0.769 59.9 79.7 
7 10 0.770 69.3 62.4 0.754 74.8 63.8 
8 10 0.710 87.7 47.4 0.786 80.7 60.4 
9 10 0.814 68.8 74.6 0.750 68.3 68.8 
10 10 0.842 89.9 61.9 0.750 74.0 64.0 
11 10 0.746 73.7 61.2 0.758 69.4 69.1 
12 10 0.787 72.1 76.5 0.755 51.2 82.0 
13 10 0.732 63.8 74.6 0.775 56.7 81.4 
14 10 0.716 77.6 57.9 0.762 73.6 64.5 
15 10 0.705 74.1 52.1 0.782 72.6 71.5 
16 10 0.849 80.3 82.5 0.773 71.5 70.7 
17 10 0.665 75.0 55.2 0.770 58.2 80.5 
18 10 0.728 63.0 64.8 0.759 81.2 57.0 
19 10 0.782 79.1 56.4 0.761 71.1 68.4 
20 10 0.752 61.4 73.9 0.766 65.3 72.9 
21 10 0.770 74.0 73.4 0.773 66.5 73.9 
22 10 0.789 80.0 63.5 0.763 68.5 70.7 
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23 10 0.778 77.1 74.3 0.739 67.0 68.2 
24 10 0.797 69.7 74.2 0.748 58.5 76.0 
25 10 0.619 55.6 51.8 0.757 67.8 70.7 
26 10 0.794 36.6 93.4 0.775 52.1 82.8 
27 10 0.741 70.0 76.3 0.763 64.7 74.9 
28 10 0.822 51.0 86.7 0.765 48.7 84.9 
29 10 0.776 71.9 68.4 0.757 72.4 67.0 
 
(b) Performance profile of PC dataset. 
 
  
Testing performance Validation performance 
Iteration Bin AUC SE(%) SP(%) AUC SE(%) SP(%) 
1 3 1.000 100.0 100.0 0.977 95.3 84.3 
6 3 1.000 83.3 100.0 0.992 90.4 94.5 
8 3 1.000 100.0 100.0 0.991 87.6 97.5 
11 3 0.958 75.0 83.3 0.979 93.9 75.0 
13 3 1.000 100.0 100.0 0.991 88.8 96.8 
14 3 1.000 83.3 100.0 0.996 98.8 91.4 
15 3 0.969 100.0 87.5 0.987 90.8 92.4 
17 3 1.000 100.0 100.0 0.983 92.2 93.8 
19 3 1.000 66.7 100.0 0.980 89.7 93.0 
21 3 1.000 83.3 100.0 0.970 82.8 93.7 
23 3 1.000 100.0 71.4 0.989 100.0 85.7 
24 3 1.000 100.0 100.0 0.986 94.7 87.2 
25 3 1.000 100.0 100.0 0.990 100.0 88.9 
26 3 1.000 100.0 100.0 0.984 92.3 92.9 
27 3 1.000 100.0 100.0 0.980 88.9 92.8 
28 3 1.000 85.7 100.0 0.986 94.0 90.7 
29 3 1.000 100.0 100.0 0.991 96.6 90.6 
0 4 1.000 100.0 100.0 0.988 93.0 93.3 
1 4 0.975 80.0 87.5 0.985 97.5 88.5 
2 4 0.971 60.0 100.0 0.990 93.0 93.4 
3 4 0.929 85.7 100.0 0.971 87.4 91.3 
4 4 1.000 100.0 77.8 0.987 93.5 93.6 
5 4 1.000 100.0 66.7 0.982 94.1 89.2 
6 4 1.000 90.9 100.0 0.983 92.5 89.4 
7 4 0.958 100.0 66.7 0.979 91.4 90.4 
8 4 0.975 90.0 91.7 0.989 86.4 96.6 
9 4 0.967 93.3 70.0 0.986 93.9 93.4 
11 4 1.000 100.0 77.8 0.978 94.7 85.7 
12 4 0.990 100.0 90.0 0.971 88.3 89.3 
13 4 1.000 100.0 100.0 0.990 87.6 97.4 
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14 4 1.000 71.4 100.0 0.990 93.9 90.1 
15 4 0.909 72.7 85.7 0.990 93.6 95.1 
16 4 0.972 83.3 100.0 0.982 90.0 86.9 
17 4 1.000 75.0 100.0 0.980 92.3 88.5 
18 4 1.000 100.0 100.0 0.984 83.9 94.5 
19 4 1.000 91.7 100.0 0.982 90.0 92.0 
21 4 1.000 83.3 100.0 0.973 87.2 94.1 
22 4 0.988 88.9 100.0 0.991 90.2 95.5 
23 4 1.000 84.6 100.0 0.991 96.4 91.7 
24 4 1.000 100.0 100.0 0.981 95.2 81.3 
25 4 0.933 77.8 80.0 0.978 90.4 90.6 
26 4 0.978 88.9 100.0 0.981 85.9 96.3 
27 4 0.986 91.7 83.3 0.990 90.0 96.7 
28 4 0.996 94.1 100.0 0.982 91.1 92.7 
29 4 0.972 77.8 87.5 0.988 92.1 93.7 
0 5 0.960 72.2 88.9 0.985 91.3 93.4 
1 5 0.984 100.0 83.3 0.975 95.0 84.8 
2 5 1.000 90.9 100.0 0.983 89.2 94.7 
3 5 0.969 88.9 77.8 0.978 89.8 93.1 
4 5 0.950 83.3 80.0 0.987 89.8 94.6 
5 5 0.964 100.0 81.8 0.981 91.5 89.9 
6 5 0.993 92.9 100.0 0.977 87.6 91.7 
7 5 1.000 100.0 75.0 0.981 90.9 92.3 
8 5 0.927 76.2 86.7 0.985 85.0 95.3 
9 5 0.965 87.5 94.4 0.977 88.4 91.4 
10 5 0.991 90.0 90.9 0.983 92.2 92.4 
11 5 0.944 91.7 66.7 0.973 89.7 87.6 
12 5 1.000 100.0 92.3 0.972 87.2 90.9 
13 5 0.993 100.0 90.9 0.996 94.7 97.8 
14 5 0.969 84.6 86.7 0.984 90.8 92.3 
15 5 0.971 78.9 94.4 0.989 93.2 94.8 
16 5 0.958 100.0 66.7 0.983 90.3 91.1 
17 5 0.986 87.5 88.9 0.980 89.3 92.6 
18 5 0.976 76.9 92.3 0.980 87.6 94.7 
19 5 0.997 100.0 89.5 0.982 89.7 92.8 
20 5 0.977 81.8 100.0 0.992 91.5 97.4 
21 5 0.983 85.0 94.4 0.974 89.5 90.1 
22 5 0.989 90.9 100.0 0.984 87.6 95.0 
23 5 0.991 83.3 94.4 0.985 94.8 87.4 
24 5 0.994 94.7 94.1 0.982 96.9 81.7 
25 5 0.975 89.5 88.2 0.978 93.1 86.4 
26 5 0.921 90.0 85.7 0.972 86.3 90.8 
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27 5 1.000 100.0 100.0 0.986 92.5 94.0 
28 5 0.969 87.5 85.7 0.984 92.8 93.1 
29 5 0.960 86.7 86.7 0.990 94.2 91.2 
0 6 0.985 90.5 94.7 0.982 89.4 92.2 
1 6 0.991 90.5 96.3 0.980 94.7 86.3 
2 6 1.000 83.3 100.0 0.984 90.2 93.9 
3 6 0.978 94.7 94.1 0.978 91.8 89.2 
4 6 0.944 76.9 94.4 0.983 88.4 93.9 
5 6 0.969 86.4 86.4 0.976 91.5 87.0 
6 6 0.988 94.4 92.6 0.973 88.5 88.9 
7 6 0.991 92.3 94.1 0.984 90.4 94.3 
8 6 0.987 96.2 83.3 0.979 86.2 93.0 
9 6 0.983 95.8 86.4 0.977 87.7 91.4 
10 6 0.925 76.5 86.7 0.988 93.1 92.4 
11 6 0.978 85.2 90.0 0.968 90.7 87.1 
12 6 0.969 95.8 89.5 0.965 87.9 87.9 
13 6 0.997 93.8 100.0 0.977 88.1 91.6 
14 6 0.977 92.3 88.2 0.984 92.8 90.7 
15 6 0.955 86.4 89.5 0.983 93.0 89.7 
16 6 0.988 100.0 75.0 0.984 93.4 87.4 
17 6 0.979 94.7 89.3 0.969 88.2 87.1 
18 6 0.934 78.9 75.0 0.980 88.0 92.9 
19 6 0.979 85.7 96.6 0.983 93.2 91.7 
20 6 0.975 89.5 89.7 0.992 94.5 95.4 
21 6 0.974 82.4 94.4 0.975 87.9 90.5 
22 6 1.000 100.0 100.0 0.985 91.7 91.6 
23 6 0.989 100.0 84.2 0.989 96.3 87.2 
24 6 0.947 100.0 75.0 0.977 94.2 85.7 
25 6 0.988 87.5 96.4 0.974 93.9 83.8 
26 6 1.000 100.0 100.0 0.972 83.5 94.0 
27 6 0.934 86.2 75.0 0.983 92.5 91.8 
28 6 0.997 100.0 95.8 0.977 88.8 91.6 
29 6 0.984 92.0 86.4 0.985 91.5 92.2 
0 7 0.984 96.2 92.3 0.973 89.0 91.0 
1 7 0.973 87.5 90.9 0.976 94.4 87.7 
2 7 0.995 95.8 95.8 0.986 93.8 91.0 
3 7 0.980 96.4 85.0 0.970 92.3 84.4 
4 7 0.981 93.1 91.7 0.973 85.0 91.6 
5 7 0.956 100.0 78.9 0.977 92.3 88.6 
6 7 0.942 83.3 89.5 0.976 91.1 87.3 
7 7 1.000 100.0 84.6 0.974 86.7 93.1 
8 7 0.949 92.9 85.7 0.968 88.7 86.8 
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9 7 0.982 95.7 90.9 0.974 89.0 90.1 
10 7 0.930 84.0 81.5 0.973 92.3 85.7 
11 7 0.954 100.0 67.7 0.976 90.5 88.4 
12 7 0.979 88.0 96.0 0.974 91.1 87.3 
13 7 0.974 87.1 89.3 0.970 86.6 89.0 
14 7 0.986 100.0 82.6 0.978 89.1 91.6 
15 7 0.903 76.2 87.5 0.975 90.0 90.9 
16 7 0.950 90.0 80.0 0.984 94.2 88.8 
17 7 0.981 95.0 87.5 0.974 90.5 87.2 
18 7 0.946 100.0 85.0 0.975 87.4 92.0 
19 7 0.977 88.0 95.7 0.976 92.3 87.4 
20 7 0.924 81.5 90.6 0.988 90.2 94.3 
21 7 0.973 92.3 82.6 0.977 92.8 87.2 
22 7 0.977 86.7 93.3 0.974 88.1 90.1 
23 7 0.973 81.8 88.9 0.976 91.0 87.3 
24 7 0.984 88.5 91.7 0.976 93.1 84.9 
25 7 0.972 88.2 89.5 0.976 90.5 87.7 
26 7 0.996 100.0 95.0 0.969 86.6 91.5 
27 7 0.987 100.0 92.9 0.970 88.0 89.8 
28 7 0.988 94.4 91.3 0.966 89.6 87.3 
29 7 0.936 90.0 83.3 0.978 90.5 89.3 
0 8 0.965 81.3 93.8 0.975 91.4 88.5 
1 8 0.937 87.0 77.8 0.978 91.3 90.8 
2 8 0.985 100.0 86.7 0.980 93.0 89.4 
3 8 0.964 84.6 80.8 0.979 94.1 86.9 
4 8 0.993 100.0 81.8 0.964 88.7 86.7 
5 8 0.990 100.0 96.2 0.976 92.7 88.2 
6 8 0.994 100.0 82.4 0.969 90.2 86.2 
7 8 0.969 90.3 87.1 0.977 91.0 90.9 
8 8 0.994 92.9 90.9 0.961 91.3 83.6 
9 8 0.984 93.3 76.5 0.970 93.0 85.5 
10 8 0.984 100.0 90.9 0.979 94.1 87.0 
11 8 0.977 94.1 87.0 0.977 90.9 88.3 
12 8 0.984 86.4 88.2 0.985 93.5 88.5 
13 8 0.993 92.9 90.0 0.962 91.2 85.2 
14 8 0.912 84.2 83.3 0.972 83.9 93.1 
15 8 1.000 100.0 63.6 0.957 89.8 86.8 
16 8 0.955 88.5 84.0 0.977 91.1 89.2 
17 8 0.990 100.0 84.2 0.983 93.0 89.6 
18 8 0.974 100.0 80.0 0.978 91.8 89.6 
19 8 1.000 88.9 100.0 0.969 88.2 87.1 
20 8 0.971 91.4 100.0 0.969 89.5 89.7 
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21 8 0.994 94.4 100.0 0.974 89.7 88.6 
22 8 0.946 81.0 86.7 0.967 89.8 86.3 
23 8 0.969 92.9 81.3 0.969 88.2 88.6 
24 8 0.980 80.0 90.0 0.977 87.6 92.7 
25 8 0.980 90.9 88.9 0.984 88.8 94.6 
26 8 0.953 93.8 75.0 0.978 92.3 86.8 
27 8 0.943 100.0 85.7 0.929 82.3 82.2 
28 8 1.000 88.2 100.0 0.960 90.4 83.9 
29 8 0.937 76.5 84.6 0.967 90.1 86.0 
0 9 1.000 100.0 100.0 0.954 87.6 78.7 
1 9 1.000 75.0 100.0 0.974 84.6 92.1 
2 9 0.973 87.5 78.6 0.962 89.7 85.4 
3 9 0.985 90.0 92.3 0.984 93.9 88.1 
4 9 0.973 90.0 90.9 0.959 95.3 73.1 
5 9 0.987 83.3 92.3 0.972 91.2 85.1 
6 9 0.500 83.3 0.0 0.954 91.5 81.0 
7 9 0.969 87.5 91.7 0.969 88.8 91.9 
9 9 1.000 90.9 100.0 0.973 94.2 82.1 
10 9 0.952 100.0 76.9 0.975 97.6 78.0 
11 9 1.000 83.3 100.0 0.978 90.1 90.0 
12 9 1.000 100.0 100.0 0.989 93.3 91.3 
13 9 0.867 83.3 60.0 0.962 93.4 72.2 
14 9 0.938 85.7 75.0 0.968 84.0 92.0 
15 9 0.971 85.7 100.0 0.924 78.4 85.5 
16 9 0.984 100.0 85.7 0.959 89.0 84.8 
17 9 1.000 75.0 100.0 0.995 97.7 91.3 
18 9 0.978 92.9 93.8 0.975 91.7 86.5 
20 9 0.933 80.0 66.7 0.907 79.6 76.8 
21 9 1.000 100.0 100.0 0.992 91.7 94.0 
22 9 0.964 93.3 73.3 0.952 88.7 81.7 
23 9 1.000 100.0 100.0 0.972 82.4 91.6 
25 9 1.000 100.0 100.0 0.993 93.1 97.3 
26 9 1.000 100.0 100.0 0.983 97.6 78.3 
27 9 1.000 83.3 100.0 0.960 90.0 93.4 
28 9 0.833 83.3 66.7 0.941 89.1 76.6 
29 9 1.000 100.0 87.5 0.973 90.0 87.9 
2 10 0.875 0.8 1.0 0.913 0.8 0.9 
3 10 1.000 1.0 1.0 0.996 1.0 1.0 
10 10 0.889 1.0 0.7 0.983 1.0 0.6 
14 10 1.000 1.0 1.0 0.993 0.9 1.0 
16 10 0.875 0.8 0.5 0.937 0.8 0.9 
18 10 1.000 1.0 1.0 0.989 1.0 0.9 
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29 10 1.000 1.0 0.3 0.997 1.0 0.8 
 
(c) Performance profile of MAGIC dataset 
 
    Testing performance Validation performance 
Iteration Bin AUC SE(%) SP(%) AUC SE(%) SP(%) 
0 5 0.938 81.3 75 0.960 87.3 94.4 
1 5 0.955 63.6 100 0.975 84.2 91.3 
2 5 1.000 78.6 100 0.977 86.5 96.9 
4 5 1.000 92.3 100 0.972 88.7 97.1 
6 5 1.000 84.6 100 0.986 85.5 100 
7 5 1.000 93.8 100 0.959 90.1 85.7 
8 5 1.000 72.2 100 0.982 83 100 
9 5 0.889 77.8 100 0.966 82.8 97 
10 5 1.000 95 100 0.953 88.2 94.4 
11 5 1.000 63.6 100 0.957 75.6 98.2 
16 5 1.000 88.9 100 0.968 84 94.9 
18 5 0.952 76.2 100 0.958 90.3 90.5 
20 5 0.979 93.8 66.7 0.967 82.2 96.7 
21 5 1.000 84.2 100 0.984 88.1 94.3 
22 5 0.905 100 0 0.976 90.8 84.6 
23 5 1.000 83.3 100 0.929 88 87 
24 5 1.000 88.9 100 0.968 84.9 97.7 
26 5 1.000 93.8 100 0.950 92.3 92.9 
27 5 0.952 90.5 100 0.973 87.3 100 
28 5 1.000 100 100 0.959 89 95.5 
29 5 0.923 61.5 100 0.976 75.6 98.4 
0 6 0.983 70 100 0.962 70.4 99 
1 6 0.992 43.8 100 0.953 65.1 96.9 
2 6 0.827 66.7 60 0.948 69.1 95.3 
3 6 0.941 94.1 83.3 0.959 67.9 98.8 
4 6 0.933 60 100 0.935 71.7 95.2 
5 6 1.000 71.4 100 0.953 74.8 96.3 
6 6 0.909 36.4 100 0.939 68.7 94 
7 6 0.917 62.5 100 0.957 73.4 97.3 
8 6 0.988 52.4 100 0.943 64.4 96.3 
9 6 0.867 33.3 100 0.955 59.9 97.2 
10 6 1.000 66.7 100 0.931 66.7 94.9 
11 6 0.933 50 88.9 0.929 43.3 97.6 
12 6 0.986 58.3 100 0.915 65 93.3 
13 6 1.000 66.7 100 0.940 71 95.7 
14 6 1.000 100 100 0.958 80.5 95.7 
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15 6 1.000 59.1 100 0.940 63.1 94.6 
16 6 1.000 30.8 100 0.954 54.6 98.1 
17 6 1.000 73.3 100 0.953 64.8 97.6 
18 6 1.000 38.5 100 0.953 67.7 96.9 
19 6 1.000 53.8 100 0.946 67.9 95.9 
20 6 0.824 82.4 83.3 0.947 65.4 96.9 
21 6 0.949 76.9 100 0.934 66 95.1 
22 6 1.000 69.2 100 0.953 75.8 96.4 
23 6 1.000 64.7 100 0.953 63.3 97.2 
24 6 0.907 61.1 100 0.930 63.4 95.3 
25 6 1.000 63.6 100 0.934 62.3 94.1 
26 6 0.908 64.7 100 0.966 76.6 96.6 
27 6 0.947 57.9 100 0.936 74.3 95.7 
28 6 1.000 87.5 100 0.960 70 97.7 
29 6 0.958 43.8 100 0.925 45.9 95.5 
0 7 0.979 40.9 100 0.920 32.8 97.3 
1 7 0.936 27.3 100 0.912 35.4 96 
2 7 0.823 23.8 92.9 0.908 37.8 97.4 
3 7 0.852 44.4 100 0.896 32.3 96.3 
4 7 0.904 44 100 0.905 38.6 95.9 
5 7 0.942 45.8 100 0.929 42.9 96.6 
6 7 0.873 35.3 89.5 0.904 34.3 96.8 
7 7 0.900 61.5 100 0.927 40.3 97.4 
8 7 0.854 27.3 95.7 0.878 33.6 96.5 
9 7 0.889 10 100 0.911 26.7 97.5 
10 7 0.871 32.3 95.8 0.869 30.6 97.5 
11 7 0.923 5.9 100 0.864 22 96.6 
12 7 0.931 24 95.5 0.878 32.5 96.2 
13 7 0.875 44 100 0.905 34.8 96.8 
14 7 0.849 47.4 100 0.907 54.8 95.2 
15 7 0.977 52.2 100 0.877 30.9 96.6 
16 7 0.901 47.6 100 0.910 30.7 97.2 
17 7 0.985 37 100 0.900 32.2 96.7 
18 7 0.983 13 100 0.923 35.9 97.2 
19 7 0.909 42.1 100 0.903 33.7 97.3 
20 7 0.914 27.8 100 0.894 32 98 
21 7 0.850 20 100 0.915 35.7 96.9 
22 7 0.970 36.4 100 0.915 40.7 96.1 
23 7 0.880 21.1 100 0.920 33.3 98.1 
24 7 0.868 16.7 100 0.891 35.7 96.8 
25 7 0.812 22.2 100 0.881 31.5 95.8 
26 7 0.828 41.2 92.6 0.933 39.6 97 
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27 7 0.883 20 100 0.888 39.6 95.9 
28 7 0.972 50 100 0.913 43.4 95.5 
29 7 0.867 17.4 94.1 0.884 21.9 97.6 
0 8 0.775 24.1 97.6 0.843 14.7 98.4 
1 8 0.862 26.9 95.3 0.821 24.5 96 
2 8 0.749 17.6 98.2 0.824 13.1 98.7 
3 8 0.755 12.5 100 0.839 10.9 98.6 
4 8 0.862 5 98.3 0.819 14.4 98.3 
5 8 0.754 21.4 94.1 0.808 23.1 97.2 
6 8 0.784 8.8 98.7 0.817 13.7 98.6 
7 8 0.846 28.2 95.8 0.815 20.9 98.4 
8 8 0.777 3.2 98.1 0.798 13.6 98.8 
9 8 0.836 5.3 97.6 0.828 11.9 98.4 
10 8 0.860 3.6 98.5 0.762 14.5 98.7 
11 8 0.694 9.3 97.4 0.763 10.8 99.3 
12 8 0.782 10.7 96.2 0.798 11.2 99.1 
13 8 0.766 13.3 97.5 0.836 13.5 98.5 
14 8 0.949 26.7 100 0.823 24.4 96.9 
15 8 0.764 6.1 100 0.782 14 98.8 
16 8 0.835 29.4 92.5 0.804 15.1 98.5 
17 8 0.766 8.1 97.5 0.833 12.4 98.9 
18 8 0.745 19.4 98.4 0.848 16.9 98.1 
19 8 0.798 5.7 100 0.831 13.4 98.3 
20 8 0.798 15.2 97.4 0.813 14.1 98.5 
21 8 0.856 19.4 100 0.820 18.8 98.3 
22 8 0.781 24.3 95.2 0.849 19.3 98.1 
23 8 0.792 12.1 100 0.830 16.8 98.1 
24 8 0.847 13.3 98.6 0.783 13.7 98.7 
25 8 0.809 11.4 100 0.788 11 98.9 
26 8 0.770 13.3 100 0.838 20.7 97.8 
27 8 0.818 24.3 96.7 0.806 13.9 98.4 
28 8 0.764 14.3 100 0.818 20.2 97.7 
29 8 0.722 9.8 100 0.800 10.2 99.2 
0 9 0.767 2.7 100 0.749 2 99.9 
1 9 0.766 15.5 97.6 0.756 14.5 96.9 
2 9 0.698 0 100 0.739 1.3 99.9 
3 9 0.636 1.1 100 0.735 0.5 100 
4 9 0.713 0 100 0.747 1.6 100 
5 9 0.781 10.8 98.8 0.747 10 98.1 
6 9 0.711 2.2 100 0.739 2.5 99.9 
7 9 0.752 10.1 98.7 0.755 7.5 99.4 
8 9 0.781 0 100 0.748 3.3 99.9 
9 9 0.736 1.3 100 0.740 1.7 99.9 
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10 9 0.746 0 100 0.748 2.6 99.9 
11 9 0.723 3.9 100 0.743 1.6 99.9 
12 9 0.728 1.1 100 0.747 1 100 
13 9 0.738 1.3 100 0.737 1.1 100 
14 9 0.816 10.1 100 0.744 6.9 99 
15 9 0.750 3 100 0.749 3.3 99.8 
16 9 0.758 16.7 97.5 0.761 5.4 99.6 
17 9 0.739 3.2 99.4 0.738 1.7 100 
18 9 0.750 5.3 100 0.746 4.6 99.8 
19 9 0.735 3.5 100 0.741 1.5 99.9 
20 9 0.772 3.7 100 0.744 2.5 99.9 
21 9 0.748 7.6 100 0.749 6.5 99.2 
22 9 0.719 4.3 100 0.741 2.7 99.8 
23 9 0.723 3.4 99.4 0.749 5.6 99.6 
24 9 0.793 0 100 0.750 2.4 99.9 
25 9 0.768 0 100 0.746 1.7 99.9 
26 9 0.774 2.2 100 0.751 5.1 99.6 
27 9 0.776 2.7 100 0.739 2.5 99.8 
28 9 0.738 4.8 100 0.754 7 99.6 
29 9 0.686 1.1 100 0.748 0.4 100 
0 10 0.720 0 100 0.745 0 100 
1 10 0.771 8.1 99.2 0.744 7.4 98.9 
2 10 0.742 0 100 0.723 0 100 
3 10 0.752 0 100 0.731 0 100 
4 10 0.727 0 100 0.743 0 100 
5 10 0.762 3.3 99.6 0.746 2.3 99.7 
6 10 0.793 0 100 0.736 0.1 100 
7 10 0.768 7 99.3 0.752 1.8 99.8 
8 10 0.804 0 100 0.755 0.2 100 
9 10 0.787 0 100 0.731 0 100 
10 10 0.771 0 100 0.719 0.1 100 
11 10 0.768 0 100 0.706 0 100 
12 10 0.732 0 100 0.728 0 100 
13 10 0.725 0 100 0.729 0 100 
14 10 0.730 0 99.7 0.748 1.6 99.8 
15 10 0.681 0 100 0.725 0.2 100 
16 10 0.793 2.6 100 0.757 0.7 99.9 
17 10 0.722 0 100 0.731 0 100 
18 10 0.762 2.9 100 0.750 0.6 99.9 
19 10 0.772 0 100 0.716 0 100 
20 10 0.744 0 100 0.741 0.1 100 
21 10 0.764 1.6 100 0.741 1.3 99.8 
22 10 0.688 0 99.6 0.728 0.1 100 
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23 10 0.773 0 99.6 0.757 0.9 99.9 
24 10 0.677 0 100 0.740 0.2 100 
25 10 0.696 0 100 0.732 0 100 
26 10 0.747 1.4 100 0.745 0.4 100 
27 10 0.702 0 100 0.722 0 100 
28 10 0.813 0 100 0.739 1.1 99.9 
29 10 0.747 0 100 0.721 0 100 
 
*- indicates the value is not available. 
 
